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ABSTRACT 
Peroxisome proliferators are a diverse group of rodent non-genotoxic carcinogens 
：：that include hypolipidemic drugs (e.g. Wy-14,643), plasticizers (e.g. DEHP) and 
herbicides (e.g. 2,4-dichlorophenoxyacetic acid). Short-term treatment of rats and mice 
with peroxisome proliferators results in an increase in liver peroxisome number, 
hepatomegaly (hypertrophy and hyperplasia) and target genes transcription. Chronic 
treatment to rodents with peroxisome proliferators results in hepatocellular carcinoma. 
As humans are frequently prescribed to hypolipidemic drugs, i.e. peroxisome 
proliferators, for prevention of coronary heart disease, pharmaceutical and government 
agencies are concerning the causes of peroxisome proliferators-induced tumor in rodents 
and might be in human. 
Earlier studies suggested that a member of steroid hormone receptor called 
peroxisome proliferator-activated receptor (PPAR) mediates the action of peroxisome 
proliferators. There are three isoforms of PPAR within vertebrates termed a, 5 and y and 
PPARa appears to be the one that is most strongly activated by peroxisome proliferators. 
Gene-knockout mice lacking PPARa definitely confirmed that PPARa mediates 
peroxisome proliferators-induced peroxisome proliferation, hepatomegaly and 
hepatocarcinogenesis. However, the underlying molecular mechanisms by which 
PPARa mediates these pleiotropic responses are still obscure. 
It is suggested that activation of PPARa by peroxisome proliferators will lead to 
alter transcription of some gene(s) involved in hepatocyte growth regulation. 





dependent might gain an insight into the molecular mechanisms involved in the PPARa-
dependent pathway in peroxisome proliferators-induced pleiotropic effects. 
The aim of the present study was to identify peroxisome proliferators responsive 
—V 
" genes that are PPARa-dependent and might play a role in short-term pleiotropic 
responses and perhaps in development of hepatocarcinoma. Time-dependent changes of 
liver weight, serum triglyceride and cholesterol levels in PPARa (+/+) and PPARa (- / - ) 
mice after exposure to Wy-14,643 for 24 hours, 1 week, 2 weeks, 6 months and II 
months were investigated in order to confirm the roles of PPARa involved in both short-
term and long-term Wy-14,643-induced pleiotropic responses. As many investigators 
had reported that the maximal short-term pleiotropic responses in PPARa (+/+) mice 
after treatment with peroxisome proliferators was at 2 weeks, liver RNA samples from 
both PPARa (+/+) and PPARa (- / - ) mice fed Wy-14,643 for 2 weeks were used for 
fluorescent differential display analysis. Fifty Wy-14,643 responsive and PPARa-
dependent differentially expressed genes were excised from four FDD gels performed 
with seven pairs of AP and ARP primers. Forty-two cDNA fragments were reamplified 
by PGR reaction and only eighteen of them were subcloned. Eleven of subcloned cDNA 
fragments were sequenced and nine sequences were derived from seven known genes 
encoding mouse Cyp4al0, mouse Cyp4al4, mouse L-specific multifunctional beta-
oxidation protein, partial cDNA (L-MFP), mouse alpha-1-protease inhibitor I (a-l-PIl), 
mouse farnesyl diphosphate farnesyl transferase (Fdftl)/squalene synthase, mouse 2-
hydroxyphytanoyl-CoA lyase (2-HPCL) and mouse 16s ribosomal RNA of 
mitochondrion complete genome. Two cDNA fragments did not show sequence 




The differentially expression patterns of the five Wy-14,643 responsive and 
PPARa-dependent genes were confirmed by Northern blot analyses. The level of 
expressions of mouse Cyp4al0, Cyp4al4, L-MFP and 2-HPCL were up-regulated in the 
livers of Wy-14,643-treated PPARa (+/+) but not in PPARa ( - / - ) mice. Down-
regulation of a-l-PIl was observed in Wy-14,643-treated PPARa (+/+) mice, whereas 
no such suppression was detected in PPARa (- / - ) mice. In addition these five isolated 
genes might serve as early marker genes for prediction of long-term development of 
hepatocarcinogenesis because the induction or suppression level of these five genes were 
persisted in PPARa (+/+) mice after exposure to Wy-14,643 from 1 week to 11 months. 
The five isolated genes showed different degree of constitutive expression and 
responsiveness to Wy-14,643 in kidney and heart. This indicated that they might have 
different roles in kidney and heart. The Wy-14,643-induced expressions of mouse 
Cyp4al0, Cyp4al4, L-MFP and 2-HPCL in kidney were depended on PPARa whereas 
Wy-14,643 treatment had no effect on the expressions of these genes in heart. There was 
no effect of Wy-14,643 treatment on the constitutive expression of mouse al-PIl in both 
kidney and heart. 
The physiological roles of the five isolated genes were known. Mouse Cyp4al0 
and Cyp4al4 are important in microsomal co- and co-1 hydroxylation while mouse 2-
HPCL and L-MFP play important roles in a and p oxidations of fatty acid respectively. 
In addition, mouse al-PIl was involved in liver diseases and hepatocarcinoma formation. 
These results demonstrated that Wy-14,643 exposure activates PPARa and results in 

























































I would like to thank God that He gave me a wonderful life for the past two years. 
-God lets me experienced His peace, grace and mercy throughout my post-graduate study. 
I would like to give my heartfelt thank to Prof. Lee Sau Tuen Susanna, my 
supervisor, for providing me a well-equipped laboratory to perform research, for her 
insightful advice on my research and critical comments on my thesis. 
I am grateful to Prof. Tsang Sau Cheuk David and Prof. Cheung Wing Tai for 
their valuable advice and encouragement. Particular thanks also go to Dr Tian Li for 
sharing her research experience with me, her constant support and encouragement, and 
companionship throughout the study. I felt so lucky that I had a chance to work with her 
in the laboratory. 
Special thanks are extended to Ms. Lee Wan Chi and Ms. Lee Yun Ling Ada for 
their technical assistance and chemical purchasing, Mr. Yang Lei for his comment on my 
Chinese version of abstract and for teaching me Putonghua, Ms. Wong Yee Mei for 
helping me subcloning, Mr. Lee Yiu Fai for helping me in the laboratory, Dr Lung Hong 
Lok for his advice on my research, and Ms. Shan Sze Wan for lending me reagents and 
cheering me up in the laboratory. 
Last but not least, I would like to thank my lovely parents for sharing both my 
happiness and frustrations, encouragement and constant support throughout my study. 
vii 
為 
TABLE OF CONTENTS 
Page 
Abstract i 
Abstract (Chinese Version) iv 
Acknowledgements vii 
Table of Contents viii 
List of Abbreviations xiv 
List of Figures xvii 
List of Tables xxiv 
Chapter 1 Introduction 1 
Chapter 2 Literature review 3 
2.1 Peroxisomes 3 
2.2 Peroxisome proliferators 5 
2.3 Human exposure pathways to peroxisome proliferators 5 
2.4 Peroxisome proliferator-induced pleiotropic effects in rodents 7 
2.4.1 Short-term effects 7 
2.4.1.1 Hepatomegaly 7 
2.4.2.1 Peroxisome proliferation 8 
2.4.1.3 Alteration of gene transcriptions 8 
2.4.2 Long-term effect 9 
2.5 Mechanisms of actions of peroxisome proliferators 9 
2.5.1 Substrate overload 9 
2.5.2 Receptor-mediated 11 
2.6 Peroxisome proliferator-activated receptors (PPARs) 11 





2.6.2 Tissue-specific expression of PPARs 15 
2.6.3 Physiological functions of PPARs 19 
: 2.6.3.1 PPARa 19 
2.6.3.2 PPARy 21 
2.6.3.3 PPAR5 23 
2.7 Role of PPARa involved in peroxisome proliferator-induced pleiotropic 
responses 24 
2.7.1 Short-term effects 24 
2.7.2 Long-term effect 24 
2.8 Mechanisms of peroxisome proliferator-induced hepatocarcinogenesis 25 
2.8.1 Oxidative stress 25 
2.8.2 Suppression of apoptosis 26 
2.8.3 Increased cell proliferation 27 
2.9 Species difference to peroxisome proliferator-induced pleiotropic effects 28 
2.10 Fluorescent differential display (FDD) 32 
Chapter 3 Objectives 35 
Chapter 4 Materials and methods 37 
4.1 Animals and treatments 37 
4.1.1 Materials 37 
4.1.2 Methods 37 
4.2 Serum triglyceride and cholesterol analyses 39 
4.2.1 Materials 41 
4.2.2 Methods 41 
4.2.2.1 Serum preparation 41 
4.2.2.2 Triglyceride determination 41 





4.3 Statistical analysis 42 
4.4 Tail-genotyping 42 
4.4.1 Materials 44 
4.4.2 Methods. 44 
4.4.2.1 Preparation of genomic tail DNA 44 
4.4.2.2 PGR reaction 45 
4.5 Total RNA isolation 45 
4.5.1 Materials 48 
4.5.2 Methods ‘ ’ 48 
4.6 DNase I treatment 48 
4.6.1 Materials 49 
4.6.2 Methods 49 
4.7 Reverse transcription of mRNA and fluorescent PGR amplification 50 
4.7.1 Materials 50 
4.7.2 Methods 53 
4.8 Fluorescent differential display (FDD) 53 
4.8.1 Materials 53 
4.8.2 Methods 54 
4.9 Excision of differentially expressed cDNA fragments 54 
4.9.1 Materials 57 
4.9.2 Methods 57 
4.10 Reamplification of differentially expressed fragments 57 
4.10.1 Materials 60 
4.10.2 Methods 60 
4.11 Subcloning of reamplified cDNA fragments 62 
4.11.1 PCR-TRAP® cloning system 62 
4.11.1.1 Materials 63 
4.11.1.2 Methods 63 





4.11.2.1 Materials 65 
4.11.2.2 Methods 66 
4^ .12 Purification of plasmid DNA from recombinant clones 69 
4.12.1 Materials 69 
4.12.2 Methods 69 
4.13 DNA sequencing of differentially expressed cDNA fragments 70 
4.13.1 CEQ 2000 Dye Terminator Cycle Sequence system 71 
4.13.1.1 Materials 71 
4.13.1.2 Methods 71 
4.13.2 ABI PRISM™ dRhodamine Terminator Cycle Sequencing system 72 
4.13.2.1 Materials 72 
4.13.2.2 Methods 72 
4.13.3 Homology search against computer databases 73 
4.14 Northern analysis of differentially expressed cDNA fragments 73 
4.14.1 Formaldehyde gel electrophoresis of total RNA 74 
4.14.1.1 Materials 74 
4.14.1.2 Methods 74 
4.14.2 Preparation of cDNA probes for hybridization 74 
4.14.2.1 PGR DIG labeling 75 
4.14.2.1.1 Materials 75 
4.14.2.1.2 Methods 75 
4.14.2.2 Random Prime cDNA DIG labeling 75 
4.14.2.2.1 Materials 75 
4.14.2.2.2 Methods 76 
4.14.3 Purification of DNA from agarose gel 77 
4.14.3.1 Materials 77 
4.14.3.2 Methods 78 
4.14.4 Hybridization 78 
4.14.4.1 Materials 78 
xi 
Page 
4.14.4.2 Methods 78 
4.14.5 Synthesis of mouse GAPDH probe from normalization 80 
.：. 4.14.5.1 Materials 80 
4.14.5.2 Methods 80 
Chapter 5 Results 82 
5.1 Liver morphology 82 
5.2 Liver weight 82 
5.3 Serum triglyceride and cholesterol levels 88 
5.4 Confirmation of genotypes 91 
5.5 DNase I treatment 91 
5.6 FDD RT-PCR and band excision 98 
5.7 Reamplification of excised cDNA fragments 111 
5.8 Subcloning of reamplified cDNA fragments 121 
5.9 DNA sequencing of subcloned cDNA fragments 124 
5.10 Confirmation of the differentially expressed cDNA fragments by Northern blot 
analysis 132 
5.11 Temporal expression pattern of differentially expressed genes 157 
5.12 Tissue distribution pattern of differentially expressed genes 171 
Chapter 6 Discussions 183 
6.1 Lack of hepatomegaly, hypotriglyceridemia and hepatic nodule formation in 
PPARa (- / - ) mice 184 
6.2 Identification of PPARa-dependent and Wy-14,643 responsive genes 185 
6.3 Functional roles of the isolated cDNA fragments 186 
6.3.1 Fragments B14 and H4 187 





6.3.3 Fragment H5 192 
6.3.4 Fragment H8 194 
6 A Temporal expression patterns of the isolated cDNA fragments 196 
6.5 Tissue distribution patterns of the isolated cDNA fragments 197 
Chapter 7 Conclusions 200 
Chapter 8 Future studies 204 
8.1 Subcloning and characterization of the other differentially expressed genes 204 
8.2 Overexpression and inhibition expression of specific genes 204 





LIST OF ABBREVIATIONS 
A Absorbance 
AGO Acyl CoA oxidase 
ACS Acyl-CoA synthetase 
AF Activating function 
a l -AT Alpha-1 -antitrypsin 
al-PI 1 Alpha-1 -protease inhibitor I 
AP Anchored primer 
ApoA-I Apoprotein A-I 
ARP Arbitrary primer 
BCIP 5-bromo-4-chloro-3-indolyl-phosphate 
BFE Bifunctional dehydrogenase/hydratase 
BLAST Basic Local Alignment Search Tool 
bp Basepair 
BR-931 4-chloro-6(2�3-xylidino)-2-pyrimidinyl-thio(N-p-hydroxyethyl)acetamide 
cDNA Complementary deoxyribonucleic acid 
CDK Cyclin-dependent kinases 
cm Centimeter 




DHCA Dihydroxycholestanoic acids 
DINP Diisononyl phthalate 
DNA Deoxyribonucleic acid 
DNTP Deoxyribonucleotide-5-phosphate 
15d-PGJ2 15-Deoxy-A i2’i4_prostaglandin J2 
DR-1 Direct repeat 1 
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
ES Embryonic stem cell 
FAAR Fatty acid-activated receptor 
FADD Fas-assciated protein with death domain 
FDD Fluorescent differential display 
Flk/KDR Vascular endothelial cell growth factor receptor 2 
Flt-1 Vascular endothelial cell growth factor receptor 1 
Fmol Femto mole 
g Gram 
GAPDH Glyceraldehyde-3 -phosphate dehydrogenase 
h Hour 
H2O2 Hydrogen peroxide 
HDL High density lipoprotein 
HNF-4 Hepatocyte nuclear factor-4 










LCAT Lecithin-cholesterol acyl transferase 
L-FABP Liver fatty acid binding protein 
L-MFP L-specific multifunctional beta-oxidation protein 
LPL Lipoprotein lipase 
LTB4 Leukotriene B4 
j L i l Microlitre 
|LIM Micromolar 
Mg/dL Minigram/deci litre 
min Minute ‘ 
ml Millilitre "“ 
mM Millimolar 
NaCl Sodium chloride 
NAD+ Nicotinamide adenine dinucleotide 
NBT Nitroblue tetrazolium chloride 




ORF Open reading frame 
PCNA Proliferating cell nuclear antigen 
PCR Polymerase chain reaction 
pg Picogram 
PKC Protein kinase C 
PP Peroxisome proliferator 
PPAR Peroxisome proliferator-activated receptor 
PPBP Peroxisome proliferator binding protein 
PPRE Peroxisome proliferator responsive element 
PUFA Polyunsaturated fatty acid 
RNA Ribronucleic acid 
rpm Round per minute 
RT-PCR Reverse transcription-polymerase chain reaction 
RXR Retinoic X receptor 
sec Second 
SCPx Sterol carrier protein-X 
SDS Sodium dodecyl sulfate 
SSC Sodium choloride/sodium citrate buffer 
TGFp 1 Transforming growth factor p 1 
THCA Trihydroxycholestanoic acids 
TMR Tetramethylrhodamine 




TR Thyroid hormone receptor 
Tris-HCl Tris (hydroxymethyl) aminomethane/hydrochloric acid 
UCP Uncoupling protein-1 
UP A Urokinase-type plasminogen activator 
V Voltage 
VEGF Vascular endothelial cell growth factor 
VLDL Very low density lipoprotein 
W Watt 
Wy-14,643 Pirinixic acid ([4-chloro-6(2,3-xylindino)2-pyrimidinylthiolacetic acid) 
X-Gal 5 -bromo-4-chloro-3 -indoly 1- p -D-thiogalactoside 
xvi 
a 
LIST OF FIGURES 
Page 
Figure 1 Electron micrograph of peroxisomes in rat liver 4 
Figure 2 The structures of some representative rodent peroxisome proliferators 6 
Figure 3 Basic mechanism of activation of peroxisome proliferators 12 
Figure 4 Functional domains of the nuclear hormone receptor, PPAR 14 
Figure 5 Functional domains of the PPARa, 5, yl andy2 16 
Figure 6 Schematic diagram to show the procedure of fluorescent differential 
display 34 
Figure 7 External morphology of three month old male PPARa (+/+) and 
PPARa (- / - ) mice 38 
Figure 8 A schematic representation of the PPARa (+/+) and PPARa (- / - ) 
mice genomic organization and the strategy of primer design 43 
Figure 9 Flowchart showing overall steps for preparation of genomic tail 
cDNA 46 
Figure 10 Flowchart showing overall strategy to identify differentially expressed 
genes by FDD RT-PCR 47 
Figure 11 GenomyxLR^^ DNA electrophoresis system 55 
Figure 12 GenomyxSC™ fluorescent imaging scanner 56 
Figure 13 Band Excision Workstation for fluorescent differential display 59 
Figure 14 Schematic diagram to show the cDNA fragment reamplification and 
priming site reconstruction using full-length Ml3 (-48) 24-mer and T7 
promoter 22-mer primers 61 
Figure 15 Partial restriction map of Insert-ready PCR-TRAP® vector 64 
Figure 16 Restriction map and multiple cloning site of the pT-Adv vector 68 
Figure 17 Liver morphology of three months old male PPARa (+/+) and 





Figure 18 Liver morphology of three months old male PPARa (+/+) and 
PPARa (- / - ) mice fed control or 0.1% Wy-14,643 rodent diet for 2 
‘ weeks 84 
Figure 19 Liver morphology of three months old male PPARa (+/+) and 
PPARa (- / - ) mice fed control or 0.1% Wy-14,643 rodent diet for 6 
months 85 
Figure 20 Liver morphology of three months old male PPARa (+/+) and 
PPARa ( - / - ) mice fed control or 0.1% Wy-14,643 rodent diet for 11 
months 86 
Figure 21 Effect of Wy-14,643 treatment on the liver weight (expressed as % 
body weight) in PPARa (+/+) and PPARa (- / - ) mice exposed for 24 
hours, 1 week, 2 weeks, 6 months and 11 months 87 
Figure 22 Effect of Wy-14,643 treatment on the serum triglyceride levels in 
PPARa (+/+) and PPARa (- / - ) mice exposed at different time 
periods 89 
Figure 23 Effect of Wy-14,643 treatment on the serum cholesterol levels in 
PPARa (+/+) and PPARa (- / - ) mice exposed at different time 
periods 90 
Figure 24 Tail-genotyping of PPARa (+/+) and PPARa ( - / - ) mice used for 24 
hours Wy-14,643 gavage treatment 92 
Figure 25 Tail-genotyping of PPARa (+/+) and PPARa (- / - ) mice used for 1 
week Wy-14,643 feeding experiment 93 
Figure 26 Tail-genotyping of PPARa (+/+) and PPARa (- / - ) mice used for 2 
weeks Wy-14,643 feeding experiment 94 
Figure 27 Tail-genotyping of PPARa (+/+) and PPARa (- / - ) mice used for 6 
months Wy-14,643 feeding experiment 95 
Figure 28 Tail-genotyping of PPARa (+/+) and PPARa (- / - ) mice used for 11 




Figure 29 Electrophoretic separation (1% agarose, 0.5X TBE gel) of the total 
liver RNA after DNase I treatment with ethidium bromide staining 97 
Figure 30 Gel B: Fluorescent differential display of liver RNAs from PPARa 
(+/+) and PPARa ( - / - ) mice treated with control (CTL) or 0.1% Wy-
14,643 (WY) diet for 2 weeks 99 
Figure 31 Gel F (part 1): Fluorescent differential display of liver RNAs from 
PPARa (+/+) and PPARa ( - / - ) mice treated with control (CTL) or 
0.1% Wy-14,643 (WY) diet for 2 weeks 101 
Figure 32 Gel F (part 2): Fluorescent differential display of liver RNAs from 
PPARa (+/+) and PPARa ( - / - ) mice treated with control (CTL) or 
0.1% Wy-14,643 (WY) diet for 2 weeks 102 
Figure 33 Gel H (part 1): Fluorescent differential display of liver RNAs from 
PPARa (+/+) and PPARa ( - / - ) mice treated with control (CTL) or 
0.1% Wy-14,643 (WY) diet for 2 weeks 105 
Figure 34 Gel H (part 2): Fluorescent differential display of liver RNAs from 
PPARa (+/+) and PPARa ( - / - ) mice treated with control (CTL) or 
0.1% Wy-14,643 (WY) diet for 2 weeks 106 
Figure 35 Gel J (part 1): Fluorescent differential display of liver RNAs from 
PPARa (+/+) and PPARa (- / - ) mice treated with control (CTL) or 
0.1% Wy-14,643 (WY) diet for 2 weeks 108 
Figure 36 Gel J (part 2): Fluorescent differential display of liver RNAs from 
PPARa (+/+) and PPARa (- / - ) mice treated with control (CTL) or 
0.1% Wy-14,643 (WY) diet for 2 weeks 109 
Figure 37 Reamplification of cDNA fragments excised from Gel B 112 
Figure 38 Reamplification of cDNA fragments excised from Gel F 114 
Figure 39 Reamplification of cDNA fragments excised from Gel H 117 
Figure 40 Reamplification of cDNA fragments excised from Gel J 119 
Figure 41 Colony-PCR screening of recombinant clones containing cDNA 




Figure 42 EcoRI restriction enzyme digestion of recombinant clones containing 
cDNA fragments B2, B7, B8 and H5 (upper panel) and J2，J5 and J6 
(lower panel) 123 
Figure 43 EcoRI restriction enzyme digestion of recombinant clones containing 
cDNA fragments HI and H6 (upper panel) and H3 (lower panel) 125 
Figure 44 EcoRI restriction enzyme digestion of recombinant clones containing 
cDNA fragments H8 (upper panel) and H12 (lower panel) 126 
Figure 45 EcoRI restriction enzyme digestion of recombinant clones containing 
cDNA fragments J7 (upper panel) and J l l (lower panel) ^ 127 
Figure 46 Sequencing comparison between the cDNA fragments B14 isolated 
from differentially display gel and mouse Cyp4al 0 ^ 幻 
Figure 47 Sequencing comparison between the cDNA fragments of B14 isolated 
from differentially display gel and mouse Cyp4al 0 ^ ^ ^ 
Figure 48 Sequencing comparison between the cDNA fragments of HI isolated 
from differentially display gel and mouse L-specific multifunctional 
beta-oxidation protein, partial cDNA ! 3 产 
Figure 49 Sequencing comparison between the cDNA fragments H3 isolated 
from differentially display gel and mouse Cyp4al4 
136 
Figure 50 Sequencing comparison between the cDNA fragments H4 isolated 
from differentially display gel and mouse Cyp4a 14 ^^^ 
Figure 51 Sequencing comparison between cDNA fragments of H4 isolated 
from differentially display gel and mouse Cyp4al4 
138 
Figure 52 Sequencing comparison between the cDNA fragments of H5 isolated 
from differentially display gel and mouse serine protease inhibitor 1-
1/mouse alpha-1 protease inhibitor 1 ^^^ 
Figure 53 Sequencing comparison between the cDNA fragments of H5 isolated 
from differentially display gel and mouse serine protease inhibitor 1-
1/mouse alpha-1 protease inhibitor 1 刚 
XX 
Page 
Figure 54 Sequencing comparison between the cDNA fragment of H6 isolated 
from differentially display gel and mouse E7.5 extraembryonic 
portion cDNA library mouse cDNA clone C0170H06 3，(EST) ^^^ 
Figure 55 Sequencing comparison between the cDNA fragments of H8 isolated 
from differentially display gel and mouse 2-hydroxyphytanoly-CoA 
lyase 142 
Figure 56 Sequencing comparison between the cDNA fragment of HI2 isolated 
from differentially display gel and mouse kidney mkia mouse cDNA 
clone 1480995 3' similar to liver carboxylesterase precursor (Human) 
( e s t ) 143 
Figure 57 Sequencing comparison between the cDNA fragments of J7 isolated 
from differentially display gel and mouse famesyl diphosphate 
famesyl transferase 1/mouse squalene synthase ^^^ 
Figure 58 Sequencing comparison between the cDNA fragments of JIO isolated 
from differentially display gel and mouse Cyp4al 0 � 
Figure 59 Sequencing comparison between the cDNA fragments of J11 isolated 
from differentially display gel and mouse mitochondrion complete 
genome/mouse chimeric 16s ribosomal RNA , . , 
146 
Figure 60 Sequencing comparison between the reamplified GAPDH fragment 
and mouse glyceraldehyde-3 -phosphate dehydrogenase ^^^ 
Figure 61 Sequencing comparison between the reamplified GAPDH fragment 
and mouse glyceraldehyde-3 -phosphate dehydrogenase ^^^ 
Figure 62 Confirmation of fluorescent differential display expression pattern of 
cDNA fragment B14 by Northern blot analysis 1 ^ ^ 
Figure 63 Confirmation of fluorescent differential display expression pattern of 
cDNA fragment HI by Northern blot analysis 
1. ^ 1. 
Figure 64 Confirmation of fluorescent differential display expression pattern of 
cDNA fragment H4 by Northern blot analysis ^^^ 
Figure 65 Confirmation of fluorescent differential display expression pattern of 





Figure 66 Confirmation of fluorescent differential display expression pattern of 
cDNA fragment H8 by Northern blot analysis 
155 
Figure 67 Temporal expression pattern of cDNA fragment B14 in PPARa (+/+) -� 
and PPARa ( - / - ) mice 1 ^ ^ 
Figure 68 Temporal expression pattern of cDNA fragment HI in PPARa (+/+) 
and PPARa ( - / - ) mice 
^ ^ ‘ 160 
Figure 69 Temporal expression pattern of cDNA fragment H4 in PPARa (+/+) 
and PPARa ( - / - ) mice 161 
Figure 70 Temporal expression pattern of cDNA fragment H5 in PPARa (+/+) 
and PPARa ( - / - ) mice 
163 
Figure 71 Temporal expression pattern of cDNA fragment H8 in PPARa (+/+) 
and PPARa (- / - ) mice 
164 
Figure 72 Time-dependent expression pattern of cDNA fragment B14 in PPARa 
(+/+)mice 166 
Figure 73 Time-dependent expression pattern of cDNA fragment HI in PPARa 
(+/+) mice 167 
Figure 74 Time-dependent expression pattern of cDNA fragment H4 in PPARa 
(+/+) mice 169 
Figure 75 Time-dependent expression pattern of cDNA fragment H5 in PPARa 
(+/+) mice 170 
Figure 76 Time-dependent expression pattern of cDNA fragment H8 in PPARa 
(+/+) mice 172 
Figure 77 Expression pattern of cDNA fragment B14 in kidney and heart 175 
Figure 78 Expression pattern of cDNA fragment HI in kidney and heart 176 
Figure 79 Expression pattern of cDNA fragment H4 in kidney and heart 177 
Figure 80 Expression pattern of cDNA fragment H5 in kidney and heart 179 




Figure 82 The schematic pathways of fatty acid p-oxidation machinery in 
peroxisome catalyzing the oxidation of straight-chain and branched-
chain fatty acid 191 
Figure 83 Schematic representation of the phytanic acid a-oxidation in rat liver 195 
xxiii 
、 
LIST OF TABLES 
Page 
Table 1 Peroxisome proliferators responsive genes 10 
Table 2 Tissue distribution of PPARa, 5 and y in the central nervous system, 
epidermis, digestive tract, liver and pancreas 17 
Table 3 Tissue distribution of PPARa, 5 and y in the kidney, immune system, 
heart, white adipose tissue and genital system 18 
Table 4 Allocation of PPARa (+/+) and PPARa (- / - ) mice in 24 hours gavage 
dosage and 1 week, 2 weeks, 6 months and 11 months feeding studies 40 
Table 5 Sequence of anchored primers (AP) used for first-strand cDNA synthesis 51 
Table 6 Sequence of arbitrary primer (ARP) used for FDD-PCR reaction 52 
Table 7 Possible gene expression patterns on fluoroDD gel 58 
Table 8 PPARa-dependent differential display genes isolated from the gel B 100 
Table 9 PPARa-dependent differential display genes isolated from the gel B 104 
Table 10 PPARa-dependent and Wy-14,643 responsive cDNA fragments excised 
from Gel H (parts 1 and 2) 107 
Table 11 PPARa-dependent and Wy-14,643 responsive cDNA fragments excised 
from Gel J (parts 1 and 2) U 0 
Table 12 Summary of cDNA fragments reamplified from Gel B 113 
Table 13 Summary of cDNA fragments reamplified from Gel F 115 
Table 14 Summary of cDNA fragments reamplified from Gel H 118 
Table 15 Summary of cDNA fragments reamplified from Gel J 120 
Table 16 Summary of eighteen cDNA fragments successfully subcloned from 
forty-two reamplified cDNA fragments 128 
Table 17 Summary of sequence homology of subcloned cDNA fragments 129 
Table 18 Summary of sequence homology of subcloned cDNA fragments (cont'd) 130 
Table 19 Summary of sequence homology of subcloned cDNA fragments (cont'd) 131 
Table 20 Summary of Northern blot expression patterns of five PPARa-dependent 




Table 21 Summary of temporal expression patterns of five PPARa-dependent and 
Wy-14,643 responsive genes 173 
Table 22 Summary of expression patterns of five PPARa-dependent and Wy-




CHAPTER 1: INTRODUCTION 
Peroxisome proliferators are an important group of chemicals that include certain 
hypolipidemic drugs, plasticizers and pollutants. Rodents treated with peroxisome 
proliferators resulting in characteristic hepatomegaly, proliferation of peroxisomes in 
parenchymal cells，and an increase in peroxisomal P-oxidation of fatty acids (Moody et 
a / .�1991). For chronic administration of peroxisome proliferators, hepatocarcinoma was 
observed in rodent (Reddy et al., 1980). Therefore, these chemicals have raised a health 
concern since there is a likelihood of human exposure, and an association between 
peroxisome proliferation and liver cancer in laboratory animal are well documented 
(Reddy and Rao, 1992; Lake, 1995). 
Throughout the 1970s and 1980s, much of the research on peroxisome 
proliferators focused on their biochemical effects in laboratory animals, such as 
alterations in lipid metabolism and enzyme induction (Lock et al., 1989). Upon the 
discovery of a nuclear hormone receptor that is activated by peroxisome proliferators, the 
research has taken a dramatic turn toward molecular and cellular biology in 1990s. In 
addition, peroxisome proliferator-activated receptors (PPARs) were isolated (Issemann 
and Green, 1990) and they are activated by peroxisome proliferators. Among different 
isoforms of PPARs, PPARa was discovered as the mediator by peroxisome proliferator 
and contributed to peroxisome proliferation. The development of a PPARa-null mouse 
in 1995 confirmed the role of PPARa as an essential mediator of peroxisome 
proliferator-induced pleiotropic effects such as hepatomegaly, peroxisome proliferation, 
transcriptional-activation of target genes and hepatocarcinogenesis (Lee et al., 1995; 
Peters et al” 1997). However, the underlying molecular mechanisms by which PPARa 
1 
mediate these pleiotropic responses are still not fully understood. Moreover, previous 
studies indicated that the short-term pleiotropic effects such as hepatomegaly and 
peroxisome proliferation in the livers of rodents showing a strong relationship with 
hepatocarcinogenicity after long-term exposure to peroxisome proliferators (Cohen and 
Grasso，1981; Reddy and Lalwani, 1983; Bentley et ai, 1993). Therefore, the aim of the 
present study was to identify some of the PPARa-dependent genes involved in 
peroxisome proliferator-induced short-term pleiotropic responses and perhaps in 
development of long-term hepatocarcinogenesis. 
2 
V 
CHAPTER 2: LITERATURE REVIEW 
2.1 Peroxisomes 
Peroxisomes are single membrane-bound organelles that are found in cells of 
animals, plants, fungi and protozoa (Leighton et a/., 1968) (Figure 1). The number per 
cell, size and specific enzyme composition of peroxisomes varies between organisms and 
between tissues. Peroxisomes contain no DNA, therefore proteins must be directed from 
the cell cytosol to the organelle (Kamiryo et al., 1982). 
At present, more than 50 enzymatic activities have been identified in mammalian 
peroxisomes (Mannaerts and Van Veldhoven，1993) and some of which are restricted to 
peroxisomes whereas others have their counterparts in other organelles. Peroxisomal 
enzymes are involved in a broad range of catabolic and anabolic enzymatic pathway, 
such as P-oxidation of long-chain fatty acids and derivatives (e.g. fatty acids, 
dicarboxylic acids, prostanoids, some xenobiotics and the side chain of cholesterol), fatty 
acid elongation, the hydrolysis of acyl-CoAs and the conversion of acyl-CoAs to 
acylcarnitines, the biosynthesis of ether glycerolipids, cholesterol and dolichols, the 
catabolism of polyamines, purines and amino acids, the conversion of glyoxylate, the 
metabolism of glucose via the hexose monophosphate pathway and the metabolism of 
reactive oxygen species (Mannaerts and Van Veldhoven, 1993 and 1996). The latter 
enzymatic reaction is of vital importance for the cells and consists of the detoxification of 
hydrogen peroxide by the peroxisomal catalase. Disturbances in the peroxisomal system, 
as demonstrated by a number of inborn errors of peroxisomal metabolism, leading to 
accumulation or shortage of certain metabolites, illustrates the vital importance of 





Figure 1. Electron micrograph of peroxisomes in rat liver. A peroxisome (P) indicated 
the single limiting membrane, the electron-dense crystalline core and the fine granular 
matrix. A mitochondrion (M) and membranes of the endoplasmic reticulum with 
associated ribosomes are shown (Adapted from Masters and Crane, 1995). 
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2.2 Peroxisome proliferators 
Peroxisome proliferators (PPs) are a large number of chemicals have been shown 
to produce peroxisome proliferation in hepatocytes of rodents and nonrodent species, 
including primates. These include a broad group of chemicals such as hypolipidemic 
drugs, phthalate ester plasticizers, solvents (e.g. tricholoroethylene)，herbicides, some 
leukotriene D4 antagonists, and adrenal steroid dehydroepiandrosterone (Lock et al., 
1989; Tikkanen, 1992; Reddy, 1994) (Figure 2). A feature of many, but not all, 
peroxisome proliferators is the presence of an acidic function (Lake et al., 1987; Lock et 
» 
al., 1989). This wide range of classes of chemicals that produce organelle proliferation 
have been shown as chemically unrelated (Cohen and Grasson, 1981) or structurally 
dissimilar (Reddy and Lalwani, 1983) compounds. 
2.3 Human exposure pathways to peroxisome proliferators 
Humans use fibrates (e.g. clofibrate, bezafibrate, fenofibrate, ciprofibrate) as 
hypolipidemic agents to decrease their plasmatic level of cholesterol and triglycerides in 
order to prevent vascular risks. All of these agents are several orders magnitude more 
potent than the prototype compound clofibrate in inducing hypolipidemia, peroxisome 
proliferation, and liver carcinogenesis (Reddy and Lalwani, 1983; Rao and Reddy, 1987; 
Reddy, 1994). Hypolipidemic agents not structurally related to clofibrate are also 
identified as potent peroxisome proliferators (Reddy and Lalwani, 1983). For example, 
[4-chloro-6(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14643), 4-chloro-6(2,3-
xylidino)-2-pyrimidinyl-thio(N-P-hydroxyethyl)acetamide (BR-931), and fibric acid are 
more potent than clofibrate in inducing peroxisome proliferation and liver tumors in rats 
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Figure 2. The structures of some representative rodent peroxisome proliferators. 
Clofibrate, clofibric acid, methylclofenapate, ciprofibrate, nafenopin, Wy-14,643, LY 
171883, bifonazole and tiadenol are therapeutic agents. Fomesafen is herbicide. DEHP, 
DEHA and DHEA are plasticizers. Cirmamyl anthranilate belongs to the class of food 
flavours and natural products. Tricholoroethylene belongs to class of solvents and 




The industrial plasticizers di(2-ethylhexyl)phthalate (DEHP) and di(2-
ethylhexyl)adipate (DEHA) are widely used as plasticizing agents in the manufacture of 
polyvinyl chloride plastics and have been identified as peroxisome proliferators (Reddy 
and Lalwani, 1983). Human population can be involuntarily exposed to these plasticizers, 
which may diffuse from-wrapping of food (especially fatty food, meat, cheese). 
Several nongenotoxic herbicides (e.g. fomesafen and lactofen) developed to 
replace some of the currently used genotoxic herbicides were found to exert potent 
peroxisome proliferative effects in rats and mice. Similarly, herbicide and pesticide 
residues can be found in vegetables and fruits (Bentley et al” 1993; Lake, 1995; Malki et 
al., 1999). 
The diverse nature of the chemical structures of compounds is known to cause 
peroxisome proliferation and induce the development of liver tumors in rats and mice. In 
addition, humans are frequently exposed to different kinds of peroxisome proliferators. 
Therefore, it is necessary to evaluate both short-term and long-term pleiotropic effects of 
peroxisome proliferators and the risk of peroxisome proliferators to humans. 
2.4 Peroxisome proliferator-induced pleiotropic effects in rodents 
2.4.1 Short-term effects 
2.4.1.1 Hepatomegaly 
Short-term administration of peroxisome proliferators (e.g. clofibrate, Wy-14,643, 
DEHP and nafenopin) to rats and mice results in hepatomegaly. It is due to both 
hepatocyte hyperplasia (increase replicative DNA synthesis and cell division) and 
hypertrophy (increase in cell size) (Cohen and Grasson, 1981; Reddy and Lalwani, 1983). 
These morphological changes can be revealed through the increased peroxisome volume 
7 
V « 
density, which results from an increase primarily in the number of peroxisomes, and size 
may also be increased (Moody et al., 1991). 
2.4:1.2 Peroxisome proliferation 
Peroxisome proliferation is consistently associated with hepatomegaly. It has 
been demonstrated in vitro in primary rat and mouse hepatocyte cultures in different 
laboratories (Lock et al, 1989; Moody et al., 1991; Lake and Lewis, 1993). On the other 
hand, the characteristics of peroxisome proliferation in vivo included the increased 
peroxisome number and volume. Rodents treated with peroxisome proliferators resulting 
in increasing the number of peroxisome from about 500-600 per cell to >5,000 per cell 
(Reddy and Chu, 1996). Moreover, morphometric analysis of liver sections from rats 
treated with peroxisome proliferators (e.g. clofibrate and nafenopin) demonstrated 7- to 
10-fold increases in peroxisomal relative volume and surface area (Rao and Reddy, 1987; 
Moody et al, 1991). 
2.4.1.3 Alteration of gene transcriptions 
Peroxisome proliferation is coincident with alteration in many peroxisomal and 
mitochondrial enzymes involved in fatty acid p-oxidation (Hawkins et al., 1987; Gulick 
et al., 1994; Auwerx et al., 1996a). The stimulation of microsomal fatty acid-oxidizing 
enzymes is due to induction of cytochrome P450 isoenymes in the CYP4A and CYP7A 
families (Gibson, 1989; Cheema and Agellon, 2000). Moreover, peroxisome 
proliferators also regulated the expression of cytosolic enzymes involved in lipid 
metabolism (Sweetser et al., 1987; Castelein et al., 1994). This indicated that 




in more than one subcellular compartment (Cohen, 1981; Hardwick, 1987; Moody et al., 
1991; Lake, 1995) (Table 1). 
2.4:2 Long-term effect 
Many peroxisome proliferators have been reported to produce liver tumors, 
including hepatocellular carcinoma in rodents (Cohen and Grasso, 1981; Reddy and 
Lalwani, 1983). Potent compounds (e.g. ciprofibrate, Wy-14,643) produced a 100% 
incidence of tumors in rat and mice within a relatively short period (e.g. 40-60 weeks), 
whereas weaker agents (e.g. clofibrate, DEHP) may required two years of administration 
to produce a lower tumor incidence (Cohen and Grasso, 1981; Reddy and Lalwani, 1983; 
Lake et al., 1987; Conway et al., 1989; Reddy and Rao, 1992; Lake, 1995). 
2.5 Mechanisms of actions of peroxisome proliferators 
2.5.1 Substrate-overload 
In order to understand how peroxisome proliferators induced pleiotropic 
responses, it is important to determine the molecular mechanism of peroxisome 
proliferators action. Substrate overload was the first hypothesis proposed for the action 
of peroxisome proliferator (Reddy and Lalwani, 1983; Lock et al., 1989). It was 
proposed that accumulation of peroxisome proliferators or its intermediate derivatives 
initiate peroxisome proliferation in liver which is an adaptive response to a perturbation 
of lipid metabolism and also involves induction of CYP4A isoenzymes (Lock et aL, 1989; 
Bentley et al., 1993). Certainly peroxisome proliferators inhibit fatty acid oxidation, 
form coenzyme A esters，increase levels of fatty acids, and displace fatty acids from the 




Table 1. Peroxisome proliferators responsive genes. 
Subcellular ^ ~ ~ ” 
Compartment ^ References 
Peroxisomes Acyl-coA oxidase Varanasi et al,, 1996 
Hydratase-dehydrogenase Chu et al., 1995 
Thiolase Huan et al., 1995 
Acyl-coA synthetase Schoonjans et al., 1995 
Uncoupling proteins 1 and 3 Teruel et al., 2000 
Cbl-associated protein Baumaim et al., 2000 
Microsomes Cytochrome P450 4A1 Hardwick et al., 1987 
Cytochrome P450 4A2 Kimura et al., 1989 
Cytochrome P450 4A4 Matsubara et al, 1987 
Cytochrome P450 4A5 Johnson et al., 1990 
Cytochrome P450 4A6 Yokotani et a/., J989 
Cytochrome P450 4A7 Yokotani et al., 1989 
Cytochrome P450 4al 0 Henderson et al., 1994 
Cytochrome P450 4al4 Heng et al., 1997 
Cytochrome P450 7A1 Cheema and Agellon, 
2 0 ^ 
Mitochondria Medium-chain acyl-CoA dehydrogenase Gulick et al, 1994 
(MCAD) 
3-Hydroxy-3-methylglutaryl-coenzyme- Gil-Gomez et al, 1993 
A-synthase (HMG-CoA synthase) 
Carnitine palmitoyltransferase I Mascaro et al, 1999 
Cytosol Malic enzyme Castelein et al, 1994 
Fatty acid binding protein 
Specific type I-Liver transport protein Dimonson and Iwanij, 
1995 
Transthyretin Costa et al., 1988 
Apolipoprotein Al Vu-Dac et al, 1994 
Apolipoprotein All Vu-Dac et al, 1995 
Apolipoprotein CIII Leff et al,, 1989 
Apolipoprotein VLD II Wijnholds et al., 1991 
Phosphoenolpyruvate carboxykinase Tontonoz et al., 1995 
Matrix metalloproteinase 9 Shu et al., 2000 
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1989; Bentley et al., 1993). 
2.5.2 Receptor-mediated 
The alternative mechanism extended to the specific receptors involved in the 
action of peroxisome proliferators. Issemann and Green identified a member of nuclear 
hormone receptor, peroxisome proliferator-activated receptor (PPAR) in 1990. Different 
classes of peroxisome proliferators such as hypolipidemic drugs, phthalate ester 
plasticizers and herbicides are ligands/activators for PPAR (Issemann and Green, 1990). 
Activated PPAR binds to DNA as a heterodimer with the retinoic X receptor (RXR) 
(where RXR is the receptor for 9-cis retinoic acid) at direct repeat 1 (DR 1) elements 
which means degeneration of AGGTCA direct repeats spaced by 1 bp. The consensus 
sequence is 5,-AACT AGGTCA A AGGTCA-3' which is termed peroxisome 
proliferator responsive element (PPRE) (Kliewer et al., 1992; Issemann et al, 1993). 
PPREs have been identified in the promoter regions of a number of genes that are 
transcriptionally regulated by peroxisome proliferators (Tugwood et al., 1992; 
Schoonjans et al, 1996). As a consequence, the interaction of the activated heterodimer 
with the promoter is the stimulation of transcription of target genes that are implicated in 
peroxisome proliferation, enzyme induction, suppression of apoptosis, and cell 
proliferation (Figure 3). 
2.6 Peroxisome proliferator-activated receptors (PPARs) 
2.6.1 Structure of PPARs 
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated 
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Figure 3. Basic mechanism of activation of peroxisome proliferators. PPs enter the cell 
and cause heterodimerisation of PPAR with RXR, which binds to the PPRE DNA 
element. Binding modulates transcription of target genes resulting in changes in 
peroxisome proliferation, enzyme induction, suppression of apoptosis and cell 




(Issemann and Green, 1990; Keller and Wahli, 1993; Sher et al., 1993; Green and Wahli, 
1994; Shalev and Meier, 1996). There are three known subtype of PPARs which are 
PPARa (Issemann and Green, 1990), PPAR6 (PPARp，FAAR or NUCI) (Schmidt et al., 
1992) and PPARy (Desvergne and Wahli, 1995). PPARy exists in several isoforms 
include PPARy 1, PPAR丫 2 and PPARyS (Fajas et al” 1998; Berg, 1999). PPARy land 
PPARy2 are identical, except for the addition of 28 amino acids in the amino-terminal 
region of PPARy2 (Zhu et al., 1995). The a, 6, and y types have been cloned in 
vertebrate species, e.g. Xenopus, mouse, rat, hamster and human (Issemann and Green, 
1990; Chen et al,, 1993; Green and Wahli, 1994; Aperlo et al., 1995). 
The genomic structures of three PPAR subtypes are similar and like other 
members of the steroid hormone receptor superfamily, PPARs have six functional 
domains, A/B, C, D and E/F (Mangelsdorf et al,, 1995). Figure 4 indicates the functional 
domains of the PPAR. The C domain is DNA binding domain of PPAR contains about 
66 amino acids and targets the receptor to specific DNA sequences or response elements. 
The DNA binding domain is stabilized by zinc atoms and each binding to four invariant 
cysteine residues. Each of these zinc finger complexes is followed by a a-helical 
structure. One of them serves as the major recognition helix that makes base-specific 
contacts within the major groove of the core site (Luisi et al., 1991; Schwabe et al., 
1993). The D domain consists three amino acid residues of the first knuckle of the 
second zinc finger, and may be involved in protein-protein interaction, such as receptor 
dimerization. The E/F is ligand-binding domain and has a key role in the transduction of 
the hormonal signal into transcriptional activation (Green and Chambon, 1988; Tsai and 
O'Malley, 1994; Vamecq and Latruffe, 1999). In addition to the constitutive activating 
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Figure 4. Functional domains of the nuclear hormone receptor, PPAR. The activation 
domains AF-1 and AF-2 are indicated. The nine heptad repeat is involved in 
dimerization. The schematic structure of two zinc fingers is in the DNA binding domain. 
The P-box is composed of the amino acid residues depicted by circles and two flanking 
cysteine residues. The amino acids in the D-box are indicated by squares. Residues in 
black determine the specificity of the P-box regarding half-site recognition or of the 




domains. Depending on the promoter, AF-1 and AF-2 may act independently or 
cooperatively (Tom et al., 1989). The transcription activities of PPAR are controlled by 
the ligand binding domain and dimerization. In comparison to the ligand binding domain 
among three isoforms of PPARs, they are less conserved between themselves (Figure 5). 
丁his may indicate that they bind similar but not identical ligand (Schoonjans et al., 1996). 
As a consequent, different PPARs have different transcription activities. 
2.6.2 Tissue-specific expression of PPARs 
The expression of PPARa, 6, and 丫 varies widely from tissue to tissue. Tables 2 
and 3 summarized the differential expression of PPARa, 6 and y in different tissues. In 
numerous cell types from among ectodermal, mesodermal, or endodermal origin, PPARs 
are co-expressed, although their concentration relative to each other varies widely 
(Braissant et al., 1996). PPARa is highly expressed in liver, kidney, heart, brown fat, 
stomach, duodenum, and immune system (Issemann and Green, 1990). PPARy exists in 
three isoforms and the tissue-specificity is different among them. PPARy 1 is expressed 
in several tissues, including fat, skeletal muscle, heart and liver. PPARY2 is found almost 
exclusively in adipose tissue, and PPARyS expression is restricted to adipose tissue and 
large intestine (Zhu et al., 1995; Berg, 1999). To date, it has been demonstrated that the 
presence of PPARa and PPARy in rat cartilage, at both mRNA and protein levels. 
Comparatively, the PPARa mRNA content in cartilage was much lower than in the liver 
but not significantly different to that of the adipose tissue. PPARy mRNA expression in 
cartilage was weak, when compared with adipose tissue, but similar to that found in the 
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Figure 5. Functional domains of the PPARa, 5, yl and y2. C, DNA binding domain; E, 
ligand binding domain. There was a difference in ligand binding among three isoforms 
of PPARs, they are less conserved between themselves. This may indicate that they bind 
similar but not identical ligand (Adapted from Braissant et al., 1996). 
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Table 2. Tissue distribution of PPARa, 5，and y in the central nervous system, epidermis, 
digestive tract, liver and pancreas (Adapted from Lemberger, et al” 1996). 
: PPARa PPAR5 PPARy 
Central Nervous System 
Telencephalon 
Olfactory Bulfs + +++ +/一 
Cortex +/一 ++ _ 
Hippocampus + +++ +/_ 
Diencephalon 
Thalamic Nuclei +/- + + 一 
Hypothalamic Nuclei ‘ +/- + — 
Retina +++ +++ ++ 
Cerebellum 
Purkinje Cells - +++ _ 
Granule Cells + +++ +/_ 
Deep Nuclei _ ++ _ 
Epidermis 
Keratinocytes - - _ 
Sebaceous Glands + +++ _ 
Hair Follicles + +++ — 
Digestive tract 
Smooth Muscular Layers - 一 — 
Oesophagus ++ ++ + 
Stomach Mucosa +++ ++ + 
Duodenum Crypts and Villi ++++ +++ ++ 
Jejunum Crypts and Villi +++ +++ ++ 
Ileum Crypts and Villi + ++ ++ 
Caecum Mucosa ++ ++ ++ 
Colon Mucosa + + + 
Liver 
Hepatocytes ++++ ++ — 
Pancreas 
Acini (exocrine) + ++ + 
Islets (endocrine) + ++ ++ 
Levels of expression: (-), absent; (+/—), barely detectable; (+), weak expression, (++), 




Table 3. Tissue distribution of PPARa, 6, and y in the kidney, immune system，heart, 
white adipose tissue and genital system (Adapted from Lemberger, et al., 1996). 
PPARa PPAR5 PPARy 
Kidney 
Glomeruli + ++ +/_ 
Proximal Tubules +++ +++ + 
Henle's Loops - +++ — 
Distal Tubules — +++ _ 
Immune System 
Spleen White Pulp ++ +++ ++++ 
Peuer's Patches ++ +++ ++ 
Heart 
Cardiomyocytes ++ ++ — 
White Adipose Tissue + ++ +++ 
Genital System 
Testis 
Sperm Cells 一 _ 
Sertoli Cells ++ ++++ -
Leydig Cells + ++ — 
Ovary 
Oocyte 一 — _ 
Follicular Cells ++ ++ + 
Uterus 
Cervix ++ ++ +/-
Uterine Glands ++ ++ +/— 
Levels of expression: (-), absent; (+/—), barely detectable; (+)，weak expression, (++), 




abundant in the developing and adult nervous tissue, in the testes (especially in Sertoli 
cells), in the mucosa of the digestive tract, in the whole nephron, and in the lymphocyte 
proliferative centers of the immune system (Braissant et al., 1996). 
2.6.3 Physiological functions of PPARs 
The distinct tissue distribution suggests that the PPAR subtypes play different 
biological roles. In fact, it is widely believed that of the different subtypes, PPARa 
predominates in hepatic lipid metabolism and PPARy plays a pivotal role in adipogenesis 
and immune responses. There is also evidence to support the role of PPAR6 in cell 
growth and differentiation. 
2.6.3.1 PPARa 
PPARa has a critical role in regulation of fatty acid metabolism, including fatty 
acid P-oxidation, apolipoproteins, and fatty acid transport proteins (Auwerx et al, 1996b; 
Martin et al., 1997; Peters et al, 1997; Ren et al., 1997; Aoyama et al., 1998; Motojima 
et al., 1998). PPARa regulates serum cholesterol, in particular, high-density lipoprotein 
cholesterol, and triglyceride levels. Both of these effects are due in part to PPARa-
dependent modulation of apolipoprotein gene expression (Peters et al., 1997). PPARa 
also mediates expression of genes encoding both peroxisomal and mitochondrial fatty 
acid-metabolizing enzymes via regulatory events at both the constitutive and inducible 
level. For example, PPARa affects constitutive expression of mitochondrial enzymes 




fatty acid P-oxidation pathways by peroxisome proliferators and perhaps other fatty acid 
metabolites (Aoyama et al., 1998). 
In addition, PPARa revealed a key function in inflammation (Devchand et al., 
19%; Michalik and Wahli, 1999). The identification of leukotriene B4 (LTB4) as a ligand 
of PPARa and the pathway conferred tight control over the activity of LTB4 during an 
inflammation response via regulation of the turnover of this potent chemotactic lipid 
mediator. This pathway involves a feedback mechanism in which LTB4 induces its own 
catabolism by activating the transcription factor PPARa (Devchand et -al, 1996). 
Binding of LTB4 to the receptor stimulates the activation of genes encoding fatty acid-
catabolizing enzymes that degrade LTB4 and should be anti-inflammatory. Given the 
promiscuous nature of PPARa, a variety of fatty acids and eicosanoids could regulate 
their own inactivation or clearance through activation of PPARa. Conversely, blocking 
PPARa function by either a receptor antagonist or gene disruption should extend the 
inflammation (Devchand et al., 1996; Roberts and Kimber, 1999). 
Apart from the roles in lipid metabolism and inflammation, PPARa also may 
regulate other genes involving in controlling the cell cycle as protein kinase C (PKC) a, 
PKC P, cyclin-dependent kinases (CDK)-l, CDK-4, cyclin D1 and c-myc (Peters et al., 
1998; Gorton et al, 1999). PPARa also is capable to suppress apoptosis in cultured rat 
hepatocyte (Roberts et al., 1998). 
The generation of PPARa-deficient mouse model that lacks PPARa expression in 
1995 helps to investigate the functions of PPARa in vivo (Lee et al., 1995). PPARa-null 
mice display abnormal hepatic lipid accumulation and this indicated that PPARa plays an 
important role in lipid homeostasis (Lee et aL, 1995; Peters et al” 1997; Aoyama et al., 
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1998). Moreover, the rate of decrease in inflammation in PPARa-null mice was 
significantly less as compared to wild type mice administrated LTB4 (Devchand et al., 
1996) demonstrating that PPARa plays an important role in controlling inflammation. 
2.6.3.2 PPARy 
Activation of PPARy has been linked to an adipocyte differentiation and 
regulation of glucose homeostasis in rodents and humans (Spigelman, 1998). It has been 
shown that the natural receptor ligand for PPARy, 15-Deoxy-A ^-prostaglandin h 
(15d-PGJ2) (Forman et al., 1995; Kliewer et al, 1995)，and synthetic antidiabetic 
thiazolidinedione drugs e.g. BRL49653 and ciglitizone, inhibit macrophage and 
monocyte activation (Jiang et aL, 1998; Ricote et al., 1998). In fact, PPARy has 
demonstrated that it is highly expressed in most colon cancer cells and breast cancer cells 
(Elstner et al., 1998; Sarraf et aL, 1998). Activation of the PPARy resulted in growth 
arrest and induction of differentiation of cancer cells and reduction of tumor cell growth 
rate, suggesting potential implications of PPARy as a target for treatment of human 
cancers (Kubota et al., 1998). Recent study has documented the expression of PPARy in 
human endothelial cells. Activation of PPARy with either naturally occurring ligand or 
synthetic selective ligands results in potent inhibition of endothelial differentiation into 
tube-like structures and proliferation in vitro and suppression of vascular endothelial cell 
growth factor (VEGF)-induced angiogenesis in vivo. PPARy activation also inhibits the 
expression of at least three important genes in the angiogenic process, the VEGF 
receptors vascular endothelial cell growth factor receptor 1 (Flt-1), vascular endothelial 




protease (uPA) (Xin et al., 1999). Moreover, PPARy mRNA was found that present in 
rat cartilage and it might be involved in the inflammation control in the modulation of the 
cytokine production. PPARy ligands, 15d-PGJ2 inhibited interleukin-1 (IL-l)P-induced 
nitrogen oxide production and partly reversed the loss of proteoglycan anabolism and 
resulted in anti-inflammation effect on cartilage (Bordji et al., 2000). However, the exact 
intracellular signaling pathways following specific activation of PPARy of preventing 
cartilage damage is not completely known. In addition, PPARy is induced in monocytes 
upon their differentiation in vitro or in vivo to macrophages. It was believed that PPARy 
contribute to the inflammation at the level of mediator secretion during atherosclerotic 
lesion and then lipid laden foam cells were formed through the release of oxidants, or 
production of oxidizing enzymes, contribute to the formation of the highly damaging 
oxidized low density lipoproteins (Berliner and Heinecke, 1996; Bishop-Bailey, 2000). It 
can be concluded that PPARy has a biological role in adipocyte differentiation, regulation 
of glucose homeostasis, tumor cell growth suppression, inhibition of angiogenesis and 
prevention of cartilage damage. 
The generation of PPARy-deficient mice in 1999 provided new information on the 
function of PPARy in vivo (Barak et al., 1999; Kubota et al., 1999). According to the 
studies on PPARy-deficient mice, it was indicated that PPARy has an obligatory role in 
adipose tissue formation and its absence leads to complete lipodystrophy. Also, PPARy 
regulates terminal epithelial differentiation of the triphoblast which given the ubiquitous 
expression of PPARy in epithelia of endocrine and exocrine tissues. Most importantly, 
PPARy plays an essential role in the structure and function of the chorioallantoic placenta 
and the development of heart, this could give a insight on the origins of congenital 
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congenital cardiomyopathies (Barak et al” 1999). Furthermore, PPARy has a role in 
hypertrophic obesity and subsequent insulin resistance. It was believed that PPARy 
appears to facilitate energy storage under a high fat diet in part by inhibiting expression 
of-the leptin gene in adipocytes, the major hormonal regulator of energy homeostasis and 
it provided a survival advantage in times of fast (Kubota et al” 1999). 
2.6.3.3 PPAR5 
Different from PPARa and PPARy, the biology of PPAR5 is the least well 
understood. This subtype activates transcription through the same type of response 
elements as PPARa and PPARy and presumably also modulates lipid and/ or glucose 
homeostasis (Schmidt et al” 1992; Kliewer et al., 1995). Recent study provided evidence 
that PPAR6 regulates acyl-CoA synthetase (ACS) 2 in reaggregated rat brain cell 
cultures. The possible biological function of ACS2 gene might coincide with the 
maturation of neurons that is cytodifferentiation and the formation of neuronal 
connectivity. Another characteristic of neuron maturation is the production of 
neurotransmitters and their vesicular transport, storage, and release (Modak et aL, 1999). 
The other study was suggested that PPAR5 was expressed in mouse mast cells that are 
known as a major cytokine-producing cell at the site of allergic inflammation. PPAR5 
also has a role in regulation of mast cell activation by controlling the cytokine production 
(Sugiyama et al., 2000). Apart from the roles of PPARS in brain function and regulation 
of mast cell, recent reports stated that PPAR5 plays roles in epidermal differentiation 
(Bastie et al., 1999), uterine implantation (Lim et al., 1999) and colon cancer (He et aL, 
1999). 
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The recent development of a PPAR6-null mouse model in 2000 provides in vivo 
evidence to support the roles of PPAR5 in lipid metabolism, epidermal differentiation 
and brain development (Peters et al, 2000). However, additional studies on PPAR6-null 
mice are required in order to better understand the influence of PPAR6 in regulation of 
mast cell and colon cancer. 
2.7 Role of PPARa involved in peroxisome proliferator-induced pleiotropic 
responses 
2.7.1 Short-term effects 
Among the three isoforms of PPARs, PPARa was delineated the role in lipid 
metabolism and it is the essential mediator of peroxisome proliferator-induced pleiotropic 
responses included hepatomegaly and peroxisome proliferation. PPARa-null mice that 
lacking PPARa do not display the typical pleiotropic responses when challenged with the 
peroxisome proliferators, Wy-14,643 and clofibrate (Lee et al.’ 1995; Peters et al., 1997). 
Activities of different classes of enzymes are significantly induced after administration of 
peroxisome proliferators to rodents, whereas no such alteration of target genes 
transcriptions was observed in PPARa-null mice. However, the underlying molecular 
mechanisms by which PPARa mediates the peroxisome proliferator-induced short-term 
pleiotropic effects are not fully understood. 
2.7.2 Long-term effect 
The involvement of PPARa in peroxisome proliferator-induced long-term 
hepatocarcinogenesis was also supported by studies using PPARa-null mice. Chronic 
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administration of peroxisome proliferators, Wy-14,643, to rodents results in formation of 
hepatocarcinoma, whereas PPARa-null mice are refractory to peroxisome proliferator-
induced hepatocarcinogenesis (Peters et al., 1997). However, the underlying molecular 
mechanisms by which PPARa mediates the peroxisome proliferator-induced long-term 
hepatocarcinogenesis are still not fully explored. 
2.8 Mechanisms of peroxisome proliferator-induced hepatocarcinogenesis 
Several plausible mechanisms were proposed to explain the devebprnent of 
» 
hepatocarcinogenesis induced by peroxisome proliferators. 
2.8.1 Oxidative stress 
Peroxisome proliferation is associated with disproportionate increases in the 
activities of enzymes that produce and degrade hydrogen peroxide during fatty acid (3-
oxidation (Reddy and Lalwani, 1983; Lake, 1995). Peroxisome proliferators markedly 
induce the enzymes of the peroxisomal fatty acid P-oxidation cycle and these inductions 
are mediated by PAPRa, but produce only a small increase in catalase activity. The first 
enzyme of the P-oxidation cycle, acyl-CoA oxidase, produces hydrogen peroxide (Lake, 
1993 and 1995). Any excess hydrogen peroxide cannot be destroyed by peroxisomal 
catalase and then hydrogen peroxide diffuses through the peroxisomal membrane into the 
cytosol where it will be a substrate for cytosolic selenium-dependent glutathione 
peroxidase. However, this enzyme activity and other enzymes like superoxide dismutase 
and glutathione ^'-transferases are often reduced by the administration of peroxisome 
proliferators to rodents (Bentley et al., 1993; Lake, 1993 and 1995). These enzyme 




which may be either directly or via reactive oxygen species (e.g. hydroxyl radical), can 
attack membranes and DNA (Reddy and Lalwani, 1983). However, the magnitude of 
such effects does not correlate with the potency of the compound to produce tumors. 
T\ms, this sustained oxidative stress is unlikely to be solely responsible for peroxisome 
proliferator-induced hepatocarcinogenesis in rodent (Lake, 1995). 
2.8.2 Suppression of apoptosis 
Rodent hepatocarcinogenesis in response to peroxisome proliferators is preceded 
by peroxisome proliferation which is due to hepatocyte hypertrophy and an induction of 
cell proliferation. This cell induction coupled with a suppression of hepatocyte 
spontaneous or transforming growth factor pi (TGFpi)-induced apoptosis (Schulte-
Hermann et al., 1979; Moody et al., 1991; Roberts et al., 1996 and 1998). For, 
suppression of spontaneous apoptosis, in vitro study using exogenous tumor necrosis 
factor a (TNFa) suggested that TNFa has a role in mediating the liver growth response 
to peroxisome proliferators. TNFa can mimic the effects of peroxisome proliferators on 
hepatocyte apoptosis and it acts downstream of PPARa to mediate growth perturbation 
(Rolfe et al., 1997; Roberts et al., 2000). Moreover, the effects of the peroxisome 
proliferator, nafenopin, on hepatocyte apoptosis can be attenuated by neutralizing TNFa 
with antibodies (Rolfe et al., 1997; West et al., 1999). For TGFpi-induced apoptosis, 
TNFa activates TNFa receptor 1 (TNFRl) causing a new gene transcription through 
nuclear factor kappa beta (NF-KP) and through jun kinase (JNK) leading to increased 
API activity (Heller and Kronke, 1994; Taub, 1996; West et cd., 1999; Holden et al., 





death domain (FADD) which activates the apoptotic protease cascade (Kuenstle et aL, 
1997; Roberts et al., 2000). These results implicated that TNFa in mediating peroxisome 
proliferators-induced growth perturbation and liver enlargement that precedes 
hep妳 carcinogenesis. 
The major source of TNFa in the rodent liver is believed to be the Kupffer cell 
(Decker, 1990). Kupffer cells are hepatic macrophages, representing around 10% of the 
total cell population. Interestingly, Kupffer cells are required for stimulation of mitosis 
by peroxisome proliferators and they stimulate Kupffer cell phagocytosis (Rose et al, 
1997; Roberts and Kimber, 1999; Roberts et al., 2000). Moreover, NF-KP was activated 
first in Kupffer cells after peroxisome proliferators treatment (Rusyn et al., 1998) and 
Kupffer cell oxidant production is required for a response to peroxisome proliferators 
(Rose et al., 1999). 
2.8.3 Increased cell proliferation 
Cell proliferation is an important factor in the development of tumors by both 
genotoxic and nongenotoxic agents (Rajewsky, 1972; Ames and Gold, 1990; Cohen and 
Ellwein, 1990). An enhanced rate of cell replication can increase the frequency of 
spontaneous mutations and the probability of converting DNA adducts. Several studies 
demonstrated that non-mutagenic peroxisome proliferators cause cancer by altering the 
expression of a particular subset of genes that in turn affects the rate of cell proliferation. 
Administration of potent peroxisome proliferators (e.g. DEHP and Wy-14,643) to rat and 
mice resulted in increase of replicative DNA synthesis persistently (Marsman et al, 
1988). This replicative DNA synthesis involved the induction of growth regulatory genes 





1990; Ledwith et al,, 1993 and 1996; Peters et al., 1998; Vanden-Heuvel, 1999). All 
these genes inductions are mediated by PPARa and these genes are critical in the 
progression of the cell cycle, in particular the Gi to S transition. This indicated that 
peroxisome proliferator induced expression of growth regulatory genes precedes entry of 
the cell into S phase (Ledwith et aL, 1996). In Wy-14,643 hepatocellular adenomas, 
membrane-bound PKCa was increased, and membrane-bound PKCp and PKC5 were 
decreased in the tumors. These provided evidence that PKC isoforms in Wy-14,643 
induced tumors may be causally linked to the high rate of cell proliferation found in the 
Wy-14,643 (LaPorta et al,, 1997; Gorton et aL, 1999). Different genes involved in 
regulating cell cycle might be contributed to the development of carcinoma cell 
proliferation. 
In conclusion, identification of the whole spectrum of genes involved in peroxisome 
proliferator-induced hepatocarcinogenesis might help to understand the potential health 
risks associated with exposure to peroxisome proliferators in humans. 
2.9 Species difference to peroxisome proliferator-induced pleiotropic effects 
There are remarkable species differences in response to nongenotoxic peroxisome 
proliferators. Species such as guinea pigs and humans are considered to be 
nonresponsive to the adverse effects of peroxisome proliferators associated with 
increased p-oxidation and peroxisome proliferation (Lake et al., 1989; Bentley et al., 
1993; Ashby et al” 1994; Williams and Perrone, 1995). In guinea pigs, there is no 
increased DNA synthesis or liver enlargement and only a small increase in peroxisome 
proliferation and peroxisomal p-oxidation enzyme activity is weak (Lake et al., 1989). 




proliferators-dependent induction of peroxisomal p-oxidation enzyme activities or 
peroxisome proliferation. (Blaauboer et aL, 1990; Perrone et al” 1998), and peroxisome 
proliferators cannot induce DNA synthesis (Williams and Perrone, 1995) or suppress 
apoptosis (Hasmall et al, 1998). However, fibrate drugs do lower elevated plasma 
cholesterol levels by acting through genes such as apolipoprotein (Apo) A-I, -II, C-III 
and also lipoprotein lipase (LPL). This would be suggested that humans are responsive 
to the effects of peroxisome proliferators (Frick et al., 1987; Sher et al., 1993; Tugwood 
et al., 1998; Macdonald et al., 1999). 
It has been suggested that the lack of an adverse response to peroxisome 
proliferators in hepatocytes from nonresponsive species may be due to insufficient levels 
of PPARa. Previously report shown that human liver contains 10-fold lower levels of 
PPARa mRNA compared with the highly responsive mouse liver (Palmer et al., 1998). 
Despite the low levels of PPARa mRNA, humans are still able to mediate the beneficial 
effects of hypolipidemic drugs via regulation of genes for enzymes and lipid transporters. 
However, levels are too low for modulation of genes that are activated in rats and mice 
such as those involved in peroxisome proliferation and perturbation of hepatocyte growth 
control (Chevalier and Roberts, 1998; Roberts et al., 2000). 
Alternately, there may be a qualitative difference between species in response to 
peroxisome proliferators with respect to growth and peroxisome proliferation. It has 
been suggested that human hepatocytes may lack an activator or have an active repressor 
of PPARa function, or that target genes such as DNA synthesis, peroxisome proliferation 
contain altered or unresponsive PPRE sequences (Holden et al., 1999). For instance, the 
PPARa/RXR heterodimer can behave as either a positive or negative regulatory factor in 
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the same cell. The receptor can activate LPL by binding to its PPRE (Schoonjans et al., 
1996) and inhibit Apo C-III by displaying the positive regulator hepatocyte nuclear 
factor-4 (HNF-4) (Hertz et al., 1995). Therefore, PPARa/RXR could behave as either a 
positive or negative regulatory factor in the same cell. It depends on the structure of the 
gene promoters and the other proteins that interact with PPARa/RXR. In addition, 
PPARa/RXR has been shown to interact with the constitutive factors AP-1 (Sakai et al., 
1995) and SP-1 (Krey et al., 1995). Some of the factors potentially regulate the function 
of PPARa/RXR, either by protein-protein interactions or by competition- for DNA 
binding. In rodents, other transcription factors can modulate the effects of PPARa/RXR 
depending on the promoter context. The hepatic factors COUP-TFl and HNF-4 
recognize direct repeat elements very similar to PPREs and both can influence the 
regulation of acyl CoA oxidase (AGO) and bifunctional dehydrogenase/hydratase (BFE) 
(Chu et al., 1995; Woodyatt et aL, 1999). Recently, the thyroid hormone receptor TRa 
(Miyamoto et al., 1997) and the nuclear orphan receptor TAKl (Yan et al., 1998) have 
been shown to repress the activity of PPARa/RXR by competitive binding to a PPRE-
like element. Clearly, there are a number of proteins, including other nuclear receptors 
that are potent regulators of PPARa function in the liver resulting to qualitative 
difference in species. 
On the other hand, qualitative differences might exist within the PPARa gene 
itself. There are two published human liver PPARa sequences that are different from 
mouse PPARa. The first of these, called hPPARa8/14 is a truncated receptor that results 
from aberrant splicing of the PPARa mRNA. Exon 6 is deleted resulting in an mRNA 
transcript that lacks 203 bp. This splice defect brought a stop codon into frame resulting 
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in a receptor truncated at 174 amino acids rather than 409 (Tugwood et al., 1996). 
However, this truncated transcript was not found in rodent liver (Roberts, 2000). The 
second aberrant human PPARa was hPPARa6/29. This form ofhPPARa is a flill-length 
receptor that binds to DNA, but it cannot be activated by peroxisome proliferators 
(Roberts et al., 1998). Therefore, hPPARa6/29 can act as a dominant negative repressor 
of PPARa-mediated gene transcription. There are four amino acid substitutions in 
hPPARa6/29, two of which are key amino acid for conferring ability to bind to DNA in 
the absence of transcriptional activation by peroxisome proliferators (Myer et al., 1997; 
Roberts et al., 1998). As this dominant negative form of hPPARa6/29 is rare, the 
presence of hPPARa6/29 does not completely explain the lack of response of human 
hepatocytes to peroxisome proliferators (Palmer, 1998; Macdonald et aL, 1999; Roberts 
et al., 2000). 
It seems that no adverse effects of peroxisome proliferators had been documented 
in humans, but humans do respond to peroxisome proliferators by an alteration in 
expression of enzymes that regulate serum cholesterol and lipid homeostasis (Schoonjans 
et al., 1996). It was because we also have functional PPARa even the expression level is 
10-fold lower when compared with responsive species such as rat and mouse (Sher et al., 
1993; Tugwood et al., 1998). In addition, inter-individual variability in hPPARa 
sequences coupled with the inducibility of PPARa expression by peroxisome 
proliferators, glucocorticoids and nutritional factors suggested that there may be certain 
individuals who are at increased risk to exposure to these potentially carcinogenic 
substances (Tugwood et al” 1996; Robert et al.s, 1998). Therefore, even peroxisome 
proliferators may pose little risk to the population as a whole, the potential human 
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carcinogenicity of these chemicals cannot be ignored (Vanden-Heuvel, 1999). 
Understanding the molecular mechanism by which peroxisome proliferators induce 
hepatocarcinoma in rodent is important to increase our confidence in the judgment of 
human risk assessment. 
2.10 Fluorescent differential display (FDD) 
The identification of differentially expressed mRNAs has been used to determine 
not only gene function but also the underlying molecular mechanisms of a particular 
biological system. In the past, subtractive hybridization (Sambrook et al., 1989; Travis, 
1989 et al.; Watson and Margulies, 1996) and electronic subtraction (Adams et al” 1993； 
Ito et al., 1994; Murakawa et al., 1994; Franco et al., 1995;) were usually used to identify 
such differentially expressed genes. However, these methods gave incomplete recovery, 
and selected only for either under- or over-expressed genes and screening was laborious. 
In order to speed up these gene hunts, differential display (DD) was developed (Liang 
and Pardee, 1992). The advantage of this method is fast, simple, and sensitive. The most 
important reason is this method permits detection of genes whose expression level is 
upregulated and those that are downregulated. Furthermore, DD is also able to compare 
more than two RNA samples simultaneously and it is capable of identifying differentially 
expressed genes that are characteristic of a process instead of only a particular cell line 
(Liang and Pardee, 1992; Zhang et al., 1998). 
DD involves isolation of high-quality nondegraded RNA, selective reverse 
transcription of polyadenylated mRNA using specific anchored oligopolydeoxythymidine 
[oligo(dT)] primers, and the subsequent PCR amplification of the cDNA with the same 
oligo(dT), an arbitrary upstream primer and radioisotopes for labeling the PCR products. 
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The radioisotopically labeled products are then separated on a sequencing gel (Liang and 
Pardee，1992; Velculescu et al., 1995). However, there was a great hazard during 
handling and disposal of radioisotopes. Therefore, an alternative approach, fluorescent 
differential display (FDD), was developed to overcome the shortage of traditional 
isotopic DD (Bauer et al, 1993; Ito et al., 1994). 
In the FDD strategy, after first-strand cDNA synthesis with the anchored primers 
(APs) is completed, PGR amplification is preceded with the fluorescent tagged, 
tetramethylrodamine (TMR) version of the original AP in combination with a second， 
upstream or arbitrary primer (ARP). ARPs contain sequences which are designed to 
anneal at sites 5' or upstream of the AP annealing site, converting the first-strand cDNA 
into one or more truncated cDNA fragments (Figure 6). Since the fluorescent tag is 
present only on the APs, the fluoroDD-PCR bands most likely represent products 
generated from the poly(A+) mRNA and the signal intensity of the TMR-labeled band is 
more representative of the actual number of cDNA band. This overcame the problem in 
radioactive incorporation products that tend to give a stronger signal for longer cDNA 
products. The fluorescent-labeled PGR product was then resolved on polyacrylamide gel 
(Bauer et al., 1993; Ito et al., 1994). After gel electrophoresis, the fluoroDD gel was 




I First-strand cDNA synthesis (Reverse transcription) 
5 , ^ ^ ^ CCAAAAAAAAAAAAA (A) n 3 , mRNA 
. 4 — 3 ‘ GGTTTTTTTTTTTTCGGGATATCACTCAGCA 5 ' 
- Reverse transcriptase 箱 護 麵 糖 讓 
5 ' CCAAAAAAAAAAAAA (A) n 3 ' 
^ 3 ‘ GGTTTTTTTTTTTTCGGGATATCACTCAGCA 5 ' 
first-strand cDNA 
II Synthesis of double-strand cDNA fragment (DD-PCR) 
5 ‘ ACAATTTCACACAGGAXXXXXXXXXX 3 ' AJtP (26-nicr) 
> , - < 
3 ' GGTTTTTTTTTTTTCGGGATATCACTCAGCA*5' 
5 , ACAATTTCACACAGGAXXXXXXXXXX 3 , 
3‘GGTTTTTTTTTTTTCGGGATATCACTCAGCA*5‘ 
TMRoI igo(dT)AP 
5 ‘ ACAATTTCACACAGGAXXXXXXXXXX 3' ^ ^ - : ' . -
3 ' “ GGTTTTTTTTTTTTCGGGATATCACTCAGCA*5' 
5 ‘ ACAATTTCACACAGGAXXXXXXXXXX 3 , 
3 ‘ GGTTTTTTTTTTTTCGGGATATCACTCAGCA* 5 ‘ 
Figure 6. Schematic diagram to show the procedure of fluorescent differential display. 
(I), first-strand cDNA synthesis. (II), double-strand cDNA fragment (DD-PCR) 





CHAPTER 3: OBJECTIVES 
As humans always have chance exposed to different types of peroxisome 
proliferators in our daily life, it is necessary to investigate the molecular basis of the 
pleiotropic effects associated with peroxisome proliferator exposure in rodents. It is 
because understanding the mechanism of peroxisome proliferator-induced pleiotropic 
effects in rodents will be an integral step toward more accurately assessing the potential 
human health risks associated with exposure to peroxisome proliferators. 
Although previous studies using PPARa-null mice, mice lacking functional 
PPARa, demonstrated that PPARa mediates the pleiotropic effects of peroxisome 
proliferators, the underlying molecular mechanisms by which PPARa regulates the 
pleiotropic responses are still not well understood. Therefore, the aim of this study was 
to identify the PPARa-dependent genes involved in Wy-14,643, a potent peroxisome 
proliferator, induced short-term pleiotropic responses in the wild-type and PPARa-null 
mice by using the fluorescent differential display technique. 
At the same time, the temporal expression of isolated PPARa-dependent genes 
will be also investigated. With the temporal data, we can determine the early gene 
markers from short-term exposure to peroxisome proliferators for prediction of long-term 
development of hepatocarcinogenesis upon peroxisome proliferator exposure. 
As there is a remarkable tissue specificity of PAPRa, it is known that PPARa is 
highly expressed not only in liver, but also in kidney and heart. Therefore, we also want 
to investigate the role of PPARa in transcriptional regulation of the isolated genes after 




The objectives of this study are summarized as follow: 
1. To identify PPARa-dependent genes involved in Wy-14,643-induced short-term 
(2 weeks) pleiotropic responses in wild-type and PPARa-null mice by FDD RT-
- PGR technique. 
2. To study the temporal expression patterns (24 hours, 1 week, 2 weeks, 6 months 
and 11 months) of isolated Wy-14,643 responsive and PPARa-dependent genes 
in order to determine the early marker for prediction of long-term development of 
hepatocarcinogenesis. 
3. To examine the role of PPARa in transcriptional regulation of the isolated Wy-
14,643 responsive genes in kidney and heart. 
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CHAPTER 4: MATERIALS AND METHODS 
4.1 Animals and treatments 
：：, In order to determine the acute effect of Wy-14,643, a single high dose of Wy-
14,643 was given to both PPARa (+/+) and PPARa (- / - ) mice by gavage. The short-
term (1 and 2 weeks) and long-term (6 and 11 months) effects of Wy-14,643 were studied 
by feeding control or Wy-14,643 rodent diet to both PPARa (+/+) and PPARa (- /-) 
mice. 
4.1.1 Materials 
Wy-14,643 and methylcellulose compounds were purchased from Chemsyn 
Science Laboratories (Lenexa, KS, USA) and Sigma (St Louis, MO, USA) respectively. 
The pelleted mouse chow containing 0.0% (control) or 0.1% Wy-14,643 were tailor-
made by Bioserv Company (Frenchtown, NJ, USA). 
4.1.2 Methods 
Three months old male PPARa (+/+) and PPARa (- / - ) mice on SV129 
background were used for all experiments (Figure 7). Both PPARa (+/+) and PPARa 
(- / - ) male mice were the offspring of breeder mice obtained from National Cancer 
Institute, Bethesda, Maryland, USA in 1995. Two to three mice from both genotypes 
were housed per cage and provided with ozonated water ad libitum. Lighting was on a 
12 hours light and 12 hours dark cycle. 
Mice (5-10 per treatment group) were treated with the potent peroxisome 
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Figure 7. External morphology of three month old male PPARa (+/+) and PPARa (- / - ) 
mice. There was no external phenotypic difference between the PPARa (+/+) and 
PPARa (- / - ) mice. 
i 
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gavage or feeding (Table 4). For the feeding study, mice from both genotypes were fed 
either the 0.0% (control) or 0.1% Wy-14,643 rodent diet for 1 week, 2 weeks, 6 months 
and 11 months ad libitum. For the gavage study, mice were given a single gavage dose 
• 'V 
(50 mg/kg body weight) in 1% methylcellulose or vehicle control alone and sacrificed 24 
hours after treatment. At the end of the experiments, animals were weighed and killed by 
decaptiation. Blood was collected and serum was separated for triglyceride and 
cholesterol analyses. About 1 cm of mouse tail was excised from each mouse for 
confirmation of the genotype. Liver, kidney and heart were removed immediately, 
weighed, wrapped in aluminum foil, snapped frozen in liquid nitrogen and then stored in 
liquid nitrogen until further analysis. 
4.2 Serum triglyceride and cholesterol analyses 
Determination of triglyceride involves enzymatic or alkaline hydrolysis of 
triglyceride to glycerol and free fatty acids (Bucolo and David, 1973). The procedure 
described here is a modification of the method of McGowan et al in 1983. Triglycerides 
are hydrolyzed by lipase to glycerol and free fatty acids. The glycerol produced is then 
measured by coupled enzyme reactions catalyzed by glycerol kinase, glycerol phosphate 
oxidase and peroxidase. A quinoneimine dye is produced after several enzymatic 
reactions and shows an absorbance maximum at 540 nm (Trinder, 1969). 
The procedure for total serum cholesterol determination was based on a 
modification of the method described by Allain et al in 1974. Cholesterol esters are first 
hydrolyzed by cholesterol esterase to cholesterol. Then，cholesterol is oxidized by 
cholesterol oxidase to cholest-4-en-3-one and hydrogen hydroxide. The hydrogen 




Table 4. Allocation of PPARa (+/+) and PPARa ( - / - ) mice in 24 hours gavage dosage 
and 1 week, 2 weeks, 6 months and 11 months feeding studies. 
Gavage — Feeding — 
Gen� - 24 Hours 1 Week 2 Weeks 6 Months 11 Months 
type MC (50mg/kg) O.oo/o 0.1% 0.0% 0.1% 0.0% 0.1% 0.0% 0.1% 
(CTL) ij^io/oMC (CTL) WY (CTL) WY (CTL) WY (CTL) WY 
5 5 6 7 5 5 5 ‘ 5 10 10 
P 二 a 5 5 6 5 5 5 5 5 10 10 




hydroxybenzenesulfonate in the presence of peroxidase to yield a quinoneimine dye 
which has an absorbance maximum at 500 nm. The intensity of the color produced is 
directly proportional to the total cholesterol concentration in the sample (Witte et al, 
19-74). 
4.2.1 Materials 
Triglycerides (GPO-Trinder) and cholesterol (GPO-Trinder) determination 
enzyme kits were obtained from Sigma (St Louis, MO, USA). 
4.2.2 Methods 
4.2.2.1 Serum preparation 
Blood samples were collected from mice and allowed to clot for 30 min at room 
temperature. The clotted blood samples were then centrifuged at 2,400 rpm at room 
temperature for 15 min. The supernatant which containing the serum was transferred to 
new eppendorf and centrifuged again at 2,400 rpm for 10 min. After centrifugation, clear 
serum was transferred to new eppendorf and stored at -20�C. 
4.2.2.2 Triglyceride determination 
Triglyceride (GPO-Trinder) reagent was freshly reconstituted with 20 ml distilled 
water and warmed to 37°C. One milliliter of triglyceride (GPO-Trinder) reagent was 
pipetted into each reaction tube. Then, 10 |LI1 of distilled water, 250 mg/dL triglyceride 
standard, and serums from different mice were added to appropriate tubes acting as blank, 
standard and test samples respectively. Tubes were incubated at 37�C for 10 min. 
Absorbance (A) of blank, standard and test samples was read at 540 nm and recorded. 
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The concentration of serum triglyceride (mg/dL) was calculated as the following equation: 
[(Atest - Abiank)丨(Astandard _ Abiank)] X Concentration of standard (mg/dL) 
4.2.2.3 Cholesterol determination 
Cholesterol (GPO-Trinder) reagent was freshly reconstituted with 10 ml distilled 
water and warmed to 37°C. One milliliter of cholesterol (GPO-Trinder) reagent was 
pipetted into each reaction tube. Then, 10 )LI1 of distilled water, 200 mg/dL cholesterol 
standard，and serums from different mice were added to appropriate tubes acting as blank, 
standard and test samples respectively. Tubes were incubated at 37°C for 10 min. 
Absorbance (A) of blank, standard and test samples was read at 500nm and recorded. 
The concentration of serum cholesterol (mg/dL) was calculated as the following equation: 
[(Atest - Abiank)丨(Astandard" Abiank)] X Concentration of standard (mg/dL) 
4.3 Statistical analysis 
Data were presented as means 土 SD. The significance difference between the 
means of control- and Wy-14,643-treated PPARa (+/+) or PPARa ( - / - ) mice was 
determined by Independent t test that performed by SPSS, ver. 10.0 (SPSS Inc, USA). 
4.4 Tail-genotyping 
PCR method was applied to confirm the genotypes of PPARa (+/+) and PPARa 
( - / - ) mice. A pair of primers flanking the region between the PstI and SphI sites in exon 
8 of the ligand binding domain of the mouse PPARa gene (Issemann and Green, 1990) 
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Figure 8. A schematic representation of the PPARa (+/+) and PPARa (- / -) mice 
genomic organization and the strategy of PGR primer design. Exons 7 and 8 encoded the 
PPARa ligand binding domain. In PPARa (- / - ) mice, the 83 bp between PstI and SphI 
restriction enzyme sites in exon 8 was deleted and replaced it with a 1.14 kb neomycin 
gene fragment. The forward primer (FP) was designed before the PstI site while the 
backward primer (BP) was designed after the SphI site. The expected PGR fragments 





(Molecular Biology Insight, Inc., CO, USA), a 18-mer forward primer (5’ 
GCCTGGCCTTCTAAACAT 3') before the PstI site (1330-1347) and a 18-mer 
backward primer (5，ACTCGGTCTTCTTGATGA 3') after the SphI site (1503-1520) in 
exon 8 of the ligand binding domain of the mouse PPARa gene were designed for PGR 
reaction. In the PPARa (+/+) mice, the expected PGR fragment was 191 bp, whereas a 
longer PGR fragment (1248 bp) was expected for the PPARa ( - / - ) mice. This was due 
to the deletion of the 83 bp gene sequence between the PstI and SphI sites in exon 8 of 
• ligand binding domain and the replacement of a 1.14 kb neomycin fragment in 
PPARa ( - / - ) mice. 
4.4.1 Materials 
Trizma base, sodium chloride and ethidium bromide were purchased from Sigma 
(St Louis, MO, USA). Proteinase K was obtained from Boehringer Mannhem (Germany). 
EDTA was purchased from Riedel-de Haen (Seelze，Germany). Magnesium chloride, 
lOX PGR buffer and AmpliTaq® enzyme were obtained from Perkin Elmer (USA). 
Agarose, dNTP, 50 bp, 100 bp and 1 kb DNA markers were purchased from Life 
Technologies (USA). Oligonucleotides were synthesized from Life Technologies (USA). 
4.4.2 Methods 
4.4.2.1 Preparation of genomic tail DNA 
About 1 cm of mouse tail tip was excised from different groups of mice and 
incubated in 0.5 ml lysis buffer (0.1 M Tris-HCl, 5 mM EDTA, 0.2 % SDS, 0.2 M NaCl， 
100 | L i g / m l Proteinase K, pH 8.5) at 65°C with shaking for overnight (Laird et al” 1991). 
Tubes were centrifUged at 3,000 rpm for 10 min and supernatant was transferred to new 
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eppendorfs. After centrifugation at 12，000g for 10 min, supernatant was transferred to 
new eppendorfs containing 0.5 ml isopropanol and the tubes were shaken laterally in 
order to precipitate out DNA strands. Pipette tip was used to swirl up and transfer DNA 
strands to new eppendorfs. DNA pellet was dried in air and resuspended in 150 |LI1 TE 
buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 7.5). Tubes were then incubated at 50°C 
for overnight to enhance dissolution of DNA pellets. Figure 9 shows the overall steps for 
preparation of genomic tail DNA. 
4.4.2.2 PGR reaction 
For each PGR reaction，1 |il of 10-fold diluted genomic tail DNA was mixed with 
IX PGR buffer, 3.75 mM MgCl2, 50 ^M dNTP, 0.35 ^M forward primer, 0.35 _ 
backward primer and 0.05 units AmpliTaq® enzyme. PGR reaction was performed in a 
thermal cycler (Perkin Elmer Gene Amp 3600) and the thermal cycling profile was as 
follows: 95�C for 2 min, followed by 34 cycles of 92�C for 15 sec, 55�C for 30 sec, 72°C 
for 2 min, and followed by final extension at 72°C for 7 min and hold at 4°C. The PGR 
product was resolved on 1.5% agarose, 0.5X TBE gels. 
4.5 Total RNA isolation 
Isolation of total RNA is the first step of FDD RT-PCR analysis. The strategy of 
FDD RT-PCR analysis is illustrated in Figure 10. Liver RNA extracts obtained from 
PPARa (+/+) and PPARa (- / - ) mice treated with control or 0.1% Wy-14,643 rodent diet 
for 2 weeks were used for FDD RT-PCR analysis. Liver RNA samples obtained from 24 
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1 cm of mouse tail + 0.5 ml lysis buffer 
U Shake at 65°C overnight 
Centrifuge at 3,000g for 10 min 
^ Transfer supernatant to new eppendorf 
Centrifuge at 12,000g for 10 min 
J] Transfer supernatant to new eppendorf 
Add of 0.5ml isopropanol to each tube 
u 
Shake tubes laterally to precipitate DNA strands 
u 
Transfer DNA strands to new eppendorf 
U 
Dissolve DNA strands in 150|al TE buffer 
u 
Incubate tubes at 50°C for overnight 
u 
PCR reaction 
Figure 9. Flowchart showing the overall steps for preparation of genomic tail DNA. 
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Total RNA isolation 
-.•� 
- DNase I treatment 
• U 
Fluorescent RT-PCR 
Fluorescent differential display gel 
Differentially expressed bands were excised 
Reamplification by PGR 
Ji 
Subcloning and sequencing 
y 
Homology search against computer databases 
(Known genes, EST match, novel genes) 
Confirmation by Northern blot analysis 
Figure 10. Flowchart showing the overall strategy to identify differentially expressed 




hours, 1 week, 6 months and 11 months were used for temporal expression studies. RNA 
extracts from heart and kidney were used for tissue distribution studies. 
4.5:1 Materials 
Trizol reagent was purchased from Life Technologies (USA). 
Chloroform,ethanol and isopropanol were obtained from Merck (Whitehouse Station, NJ, 
USA). Nuclease free water was purchased from Promega (USA). 
4.5.2 Methods 
One milliliter of Trizol reagent was added to 0.1 g of tissue and mixed by tissue 
tearor (Dremel®, USA). A 0.2 ml of chloroform was added per 1 ml of Trizol reagent. 
The mixture was centrifuged at 12,000g for 15 min and the supernatant was transferred to 
a new tube. Then, 0.5 ml of isopropanol was added per 1 ml of Trizol reagent. RNA was 
precipitated for overnight at -80�C. The content was then centrifuged at 12,000g for 15 
min and the supernatant was discarded. The pellet was washed with 1 ml of 70% ethanol 
for three times. Pellet was air dried thoroughly and finally dissolved in nuclease free 
water. The RNA concentration of the extracts was determined from the absorbance at 
260 nm. Additionally, the purity of RNA was quantified by the ratio of 260 run to 280 
nm. 
4.6 DNase I treatment 
Trace amounts of contaminating DNA will be amplified during FDD RT-PCR 




DNase I digestion of the total RNA samples in order to remove genomic DNA 
contamination from the total RNA samples. 
4.6:1 Materials 
Sodium acetate and ethidium bromide were purchased from Sigma (St Louis, MO, 
USA). RNase-free DNase I and nuclease free water were obtained from Promega (USA). 
RNase inhibitor was purchased from Boehringer Mannhem (Germany). 
Phenolxhloroformrisoamyl alcohol (125:24:1, pH 4.7) and agarose were obtained from 
Life Technologies (USA). 
4.6.2 Methods 
Fifty micrograms of total RNA was incubated with IX DNase I buffer, 10 units 
RNase-free DNase I and 100 units RNase inhibitor at 37°C for 15 min. Fifty microliters 
of phenol: chloroform: isoamyl alcohol (125: 24: 1, pH 4.7) was added to the reaction 
tube and it was vortexed vigorously for 1 min. The aqueous phase was which containing 
the RNA separated from the organic phase by centrifuging the mixture at 15,000g for 5 
min. After centrifbgation, 50 |LII of 100% ethanol and 10 |LI1 of 3 M sodium acetate were 
added to precipitate the RNA at -80�C for overnight. The RNA pellet was then obtained 
by centrifuging the solution at 15,000g for 15 min, washed twice with 70% ethanol, air 
dried, and resuspended in 20 [d nuclease free water. The RNA concentration was 
determined from the absorbance at 260 nm. One microliter of the DNase I treated total 
RNA was resolved on 1% agarose, 0.5X TBE gel. Only the RNA without degradation 
was used for further analysis. 
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4.7 Reverse transcription of mRNA and fluorescent PCR amplification 
The first-strand cDNA synthesis was performed using the HIEROGLYPH kit. In 
this kit, there were 12 anchored primers (AP) for reverse transcription of mRNA (Table 
5), There were different two-base combinations on the upstream of the poly (A+) region 
which represents a considerable smaller subset of the mRNA pool rather that single-base 
permutations. Each respective two-base AP would encompass approximately one-twelfth 
of the mRNA pool constituency and would render approximately 800-1,200 different 
first-strand cDNAs. In addition, four arbitrary primers (ARP) were available in the kit 
for FDD-PCR reaction (Table 6). Particular long lengths of APs and ARPs primers allow 
for stringent annealing conditions and prevent mispriming, nonspecific products and false 
positives (Mou et al., 1994; Zhao et al., 1995). For the fluorescent PCR amplification, 
the other kit, fluoroDD kit was used. The fluoroDD kit contains twelve APs identical in 
DNA sequence to the HIEROGLYPH APs and 3'-end labeled with the fluorescent tag, 
tetramethylrodamine (TMR). Seven sets of AP and ARP primer combinations (AP2 & 
ARPl , AP4 & ARPl，AP4 & ARP2，APS & ARPl , APS & ARP2，AP9 & ARP3 and 
AP9 & ARP4) were used in my study. All FDD RT-PCR was generated in duplicate per 
sample to verify PCR reproducibility. To identify inter-animal variability, RNAs from 
two controls and two treated animals of both genotypes were used for the FDD RT-PCR 
analysis. On the other hand, negative RT-PCR (without reverse transcriptase) reaction 
was performed in order to test for genomic DNA contamination that can contribute 





Table 5. Sequence of anchored primers (AP) used for first-strand cDNA synthesis 
(Adapted from fluoroDD manual, Genomyx). 
� A P 1 5 ' ACGACTCACTATAGGGCTTTTTTTTTTTTGA 3 ' 
A P 2 5 ' ACGACTCACTATAGGGCTTTTTTTTTTTTGC 3 ' 
A P 3 5 ' ACGACTCACTATAGGGCTTTTTTTTTTTTGG 3 ' 
A P 4 5 ' ACGACTCACTATAGGGCTTTTTTTTTTTTGT 3 ' 
APS 5 ' ACGACTCACTATAGGGCTTTTTTTTTTTTCA 3 ' 
A P 6 5 ' ACGACTCACTATAGGGCTTTTTTTTTTTTCC 3 ' 
A P 7 5 ' ACGACTCACTATAGGGCTTTTTTTTTTTTCG 3 ' 
APS 5 ' ACGACTCACTATAGGGCTTTTTTTTTTTTAA 3 ' 
AP9 5 ' ACGACTCACTATAGGGCTTTTTTTTTTTTAC 3 ' 
APIO 5 ' ACGACTCACTATAGGGCTTTTTTTTTTTTAG 3 ' 
A P l l 5 ' ACGACTCACTATAGGGCTTTTTTTTTTTTAT 3 ' 
A P 1 2 5 ' ACGACTCACTATAGGGCTTTTTTTTTTTTCT 3 ' 
Note: The 17 nucleotides of the T7 promoter sequence are underlined and the two bases 
locate upstream are bolded. 
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Table 6. Sequence of arbitrary primers (ARP) used for FDD-PCR reaction (Adapted 
from fluoroDD manual, Genomyx). 
- , ‘ 
A R P 1 5 ' ACAATTTCACACAGGACGACTCCAAG 3 ' 
A R P 2 5 ' ACAATTTCACACAGGAGCTAGCATGG 3 ' 
A R P 3 5 ' ACAATTTCACACAGGAGACCATTGCA 3 ' 
A R P 4 5 ' ACAATTTCACACAGGAGCTAGCAGAC 3 ' 




HIEROGLYPH kit, dNTP mix (1:1:1) and fluoroDD kit 1 were obtained from 
Genomyx (USA). SuperScript II RT buffer, SuperScript II RT enzyme and DTT were 
purchased from Life Technologies (USA). 
—'V 
4.7.2 Methods 
DNase I treated total RNA (0.2 |Lig) were reverse-transcribed in the presence of 
0.2 [iU AP, IX superscript II RT buffer, 25 ^M dNTP mix (1:1:1)，10 mM DTT and 2 
units superscript II RT enzyme. For negative RT, reverse transcriptase was excluded 
from reaction mixture. Reverse transcription reaction was performed in a thermal cycler 
(Perkin Elmer GenAmp 9600). The condition of RT reaction was as follows: 42�C for 5 
min, 50°C for 50 min and followed by final extension at 70°C for 15 min and hold at 
4°C. After first-strand cDNA synthesis, 1 [i\ RT mixture was used for PGR reaction and 
mixed with IX PGR buffer, 3.75 mM M g C l � � 5 0 |LIM dNTP mix (1:1:1), 0.35 |aM 5'-
A R P , 0 .35 |LIM 3 , - T M R - A P and 0 .05 units AmpliTaq enzyme. P G R was performed in a 
thermal cycler (Perkin Elmer GeneAmp 9600) and the thermal cycling profile was as 
follows: 95°C for 2 min, followed by 4 cycles at 92�C for 15 sec, 50�C for 30 sec, and 
72°C for 2 min, followed by 30 cycles at 92�C for 15 sec, 60�C for 30 sec, and 72�C for 
2 min and followed by final extension at 72°C for 7 min and hold at 4°C. 
4.8 Fluorescent differential display (FDD) 
4.8.1 Materials 
TMR-molecular weight DNA standard marker, fluoroDD loading dye, 5.6% clear 





(USA). Ammonium persulfate and TEMED were purchased from Sigma (St Louis, MO, 
USA). 
4.8.2 Methods 
Following FDD RT-PCR, the TMR-labeled cDNA fragments were 
electrophoretically separated on a high resolution polyacrylamide gel under denaturing 
conditions. High resolution fluoroDD gel was prepared by mixing 70 ml of 5.6% clear 
denaturing HR-1000 gel with 400 of freshly prepared 10% ammonium persulfate and 
40 |Lil TEMED. The fluoroDD gel was allowed to polymerize for overnight at room 
temperature. Four microliters of each fluoroDD PGR product with 1.5 |LI1 of fluoroDD 
loading dye were denatured at 95°C for 2 min. The TMR-molecular weight marker was 
prepared in the same manner as the fluoroDD PGR samples. The lower and upper buffer 
chambers were filled with 250 ml of IX TBE buffer and 120 ml of 0.5X TBE buffer 
respectively. The TMR-labeled fluorescent PGR products and TMR-molecular weight 
marker were electrophoresed on a 5.6% denatured polyacrylamide gel at 3000 V, 100 W, 
50°C for 4.5 hours using a GenomyxLR^^ DNA electrophoresis system (Genomyx, USA) 
(Figure 11). After gel electrophoresis, the gel was dried in the same machine and the 
image was scanned in GenomyxSC™ fluorescent imaging scanner (Genomyx, USA) 
(Figure 12). 
4.9 Excision of differentially expressed cDNA fragments 
Only the Wy-14,643 responsive and PPARa-dependent differentially expressed 
cDNA fragments that showed consistent changes among four different treatment 
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Figure 11. GenomyxLR^^ DNA electrophoresis system (Genomyx, USA). A complete 
electrophoresis system possesses full programmability of all electrophoresis run 
parameters (temperature, voltage, wattage, gel temperature, and run-time). Following 
electrophoresis, gels are dried within the instrument, eliminating the requirement for gel 







Figure 12. GenomyxSC fluorescent imaging scanner (Genomyx, USA). The 
fluorescent-labeled PGR products are read and exported to the computer for data analysis 
(Adapted from fluoroDD catalogue, Genomyx). 
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groups were excised from the fluoroDD gels. Table 7 indicates the PPARa-dependent 
and Wy-14,643 responsive differentially expressed bands were excised from the 
fluoroDD gels for analysis. 
•--
4.9.1 Materials 
Sterile scalpel blades were purchased from Hecos (Shanghai, China). 
4.9.2 Methods 
A physical grid (Genomyx, USA) was used to locate the position of the interested 
bands and the Excision Workstation (Genomyx, USA) was used to hold the fluoroDD gel 
(Figure 13). The physical grid was placed down on the gel platform of the Excision 
Workstation for location of the interested gel bands. Gel slices were excised from the 
fluoroDD gels with sterile scalpel blades and transferred into an eppendorf containing 25 
|Lil TE buffer (10 mM Tris-HCl, 1 mM EDTA，pH 7.4). Tubes with different gel slices 
were incubated at 37°C for 1 hour in order to allow diffusion of DNA out of the gel slices. 
After gel band excision, the fluoroDD gels were re-scanned in order to check for the 
accuracy of band excision. 
4.10 Reamplification of differentially expressed fragments 
The excised differential display cDNA fragments were reamplified by PCR 
reaction with Ml3 reverse (-48) 24-mer (5，AGCGGATAACAATTTCACACAGGA 3’) 
and T7 promoter 22-mer (5' GTAATACGACTCACTATAGGGC 3') primers. Each of 
the ARP used in FDD RT-PCR incorporates a 16 nucleotides segment of the Ml 3 reverse 




Table 7. Possible gene expression patterns on fluoroDD gels. 
FDD Expression Pattern 
PPARa (+/+) PPARa ( - / - ) 
： Up- or Down- PPARa-
Control Wy-14,643 Control Wy-14，643 "egulated dependent 
一 + — — Up-regulated Yes 
+ +++ + + Up-regulated Yes 
+ — + + Down-regulated Yes 
++ + ++ ++ Down-regulated Yes 
— — — + Down-regulated Yes 
+ + + — Up-regulated Yes 
— + — + Up-regulated No 
+ — + — Down-regulated No 
The (+) indicated that the differential expressed gene was more intense than the other 
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Figure 13. Band Excision Workstation for fluorescent differential display. The physical 
grid is placed down on the gel platform of the excision workstation to locate the position 




end of the original transcript. Furthermore, each of the AP used in FDD RT-PCR 
incorporates a 17 nucleotides segment of the T7 promoter 22-mer priming sequence 
(Table 5) which allows directional sequencing from 3' end of the original transcript. The 
expected size of reamplified PCR product is 13 nucleotides longer than the size of 
fragments showed on fluoroDD gels because the Ml3 reverse primer was lengthened by 
8 nucleotides and the T7 promoter primer was lengthened by 5 nucleotides (Figure 14). 
4.10.1 Materials 
Trizma base and EDTA were purchased from Sigma (St Louis, MO, USA) and 
Riedel-de Haen (Seelze, Germany) respectively. Ml3 reverse (-48) 24-mer primer, T7 
promoter 22-mer primer and dNTP mix (1:1:1) were purchased from Genomyx (USA). 
Magnesium chloride, lOX PCR buffer and AmpliTaq® enzyme were obtained from 
Perkin Elmer (USA). Agarose and 100 bp DNA marker were purchased from Life 
Technologies (USA). Ethidium bromide was obtained from Sigma (St Louis, MO, USA). 
GenerulerTM 100 bp DNA marker and Generuler^'^ DNA marker mix were purchased 
from (Fermentas, USA). 
4.10.2 Methods 
About 4 gel band eluent was used for PCR reamplification and mixed with IX 
PCR buffer, 1.5 mM MgCh, 20 |LIM dNTP mix (1:1:1), 0.2 |LIMM13 reverse (-48) 24-mer 
primer, 0.2 jiiM T7 promoter 22-mer primer and 0.05 units AmpliTaq® enzyme. PCR was 
performed in a thermal cycler (Perkin Elmer GeneAmp 3600) and the thermal cycling 
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I. cDNA fragment excised from the gel • 
ARP 
5’ ACAATTTCACACAGGAXXXX J J 3’ 
3， f ! rTfim,�CGGGATATCACTCAGCA 5’ 
� AP 
- , -
II. Priming of M13 reverse (-48) 24-mer and T7 promoter 22-mer primers to cDNA fragments 
5，ACAATTTCACACAGGAXXXX J J 3, 
, , " 〜 ， - . , , 〜 - , 、 . 、 广 广 ， , 一 ， . 令 3, CGGGATATCACTCAGCATAATG 5, 
Ml3 reverse (-48) primer � ’ � ’ ’’’“… ^ ~ 
(8 nt longer than ARP) 丨；：•爾麵t 
丨 ： : • 哪 — 姆 
5’ AGCGGATAACAATTTCACACAGGA 3' 
3' f ^  GGmnCGGGATATCACTCAGCA 5， 
T 
5’ AGCGGATAACAATTTCACACAGGA ^ 3, 
令 3 ’ CGGGATATCACTCAGCATAATG 5 ’ 
5，AGCGGATAACAATTTCACACAGGA 3 ， ^ 
3， f - GGOVCGGGATATCACTCAGCATAATG 5’ 
Full-length M13 (-48) reverse sequence 
5' AGCGGATAACAATTTCACACAGGAXXXX ~ ~ f y 
3' f JL GGCHnCGGGATATCACTCAGCATAATG 5' 
� > " � � • > > � … < >'*> > > � 
Full-length T7 promoter ^equencef； 
Figure 14. Schematic diagram to show the cDNA fragment reamplification and priming site 
reconstruction using full-length Ml3 reverse (-48) 24-mer and T7 promoter 22-mer primers 
(Adapted from fluoroDD manuel, Genomyx). AP, anchored primer; ARP, arbitrary primer; 




profile was as follows: 95�C for 2 min, followed by 4 cycles at 92�C for 15 sec, 50�C for 
30 sec, and 72�C for 2 min, then followed by 25 cycles at 92�C for 15 sec, 60�C for 30 
sec, and 72�C for 2 min and followed by final extension at 72°C for 7 min and hold at 
-'V 
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4°C. Ten microliters of reamplified PGR product was resolved on 1% agarose, 0.5X 
TBE gel with ethidium bromide staining. 
4.11 Subcloning of reamplified cDNA fragments 
PCR-TRAP® and AdvaTAge™ PGR cloning systems were used for subcloning 
the reamplified cDNA fragments. Screening recombinant clones from PCR-TRAP® 
vector was performed by colony-PCR in the presence either Lgh & Rgh or T7 promoter 
& Ml3 (-48) primers. If Lgh and Rgh primers were used, the expected colony-PCR 
product is 124 nucleotides longer than the size of reamplified PGR products because the 
17-mer Lgh and 17-mer Rgh primers flanks before and after 45 nucleotides of the cloning 
site of PCR-TRAP® vector respectively. However, there was no change in length of 
colony-PCR product when T7 promoter and Ml 3 reverse (-48) primers were used for 
colony-PCR reaction. For screening recombinant clones from pT-Adv vector, it was 
achieved by alkaline lysis or microprep method and the inserts were isolated from 
plasmid DNA by EcoRI restriction enzyme digestion. The insert size was ten nucleotide 
longer than the reamplified PCRproducts because there are extra four nucleotides before 
and after cloning site in pT-Adv vector and two nucleotides left after EcoRI restriction 
enzyme digestion. 





PCR-TRAP® cloning kit was purchased from GenHunter® Corporation (USA). 
Bacto-typtone and yeast extract were obtained from Becton Dickinscon (USA). Sodium 
chloride and tetracycline were purchased from Sigma (St Lousis, MO, USA) and 
Boehringer Mannhem (Germany) respectively. 
4.11.1.2 Methods 
The reamplified PGR product was diluted two times in nuclease free water before 
being used in the ligation reaction. The ligation mixture was prepared by mixing 5 jul of 
diluted PGR product, IX ligation buffer, 300 ng Insert-ready PCR-TRAP® vector and 200 
units T4 DNA ligase. The ligation mixture was incubated at 16°C for overnight. After 
ligation reaction, 10 |LI1 of ligation mixture was incubated on ice with 100 jul GH-
competent cells for 45 min. Ligated vector was transformed into the cells by heat shock 
for 2 min at 42°C. Then, 400 of LB medium (1% Bacto-tryptone, 0.5% yeast extract, 
1% NaCl, pH 7.0) was added into the cells and it was shaken at 37°C for an hour at 225 
rpm in a rotary shaking incubator (Lab-Line, USA). After vortexing briefly, 100 and 200 
|Lil of transformed cells were spread on the LB agar plates containing 20 f^g/ml 
tetracycline. The plates were then incubated at 37°C inverted overnight. 
Screening for plasmids containing a DNA insert was performed by the colony-
PCR method in the presence of Lgh (5，CGACAACACCGATAATC 3，）and Rgh 
primers (5' CTGCGCTTGCTTCGTTG 3，）that flank the cloning site of the PCR-TRAP® 
vector. The partial restriction map of Insert-ready PCR-TRAP® vector is shown in Figure 




/ PCR-TRAP \ 
I {6.5 kb) j 
^ c| gene l e t “ > 
I I _ I _ I 
2 kb 280 bp 264 bp 
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义 Rgh Pr imer 
TCCATTCACTGGCTCGCGTCCAGTATGTACTAACAC 
AGGTAAGTGAcc;jgLQc^(M-^TAGATGATTGTG (The gap indicates the cloning site in cl gene) 
Figure 15. Partial restriction map of Insert-ready PCR-TRAP® vector (Adapted from 
PCR-TRAP® cloning system manual, GenHunter). 
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plate and transferred into eppendorfs containing 50 |LI1 colony lysis buffer obtained from 
the kit. The tubes were incubated at 95°C for 10 min in the thermocycler (MJ Research). 
Then，cell debris was pelleted by centrifugation at 12,000g for 2 min and the supernatant 
(colony lysate) was transferred into a new eppendorf for colony-PCR reaction. Two 
microliters colony lysate was mixed with IX PCR buffer, 1.5 mM MgCl� ,20 |LIM dNTPs， 
0.2 ILIM Lgh primer, 0.2 jaM Rgh primer and 0.05 units AmpliTaq® enzyme. PCR was 
performed in a thermal cycler (Perkin Elmer GeneAmp 3600) and the thermal cycling 
profile was as follows: 30 cycles at 94�C for 30 sec, 52°C for 40 sec, 72°C for 1 min, 
followed by final extension at 72°C for 7 min and hold at 4°C. Ten microliters of PCR 
products were resolved on a 1% agarose, TBE gel with ethidium bromide staining. 
Since colony-PCR was the only method to generate the insert from the 
recombinant clones, it is difficult to generate large amount insert for probe labeling in the 
following Northern blot analysis. Moreover, the efficiency of PCR-TRAP® cloning 
system is less than the other AdvaTAge^^ PCR cloning system. Therefore, the 
AdvaTAgeTM PCR cloning 
system was chosen to subclone the cDNA fragments 
subsequently. 
4.11.2 AdvaTAge™ PCR cloning system 
This cloning system allowed generating the inserts from recombinant clones by 
restriction enzymes digestion and large amount of inserts could be purified from 





AdvaTAge™ cloning kit was purchased from clontech (USA). Bacto-typtone and 
yeast extract were obtained from Becton Dickinscon (USA). X-Gal and isopropyl-P-D-
thiogalactoside (IPTG) were purchased from Boehringer Mannhem (Germany). 
Ampicillin, acetic acid, glucose, potassium acetate and sodium chloride were obtained 
from Sigma (St Louis, MO, USA). Agarose and phenol: chloroform: isoamyl alchohol 
(125:24:1, pH 4.7) were purchased from Life Technologies (USA). EDTA and SDS were 
obtained from Riedel-de Haen (Seelze, Germany). EcoRI buffer and EcoRI restriction 
enzyme were purchased from New England Biolabs (UK). -
4.11.2.2 Methods 
The reamplified PGR product was ligated with pT-Adv vector for a 1:1 molar 
ratio and generally, 1 [il of PGR product will give the proper vectoriinsert ratio of 1:1. 
Then, 1 |LI1 PGR product was mixed with IX ligation buffer, 50 ng pT-Adv vector and 4 
units T4 DNA ligase. The ligation reaction was incubated at 14�C overnight. Two 
microliters of 0.5 M P-mercaptoethanol was added to 50 TOPI OF' E. coli competent 
cells and then 2 |al ligation mixture was added to the cell mixture. Follow the incubation 
of cell mixture on ice for 30 min, ligated vector was transformed into TOPI OF，E. coli 
competent cells by heat shock for exactly 30 sec in the 42°C. Two hundred and fifty 
microliters of SOC medium (2% tryptone，0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 
10 mM MgCli, 10 mM MgSCU, 20 mM glucose) were added into the cell mixture and it 
was shaken at 37°C for an hour at 225 rpm in a rotary shaking incubator (Lab-Line, 
USA). Fifty and two hundred microliters of cell mixtures were spread on LB/X-




plates were then incubated at 37�C inverted for at least 18 hours. The partial restriction 
map and multiple cloning sites of pT-Adv vector are shown in Figure 16. 
Chloroform extraction method (Ohyama, 1997) was used for screening the 
recDinbinant clones. Twelve white or pale blue colonies were picked with sterile 
toothpicks from each plate and the bacteria were transferred into 15 ml culture tube 
containing 3 ml LB medium with 50 ^g/m\ of ampicillin. The bacteria were incubated at 
37°C for overnight at 225 rpm in a rotary shaking incubator (Lab-Line, USA). On the 
next day，20 |al phenol: chloroform: isoamyl alcohol (125:24:1, pH 4.7) was mixed with 
equal volume of bacterial culture by vortexing and then the mixture was centrifuged at 
12，000g for 1 min. Ten microliters of supernatant was separated on a 1% agarose, 0.5X 
TBE gel for screening the recombinant clones. If the DNA band was shifted up when 
comparing with the self-ligated clone, this indicated that this clone might have a DNA 
insert and the size of the insert was checked by either alkaline lysis or 'Microprep' 
methods (Shepard and Rae, 1998). 
For alkaline lysis method, 3 ml overnight bacterial culture was centrifuged at 
2,500 rpm at 4°C for 8 min. The pelleted bacteria was resuspended in 0.1 ml of solution I 
(50 mM glucose, 25 mM Tris-HCl, 10 mM EDTA, pH 8.0)，lysed with 0.2 ml solution II 
(0.2 M NaOH, 1% SDS) and neutralized with 0.15 ml solution III (30 mM potassium 
acetate, 11.5% acetic acid). The mixture was further purified by phenol/chloroform 
extraction and ethanol precipitation. The resulting plasmid DNA was resuspended with 
autoclaved distilled water. One microliter of isolated plasmid was mixed with IX EcoRI 
buffer and 1 |j,l of EcoRI restriction enzyme. After one hour incubation at 37°C, 10 jul of 
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CCCTATAGT6A6TC6TAnACAAnCACT66CCGTC6TTTTACAACGTCGTGACTGGGAAAAC 
T7 Promoter M13 Sequencing Primer M13 (-40) forward primer 
Figure 16. Restriction map and multiple cloning site of the pT-Adv vector (Adapted 
from AdvanTAge™ PCR cloning system manual, CLONTECH). 
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For the ‘Microprep’ method, bacterial cells from 500 overnight bacterial 
culture were pelleted by centrifUging 1 min in a microcentrifuge at 14，000g. The LB 
medium was completely removed and the bacterial pellet was resuspended in 19 [i\ 
autoclaved distilled water by vigorous vortex mixing. The plasmid DNA was liberated 
from the bacteria after boiling the tubes for 1 min. Bacterial debris was pelleted by 
centrifuging the tubes for 1 min at 14,000g. Five microliters of supernatant was 
transferred to new eppendorf containing premixed IX EcoRI buffer and 1 |il EcoRI 
restriction enzyme. After one hour incubation at 37°C, 10 [i\ of the restriction digest was 
resolved on a 1% agarose, 0.5X TBE gel with ethidium bromide staining. 
4.12 Purification of plasmid DNA from recombinant clones 
4.12.1 Materials 
Bacto-typtone and yeast extract were obtained from Becton Dickinscon (USA). 
• � Ivl 
Wizard Plus Minipreps DNA Purification System was purchased from Promega. 
EcoRI buffer and EcoRI enzyme were purchased from New England Biolabs (UK). 
4.12.2 Methods 
The WizardTM plus Minipreps DNA Purification System was applied to isolate 
plasmid DNA for sequencing reaction. Interested clones were picked and transferred to 5 
ml LB with 50 |ig/ml tetracycline or ampicillin according to the appropriate cloning 
systems. The bacterial cells were shaken at 37°C at 225 rpm in a rotary shaking 
incubator (Lab-Line, USA). After overnight incubation, bacteria was pelleted by 
centrifuging at 4°C at 2，500g for 8 min. The supernatant was poured off and the tube was 




resuspended in 300 |il of Cell Resuspension Solution and 300 |LI1 of Cell Lysis Solution 
was added to the cell resuspension. Then, 300 |LI1 of Neutralization Solution was added to 
the cell lysate. After neutralization of cell lysate, cell was pelleted by centrifuging the 
lysate at 12,000g for 15 min. The supernatant was transferred to a new eppendorf and 
mixed with 1 ml resuspended resin. For each miniprep, one Wizard^^ Minicolumn and 
one 3 ml disposable syringe were used. The syringe barrel was attached to the Luer-
Lok® extension of the Minicolumn. The mixture of resin was transferred to the barrel of 
the Minicolumn/syringe assembly and the syringe plunger was inserted. The slurry was 
gently pushed into the Minicolumn. The Minincolumn was washed with 2 ml of Column 
Wash Solution for twice. Ethanol residue in the Minicolumn was removed by 
centrifuging the Minicolumn at 10,000g for 2 min. For elution of plasmid DNA, 50 |LI1 of 
nuclease free water was applied in the Minicolumn and centrifuged at 10,000g for 20 sec. 
The concentration (ng/|Lil) of purified plasmid DNA was determined from the absorbance 
at 260 nm. 
4.13 DNA sequencing of differentially expressed cDNA fragments 
The sequencing reaction was based on CEQ 2000 Dye Terminator Cycle 
Sequencing system (Beckman, USA) and ABI PRISM™ dRhodamine Terminator Cycle 
Sequencing system (Perkin Elmer, USA). As Ml3 reverse (-48) 24-mer (5, 
AGCGGATAACAATTTCACACAGGA 3') and T7 promoter 22-mer primers (5' 
GTAATACGACTCACTATAGGGC 3，）were used for reamplification of differential 
expressed gene, these two primers were also used for cycle sequencing. In addition, for 
plasmid DNA subcloned in pT-Adv vector, Ml3 reverse (5' AAACAGCTATGACCATG 
3') or M13 sequencing primer (5’ GTAAAACGACGGCCAGT 3') was used for cycle 
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sequencing. For plasmid DNA subcloned in PCR-TRAP® vector, Lseq primer (5, 
ATCACGAGGCCCTTTCG 3') or Rseq primer (5’ CTATGACCTGCGCTCG 3,) was 
used for cycle sequencing. 
•,-
. -
4.13.1 CEQ 2000 Dye Terminator Cycle Sequencing system 
4.13.1.1 Materials 
CEQ 2000 terminator cycle sequencing kit was purchased from Beckman (USA). 
Formamide, lOO.mM NaiEDTA and 3 M sodium acetate were obtained from- Sigma (St 
Louis, MO, USA). Ethanol was purchased from Merck (Whitehouse Station, NJ, USA). 
Ml3 sequencing, Ml3 reverse, Lseq, and Rseq primers were synthesized from Life 
Technologies (USA). 
4.13.1.2 Methods 
In brief, the sequencing mixture included 75 fmol purified plasmid DNA template, 
IX sequencing reaction buffer, 2 jil dNTP mix, 2 |LI1 ddUTP dye terminator, 2 jul ddGTP 
dye terminator, 2 \i\ ddCTP dye terminator, 2 jil dd ATP dye terminator, 1 jiil units 
Polymerase enzyme and 3.2 pmol sequencing primer. The sequencing reaction was 
performed in a thermal cycler (Perkin Elmer GenAmp 9600) and the thermal cycle 
profile was as follows: 30 cycles at 96�C for 20 sec, 50�C for 20 sec, and 60�C for 4 min 
and hold at 4°C. Then, ethanol precipitation was applied to remove the excess dye 
terminators. Four microliters stop solution (1.5 M sodium acetate and 50 mM EDTA) 
and 20 glycogen were added to each sequencing reaction. For precipitation, 60 jiil of 
ice-cold 95% ethanol was added to the mixture and the tube was immediately centrifuged 




pellet was rinsed twice with 200 ice-cold 70% ethanol. For each rinse, the tube was 
centrifuged immediately at 14,000 rpm at 4°C for 15 min. After centrifugation, all of 
supernatant was carefully removed by a micropipette. The pellet was then dried under 
•� 
vacuum for 40 min and was resuspended in 40 |il deionized formamide. Deionized 
formamide was prepared by mixing 5 g of resin with 100 ml formamide completely for 
30 min. The resin and formamide mixture were filtered through a 0.2 jum Nylon filter 
and filtered formamide was stored at -20�C. The resuspended samples were transferred 
to the appropriate wells of the CEQ polypropylene sample plate from Beckman (USA). 
Each of the resuspended sample was overlaid with one drop of light mineral oil from 
Beckman (USA). The CEQ sample plate was then loaded into the CEQ capillary 
automatic sequencer (Beckman, USA) for automated sequencing. 
4.13.2 ABI PRISM™ dRhodamine Terminator Cycle Sequencing system 
4.13.2.1 Materials 
丁 ivi 
ABI PRISM dRhodamine terminator cycle sequencing ready reaction kit and 
magnesium chloride were purchased from Perkin Elmer (USA). Ethanol was obtained 
from Merck (Whitehouse Station, NJ, USA). M13 sequencing, M13 reverse, Lseq and 
Rseq primers were synthesized from Life Technologies (USA). 
4.13.2.2 Methods 
The cycle sequencing reaction mix was prepared which contained 8 |LI1 terminator 
ready reaction mix, 150 ng of plasmid DNA, 3.2 pmol sequencing primer. The 
sequencing reaction was performed in a thermal cycler (Perkin Elmer GenAmp 9600) and 
the thermal cycle profile was as follows: 25 cycles at 96°C for 10 sec, 50°C for 5 sec, and 
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60°C for 4 min and hold at 4°C. Then, ethanol precipitation was applied to remove the 
excess dye terminators. The entire contents of sequencing reaction mix were transferred 
into new eppendorf and mixed with 74 |il of 70% ethanol/0.5 mM MgCl�. The tube was 
left at room temperature for 15 min to precipitate the extension products. Then, the tube 
was centrifuged at 13,000 rpm at room temperature for 15 min. The supernatant was 
carefully removed by a micropipette and the pellet was dried in vacuum centrifuge for 3 
min. Dried pellet was resuspened in 12 [il template suppression reagent. The mixture 
was denatured at 95�C for 2 min and hold at 4°C. The resuspended samples were 
transferred to the vial and was then loaded into the ABI PRISM 377 DNA sequencer 
(Perkin Elmer, USA) for automated sequencing. 
4.13.3 Homology search against computer databases 
DNA sequences obtained were first edited and then submitted to the Basic Local 
Alignment Search Tool (BLAST) for searching the homology of sequences against the 
known genes or ESTs in the genebank databases (http://www.ncbi.nlm.nih.gov/cgi-
bin/BLAST/nph-newblast). 
4.14 Northern analysis of differentially expressed cDNA fragments 
The transcript size was estimated by DIG-labeled RNA molecular marker I 
because DIG-labeled RNA transcripts of the marker could be detected simultaneously 
with hybridized DIG-labeled probes during the immuodetection (see 4.14.4.2). In 
addition, RNA migrates through gel matrices at rates that are inversely proportional to 
logio of the number of base pairs (Helling et al., 1974). Therefore, a ruler was placed 
aside on the gel during gel photo taking after gel electrophoresis in order to estimate the 
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size of the transcripts with reference to the size of the 28S rRNA (4.7 kb) and 18S rRNA 
(1.9 kb). 
4,14.1 Formaldehyde gel electrophoresis of total RNA 
4.14.1.1 Materials 
Formaldehye, formamide, MOPS, ethidium bromide, sodium chloride and sodium 
citrate were obtained from Sigma (St Louis, MO, USA). Agarose and DIG-labeled RNA 
molecular marker I were purchased from Life Technologies (USA) and Boehringer 
Mannhem (Germany) respectively. A positively charged nylon membrane was obtained 
from Amershram (USA). 
4.14.1.2 Methods 
Total RNA (15 fig) samples from different treatment groups were mixed with 17 
|il loading buffer (10 |LI1 formamide, 2.2 M formaldehye, IX MOPS, 2 |LI1 loading dye and 
0.1 fil ethidium bromide). RNA mixture was denatured by heating at 68°C for 10 min 
and quick chilled on ice. The DIG-labeled RNA molecular weight marker I was prepared 
in the same manner as the RNA samples. RNA samples and DIG-labeled RNA 
molecular marker I were then separated on a 1% agarose gel containing IX MOPS and 
2.2 M formaldehyde, and fractionated by horizontal gel electrophoresis at 80V for 5 
hours. After electrophoretic fractionation, RNA was transferred to a positively charged 
nylon membrane in lOX SSC buffer by capillary transfer method for overnight. The 
membranes were baked for 2 hours at 80°C in order to fix RNA on the membranes. 
4.14.2 Preparation of cDNA probes for hybridization 
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PCR DIG probe synthesis and random primed DIG labeling systems were used 
for labeling the plasmid DNA from PCR-TRAP® and pT-Adv vectors respectively. 
4.1-4.2.1 PCR DIG labeling 
4.14.2.1.1 Materials 
PCR DIG Probe synthesis kit was purchased from Boehringer Mannhem 
(Germany), Agarose and ethidium bromide were obtained from Sigma (St Louis, MO, 
USA). 
4.14.2.1.2 Methods 
The DNA insert in PCR-TRAP® vector was directly amplified and labeled with 
DIG-dUTP with the PCR DIG Probe synthesis kit. Fifty nanograms of plasmid DNA 
was mixed with IX PCR buffer with MgCl� �200 [iM dNTP mix with DIG-dUTP, 0.2 |iM 
TXyf 
Lgh, 0.2 |iM Rgh and 2.6 units Expand HighFidelity enzyme. For control reaction, 
dNTP mix with DIG-dUTP was replaced by 200 |iM dNTP (1:1:1). The PCR reaction 
profile was the same as described in the FDD RT-PCR. All DIG-labeled PCR product 
was separated on a 1% agarose, 0.5X TBE gel and recovered from the agarose gel with 
Qiagen gel extraction kit (Qiagen，USA). The procedure of Qiagen gel extraction kit will 
be described in 4.14.3 later. As for Northern blot hybridization, 5 |LI1 of purified DIG-
labeled PCR product was used per 1 ml of DIG Easy Hyb solution. 





Random Prime DNA DIG Labeling kit and glycogen were obtained from 
Boehringer Mannhem (Germany). EcoRI buffer and EcoRI enzyme were purchased from 
New England Biolabs (UK). Lithium chloride and EDTA were obtained from Sigma (St 
Loms, MO, USA) and Riedel-del Haen (Seelze, Germany) respectively. Ethanol was 
purchased from Merck (Whitehouse Station, NJ, USA). 
4.14.2.2.2 Methods 
The DNA insert was isolated from the pT-Adv vector by EcoRI- restriction 
enzyme digestion. The restricted digest was purified with Qiagen gel extraction kit (see 
4.14.3) and the concentration of DNA insert was determined from the absorbance at 260 
nm. About 300 ng of DNA template was heat-denatured in a boiling water bath for 10 
min and it was chilled quickly on ice. Four microliters DIG-High Prime mix (random 
hexamers, 1 mM dATP，1 mM dCTP, 1 mM dGTP, 0.65 mM dTTP, 0.35 mM alkali-
labile-digoxigenin-11-dUTP, 1 unit/|Lil labeling-grade Klenow enzyme, 5X reaction 
buffer) was added to DNA template. The reaction tube was incubated at 37°C for at least 
20 hours. The labeling reaction was terminated by addition of 0.2 M EDTA. Labeled 
DNA was purified by ethanol precipitation in the presence of 4 M lithium chloride, 75 |il 
of 70% ethanol and 20 [ig glycogen. After precipitation for overnight, the pellet was 
rinsed twice with 70% ethanol and centrifuged at 12,000g for 15 min. The pellet was 
dissolved in 40 \i\ nuclease free water. The yield of DIG-labeled, newly synthesized 
DNA was roughly determined in comparison to a DIG-labeled control-DNA in a dot blot 
followed by direct immunodetection with the color development. An aliquot of the 
labeling reaction was diluted to a concentration of roughly 1 |Lig/ml. The DIG-labeled 
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control-DNA was diluted to a concentration of 1 |Lig/ml. The following dilution series of 
DIG-labeled control DNA and the labeled probe were prepared in DNA dilution buffer. 
~DIG-labeled 
control DNA, ^ . . 
diluted 1:5, S t e = s e d i l , n . 
111 DNA dilutioii + . Total dilution starting concentration 去 了. buffer concentration 
(1 股/ml) 
(A) 1 ng/^il 1 )Lil / 9 1^1 100 pg/|Lil 1:10 
(B) 100 pg/^il 1 III / 9 Ml 10 pg/^il i T l ^ 
(C) 10 pg/^il 1 |Lil / 9 |Lil 1 pg/^il 1:1,000 
(D) 1 pg/|jl 1 |Lil / 9 |Lil 0.1 pg/|Lil 1:10,000 
(E) 0.1 pg/|Lil 1 |Lil / 9 |Lil 0.01 pg/|Lil 1:100,000 
One microliter from a series of the dilutions ranging from 0.01 to 10 pg was 
spotted onto the positively charged nylon membrane. DNA was fixed on the nylon 
membrane by baking it for 2 hours and then immunodetection was performed as 
described later (see 4.14.4.2). The spot intensities of control and experimental dilutions 
were compared to estimate the concentration of the DIG-labeled probe DNA. For 
Northern blot hybridization, about 25 ng of DIG-labeled DNA was used per 1 ml of DIG 
Easy Hyb solution. 
4.14.3 Purification of DNA from agarose gel 
4.14.3.1 Materials 
Qiagen gel extraction kit and nuclease free water were purchased from Qiagen 
(USA) and Promega (USA) respectively. 
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4.14.3.2 Methods 
DNA was recovered from agarose gel with Qiagen gel extraction kit (Qiagen, 
USA). About 0.1 g of gel slice was dissolved in 300 |il QX 1 solution. Ten microliters 
of-QIAEXII was added to the gel mixture and incubated at 50°C for 10 min. After 
vigorous vortexing, the gel mixture was applied into Qiagen column and the column was 
centrifuged at 12，000g for 2 min. The column was washed with 0.5 ml QX 1 solution 
and centrifuged at 12,000g for 2 min. Then, the column was washed twice with 0.5 ml 
PE solution and centrifuged at 12,000g for 2 min. For elution of DNA, 30 [i\ of nuclease 
free water was added at the middle of the column. DNA was eluted by centrifugation at 
12,000g for 2 min. 
4.14.4 Hybridization 
4.14.4.1 Materials 
DIG Easy Hyb solution, blocking powder, polyclonal antibody against 
digoxigenin, nitroblue tetrazolium chloride (NBT) and 5-bromo-4-chloro-3-indolyl-
phosphate (BCIP) were purchased from Boehringer Maimhem (Germany). Maleic acid, 
sodium chloride, sodium citrate, trizma base, tween 20 and magnesium chloride were 
obtained from Sigma (St Louis, MO, USA). Dimethylformamide was purchased from 
Flukn (USA). 
4.14.4.2 Methods 
Pre-hybridization is necessary before performing hybridization. The nylon 
membrane was pre-hybridized at 42°C for 4 hours in 15 ml DIG Easy Hyb solution. Pre-




hybridization buffer. The nylon membrane was hybridized in 10 ml hybridization buffer 
at 42°C overnight. The following post-hybridization washes were performed: twice for 
15 min in 2X SSC/0.1% SDS at room temperature and twice for 15 min in O.IX 
SSC/0.1% SDS at 65°C. The membranes were then rinsed briefly with washing buffer 
containing 0.1 M maleic acid (pH 7.5)，0.15 M NaCl and 0.3% Tween 20. The 
membranes were blocked by incubation for 30 min at room temperature with blocking 
buffer [1% blocking reagent, 0.1 M maleic acid (pH 7.5), 0.15 M NaCl] and incubated for 
extra 30 min (at the same conditions as described above) with blocking buffer containing 
a polyclonal antibody against digoxigenin (Fab fragment conjugated to alkaline 
phosphatase diluted 1:20,000). After being washed twice for 15 min with washing buffer, 
the membranes were rinsed for 5 min with detection buffer (0.1 M Tris-HCl, 0.1 M NaCl, 
pH 9.5) and immersed in 40 ml staining solution [0.1 M Tris-HCl, 0.1 M NaCl, 50 mM 
MgCli, 200 1^1 NBT and 150 BCIP solutions (pH 9.5)] for color development in dark. 
After color development, the signal was purple in color and the image was captured by 
camera for record. 
In order to assess for RNA loading and transfer efficiency, membranes were 
stripped and reprobed with the mouse glyceraldehydes-3 -phosphate dehydrogenase 
(GAPDH) probe for normalization. Synthesis of mouse GAPDH probe will be described 
in subsequent section. Purple color precipitate on membranes was removed by 
incubating the membranes in 25 ml wanned dimethylformamide. After the purple color 
had been removed, the membranes were rinsed thoroughly in distilled water. Removal of 
probe was performed by incubating the membranes in 200 ml of 0.1% SDS for 15 min at 




buffer for 5 min at room temperature and the membranes were ready for hybridization 
with GAPDH probe. 
4.14.5 Synthesis of mouse GAPDH probe for normalization 
4.14.5.1 Materials 
superscript II RT buffer, SuperScript II enzyme, DTT, forward and backward 
primers were purchased from Life Technologies (USA). PGR buffer and AmpliTaq 
enzyme were obtained from Perkin Elmer (USA). AdvaTAge™ cloning kit was 
purchased from Clontech (USA). 
4.14.5.2 Methods 
Mouse GAPDH cDNA probe was generated by RT-PCR method according to the 
published sequence (Sabath et aL, 1990). The first-strand cDNA was synthesized by RT 
in the presence of 0.2 |LIM oligo dT primer, IX SuperScript II RT buffer, 25 jiiM dNTP, 
10 mM DTT and 2 units SuperScript II RT enzyme. Reverse transcription reaction was 
performed in a thermal cycler (Perkin Elmer GenAmp 9600). The condition of RT 
reaction was as follows: 42°C for 5 min, 50�C for 50 min and followed by final extension 
at 70°C for 15 min and hold at 4°C. 
After first-strand cDNA synthesis, double-strand DNA of mouse GAPDH was 
synthesized by PGR. The forward (5, TCCACTCACGGCAAATTCAACG 3') (191-212) 
and backward (5' TCCACCACCCTGTTGCTGTA 3') (992-1017) primers were 
designed according to the published mouse GAPDH cDNA sequence (Sabath et al., 
1990). The size of expected PGR product was 827 bp. One microliter of RT mixture was 





0.35 |aM forward primer, 0.35 |LIM backward primer and 0.05 units AmpliTaq enzyme. 
PCR was performed in a thermal cycler (Perkin Elmer GeneAmp 9600) and the thermal 
cycling profile was as follows: 94�C for 5 min, followed by 30 cycles at 94�C for 1 min, 
50°C for 1 min, 72°C for 2 min and followed by final extension at 72°C for 7 min and 
hold at 4°C. After the double-strand DNA synthesis, the PCR product was subcloned 
into pT-Adv vector for sequencing. The procedures of screening recombinant clones and 
sequencing of GAPDH were described as previously. The expected transcript size of 
mouse GAPDH was 1228 bp. After the GAPDH sequence was confirmed, tfie GAPDH 
DNA was labeled by Random Prime cDNA DIG labeling method. 
81 
V 
CHAPTER 5: RESULTS 
5.1 Liver morphology 
It was found that livers of Wy-14,643-treated PPARa (+/+) mice for 2 weeks 
(Figure 18), 6 months (Figure 19) and 11 months (Figure 20) were darker than those of 
the other three groups. However, no such color change was observed in livers of Wy-
14,643-treated PPARa (+/+) mice for 24 hours (data not shown) and 1 week (Figure 17). 
Moreover, there were grossly nodules observed in liver of Wy-14,643-treated PPARa 
(+/+) mice for 11 months, but no such nodules formation was observed in PPARa (- / - ) 
mice after treatment with 0.1% Wy-14,643 for 11 months. This data was in agreement 
with the results obtained by previous study (Peters et al, 1997) and indicating that 
PPARa is involved in Wy-14,643 induced long-term hepatocarcinogenesis. 
5.2 Liver weight 
It is well established that administration of peroxisome proliferators such as Wy-
14,643 to rodents results in liver enlargement (Reddy and Lalwani, 1983; Moody et al” 
1991). As expected, Wy-14,643 treatment produced a significant time-dependent 
increase in liver weight in PPARa (+/+) mice after treatment with rodent diet containing 
0.1% Wy-14,643 for 1 week (2.4-fold), 2 weeks (3.3-fold), 6 months (4.1-fold) and 11 
months (5.2-fold) (Figure 21). However, there was no significant increase in liver weight 
in PPARa (+/+) mice fed Wy-14,643 by gavage (50 mg/kg) for 24 hours (Figure 21). In 
contrast, treatment with Wy-14,643 for 24 hours, 1 week, 6 months and 11 months did 
not result in significant liver enlargement in the PPARa (-/-) mice. Slightly liver 
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PPARa (+/+) PPARa ( - / - ) 
I 1 I 1 
Control 0.1% Wy-14,643 Control 0.1% Wy-14,643 
Figure 17. Liver morphology of three months old male PPARa (+/+) and PPARa (- / - ) 
mice fed control or 0.1% Wy-14,643 rodent diet for 1 week. Significant liver 
enlargement was observed in the PPARa (+/+) mice fed 0.1% Wy-14,643 diet for 1 week 
as compared to their corresponding controls. No such liver enlargement was observed in 
PPARa ( - / - ) mice treated with neither control nor 0.1% Wy-14,643 rodent diet for 1 
week. 
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PPARa (+/+) PPARa (- / - ) 
〜 I I I 1 
• , -
Control 0.1% Wy-14,643 Control 0.1% Wy-14,643 
m ^ w m 
Figure 18. Liver morphology of three months old male PPARa (+/+) and PPARa (- / - ) 
mice fed control or 0.1% Wy-14,643 rodent diet for 2 weeks. Livers of 0.1% Wy-
14,643-treated PPARa (+/+) mouse group was darker than the other three treatment 
groups. Significant liver enlargement was observed in the PPARa (+/+) mice fed 0.1% 
Wy-14,643 diet for 2 weeks as compared to their corresponding controls. No such liver 
enlargement and color change were observed in PPARa (- / -) mice treated with neither 




PPARa (+/+) PPARa (- / -) 
I I I 1 
Control 0.1% Wy-14,643 Control — 0.1% Wy-14,643 
ITS 
W m m r n 
I . W m m 
Figure 19. Liver morphology of three months old male PPARa (+/+) and PPARa (- / -) 
mice fed control or 0.1% Wy-14,643 rodent diet for 6 months. Livers of 0.1% Wy-
14,643-treated PPARa (+/+) mouse group was darker than the other three treatment 
groups. Significant liver enlargement was observed in the PPARa (+/+) mouse fed 0.1% 
Wy-14,643 diet for 6 months as compared to their corresponding controls. No such liver 
enlargement and color change were observed in PPARa (- /-) mice treated with neither 





PPARa (+/+) PPARa ( - / - ) 
Control 0.1% Wy-14,643 Control 0.1% Wy-14,643 
Figure 20. Liver morphology of three months old male PPARa (+/+) and PPARa (- /-) 
mice fed control or 0.1% Wy-14,643 rodent diet for 11 months. Livers of 0.1% Wy-
14,643-treated PPARa (+/+) mouse group was darker than the other three treatment 
groups. Significant liver enlargement and grossly nodules were observed in the PPARa 
(+/+) mice fed 0.1% Wy-14,643 diet for 11 months as compared to their corresponding 
controls. No such liver enlargement, color change, and nodule formation were observed 
































































































































































































































































































































































































































































enlargement (1.2-fold) was observed in PPARa (- / - ) mice after treatment with Wy-
14,643 for two weeks, but this liver enlargement was not as obvious as that observed in 
Wy-14,643-treated PPARa (+/+) mouse liver. These data suggested that PPARa plays a 
major role in peroxisome proliferator-induced hepatomegaly. 
5.3 Serum triglyceride and cholesterol levels 
As humans are always prescribed to have hypolipidemic agent to decrease their 
plasma triglyceride and cholesterol levels in order to prevent vascular risks, the effect of 
Wy-14,643 treatment on the serum triglyceride and cholesterol levels in the PPARa (+/+) 
and PPARa ( - / - ) mice were determined. 
Figure 22 illustrated the effect of Wy-14,643 treatment on the serum triglyceride 
level in the PPARa (+/+) and PPARa (- / - ) mice treated at different time period. In 
comparison to the PPARa (+/+) mice treated with control diet, the serum triglyceride 
levels were significantly decreased in PPARa (+/+) mice after exposure to Wy-14,643 
for 24 hours (-41%), 1 week (-49%), 2 weeks (-33%), 6 months (-82%) and 11 months (-
76%). In contrast, there was no significant change in serum triglyceride level in Wy-
14,643-treated PPARa (- / - ) mice as compared to their corresponding controls. These 
data indicated that PPARa is required for the Wy-14,643 induced lowering of serum 
triglyceride level in the wild-type mice. 
The effect of Wy-14,643 treatment on the serum cholesterol level in the 
PPARa (+/+) and PPARa (- / -) mice was illustrated in Figure 23. There was no 
significant difference in the serum cholesterol level in PPARa (+/+) mice after treatment 















































































































































































































































































































































































































































































































































































































































































































































































































































the serum cholesterol level was observed in PPARa (+/+) mice after treatment with Wy-
14,643 for 6 months (1.18-fold) and 11 months (1.28-fold). On the contrary, there was 
no significant change in serum cholesterol level in the PPARa (- / - ) mice after treatment 
A^ dth Wy-14,643 for 24 hours, 6 months and 11 months. However, a significant decrease 
in the serum cholesterol level was determined in PPARa (- / - ) mice after treatment with 
Wy-14,643 for 1 week (-9%) and 2 weeks (-23%). 
5.4 Confirmation of genotypes 
Since there was no external phenotypic difference observed between the 
PPARa (+/+) and PPARa (- / - ) mice, PCR tail-genotyping was used to confirm the 
genotypes of the mice used in all experiments. The PCR products obtained from the 
PPARa (+/+) and PPARa (- / - ) mice were 191 and 1248 bp respectively (Figures 24-28). 
This was in agreement with the expected size for these genotypes. 
In order to eliminate the inter-individual differences, at least four mice per 
treatment group were used in all experiments. All of the PPARa (+/+) and PPARa (-/-) 
mice used for 24 hours gavage (Figure 24), 1 week (Figure 25), 2 weeks (Figure 26), 6 
months (Figure 27), and 11 months (Figure 28) feeding experiments were shown to have 
the correct genotypes. 
5.5 DNase I treatment 
Liver RNAs from PPARa (+/+) and PPARa (- /-) mice treated with control or 
0.1% Wy-14,643 for 2 weeks were used for FDD RT-PCR analysis. Trace amounts of 
contaminating DNA in liver RNA samples will be amplified and contribute false 




(A) P P A R a (+/+) 
CTL WY 
600 bp 
400 bp — 
200 bp — 
(B) P P A R a ( - / - ) 
CTL WY 
ioi8 bp z ^ ^ m m m j j i j m j f l m j ^ … . m s bp 
Figure 24. Tail-genotyping of PPARa (+/+) and PPARa (- / - ) mice used for 24 hours 
Wy-14,643 gavage treatment. The PGR products of PPARa (+/+) (panel A) and 
PPARa ( - / - ) (panel B) mice injected with control vehicle or 50 mg/kg Wy-14,643 
were loaded on 2% and 1% agarose, 0.5X TBE gels with ethidium bromide staining 
respectively. The expected PCR products from PPARa (+/+) and PPARa (- / - ) mice 
were 191 and 1248 bp respectively. 100 bp, 100 bp DNA marker; 1 kb, 1 kb DNA 




PPARa (+/+) PPARa ( - / - ) 
CTL CTL 
100 b p | I • " l l k b 
E ^ ^ ^ ^ ^ ^ ^ H f H i i ^ ^ H ^ ^ S ^ 1636 bp 
- 1248 bp 
506 bp 
� PPARa (+/+) PPARa ( - / - ) 
WY WY 
50 bp| I I I 100 bp ^ ^ ^ 
350 bp 
Figure 25. Tail-genotyping of PPARa (+/+) and PPARa (- / - ) mice used for 1 week 
Wy-14,643 feeding experiment. The PGR products of PPARa (+/+) and PPARa (- /-) 
mice treated with control (panel A) or 0.1% Wy-14,643 (panel B) were loaded on 2% 
agarose, 0.5X TBE gels with ethidium bromide staining. The expected PCR products 
from PPARa (+/+) and PPARa (- / -) mice were 191 and 1248 bp respectively. 50 bp, 
50 bp DNA marker; 100 bp, 100 bp DNA marker; 1 kb, 1 kb DNA marker; CTL, 
control group; WY, Wy-14,643 group. 
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Figure 26. Tail-genotypmg of PPARa (+/+) and PPARa (-/-) mice used for 2 weeks 
Wy-14,643 feeding experiment. The PGR products of PPARa (+/+) and PPARa 
(-/-) mice treated with control (panel A) or 0.1% Wy-14,643 (panel B) were loaded 
on 2% agarose, 0.5X TBE gels with ethidium bromide staining. The expected PGR 
products from PPARa (+/+) and PPARa (-/-) mice were 191 and 1248 bp 
respectively. 50 bp, 50 bp DNA marker; 100 bp，100 bpDNA marker; Ikb, Ikb DNA 
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Figure 27. Tail-genotyping of PPARa (+/+) and PPARa (- / - ) mice used for 6 
months Wy-14,643 feeding experiment. The PGR products of PPARa (+/+) and 
PPARa ( - / - ) mice treated with control (panel A) or 0.1% Wy-14,643 (panel B) were 
loaded on 2% agarose, 0.5X TBE gels with ethidium bromide staining. The expected 
PGR products from PPARa (+/+) and PPARa (- /-) mice were 191 and 1248 bp 
respectively. 100 bp, 100 bp DNA marker; Ikb, DNA marker; CTL, control group; 




(A) P P A R a (+/+) 
100 CTL WY 
bp f " 7 7 ~ 7 ~ ~ " i r — I 
(B) P P A R a ( - / - ) 
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•
Ikb I “ I 
f ； ^ ^ ^ ^ ^ ^ 
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Figure 28. Tail-genotyping of PPARa (+/+) and PPARa (- /-) mice used for 11 
months Wy-14,643 feeding experiment. The PCR products of PPARa (+/+) (panel A) 
and PPARa (-/-) (panel B) mice treated with control or 0.1% Wy-14,643 were loaded 
on 2% and 1% agarose, 0.5X TBE gels with ethidium bromide staining respectively. 
The expected PCR products from PPARa (+/+) and PPARa (-/-) mice were 191 and 
1248 bp respectively. 100 bp, 100 bp DNA marker; 1 kb, 1 kb DNA marker; CTL, 
control group; WY, Wy-14,643 group. 
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PPARa (+/+) PPARa (-/-) 
Control Wy-14,643 Control Wy-14,643 
n n n m n i n i i i i g ^ ^ i i i ^ i i g i i i i i i i ^ i i i ^ 5s 
Figure 29. Electrophoretic separation (1% agarose, 0.5X TBE gel) of the total 
liver RNA after DNase I treatment with ethidium bromide staining. For each 
sample, approximately 10 |ig of total RNA was loaded per lane. No obvious 
degradation of RNA was observed in the liver RNA samples after DNase I 
treatment. Two of the high quality RNA samples per each treatment group were 
chosen for the FDD RT-PCR analysis. 
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R N A was observed in the liver R N A samples after DNase I treatment. The ratio of 
OD260 to OD280 in the liver R N A samples was greater than 1.8. These high quality liver 
R N A samples were subjected to the F D D RT-PCR analysis. 
5.6 FDD RT-PCR and band excision 
Fluorescent differential display was applied to search for PPARa-dependent 
differential expressed genes involving in Wy-14,643-induced short-term pleiotropic 
responses. Seven pairs of AP and A R P in different combinations (AP2 & ARPl, AP4 & 
ARPl, AP4 & ARP2，APS & ARPl, APS & ARP2，AP9 & ARP3 and AP9 & ARP4) 
were used to screen for the differentially expressed genes. Four fluoroDD gels were run 
and a total of fifty PPARa-dependent and Wy-14,643 responsive c D N A fragments were 
excised from the gels. 
The TMR-labeled fluorescent P C R products from AP2 & ARPl (Gel B) were 
illustrated in Figure 30. Fourteen PPARa-dependent and Wy-14,643 responsive cDNA 
fragments (B1-B14) were excised from Gel B (Table 8). Among them, six cDNA 
fragments (B2，B5, B9, Bll, B13 and B14) were up-regulated while eight cDNA 
fragments (Bl, B3, B4, B6, B7, B8, BIO and B12) were down-regulated in PPARa (+/+) 
mice after treatment with Wy-14,643 for two weeks. In contrast, the expression patterns 
of these fourteen c D N A fragments were not altered in PPARa (-/-) mice receiving the 
same treatment indicating that PPARa mediates the transcriptional regulation of these 
c D N A fragments upon short-term Wy-14,643 treatment. 
Figures 31 and 32 illustrated the TMR-labeled fluorescent PCR products obtained 
from APS & ARPl (Gel F, part 1) and APS & ARP2 (Gel F, part 2) respectively. Nine 
PPARa-dependent and Wy-14,643 responsive c D N A fragments (F1-F9) were excised 
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Figure 30. Gel B: Fluorescent differential display of liver RNAs from PPARa (+/+) and 
PPARa (-/-) mice treated with control (CTL) or 0.1% Wy-14,643 (WY) diet for 2 weeks. 
Total R N A was reverse transcribed using the AP2 primer. PCR reactions were 
performed in duplicate for each mouse in the presence of 3'-TMR-labeled AP2 and 5'-
ARPl primers. The TMR-labeled fluorescent PCR products were run on a 5.6% 
denaturing polyacrylamide gel. Each lane represents one PCR reaction. A total of 2 
mice (i.e. 4 PCR reactions) were used for each treatment group. Arrows indicate the 
fragments were excised from the gel for reamplification. M , TMR-labeled molecular 
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Figure 31. Gel F (part 1): Fluorescent differential display of liver RNAs from PPARa 
(+/+) and PPARa (-/-) mice treated with control (CTL) or 0.1% Wy-14,643 (WY) diet 
for 2 weeks. Total R N A was reverse transcribed using the APS primer. PCR reactions 
were performed in duplicate for each mouse in the presence of 3'-TMR-labeled APS and 
5'-ARPl primers. The TMR-labeled fluorescent PCR products were run on a 5.6% 
denaturing polyacrylamide gel. Each lane represents one PCR reaction. A total of 2 
mice (i.e. 4 P C R reactions) were used for each treatment group. Arrows indicate the 
fragments were excised from the gel for reamplification. M，TMR-labeled molecular 
weight D N A marker. 
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Figure 32. Gel F (part 2): Fluorescent differential display of liver RNAs from PPARa 
(+/+) and PPARa (-/-) mice treated with control (CTL) or 0.1% Wy-14,643 (WY) diet 
for 2 weeks. Total R N A was reverse transcribed using the APS primer. PCR reactions 
were performed in duplicate for each mouse in the presence of 3,-TMR-labeled APS and 
5'-ARP2 primers. The TMR-labeled fluorescent PCR products were run on a 5.6% 
denaturing polyacrylamide gel. Each lane represents one PCR reaction. A total of 2 
mice (i.e. 4 PCR reactions) were used for each treatment group. Arrows indicate the 
fragments were excised from the gel for reamplification. M，TMR-labeled molecular 




from Gel F (Table 9). Among them, six cDNA fragments (Fl, ¥2, F3, F4, F5 and F9) 
were up-regulated while three cDNA fragments (F6, F7 and F8) were down-regulated in 
PPARa (+/+) mice after treatment with Wy-14,643 for two weeks. In contrast, the 
expression patterns of these nine cDNA fragments were not altered in PPARa (-/-) mice 
receiving the same treatment indicating that PPARa mediates the transcriptional 
regulation of these cDNA fragments upon short-term Wy-14,643 treatment. 
The TMR-labeled fluorescent PGR products from AP9 & ARP3 (Gel H, part 1) 
and AP9 & ARP4 (Gel H, part 2) were illustrated in Figures 33 and 34 respectively. 
Fourteen PPARa-dependent and Wy-14,643 responsive cDNA fragments (HI-HI4) were 
excised from Gel H (Table 10). Among them, ten cDNA fragments (HI, H2, H3, H4, H6, 
H7, H8, H9, HIO and Hll) were up-regulated while four cDNA fragments (H5, H12， 
HI3 and HI4) were down-regulated in PPARa (+/+) mice after treatment with Wy-
14,643 for two weeks. In contrast, the expression patterns of these fourteen cDNA 
fragments were not altered in PPARa (-/-) mice receiving the same treatment indicating 
that PPARa mediates the transcriptional regulation of these cDNA fragments upon short-
term Wy-14,643 treatment. 
Figures 35 and 36 illustrated the TMR-labeled fluorescent PGR products obtained 
from AP4 & ARPl (Gel J, part 1) and AP4 & ARP2 (Gel J，part 2) respectively. Thirteen 
PPARa-dependent and Wy-14,643 responsive cDNA fragments (J1-J13) were excised 
from Gel F (Table 11). Among them, eight cDNA fragments (Jl, J5, J7, J8, J9, JIO, Jl 1 
and J12) were up-regulated while five cDNA fragments (J2，J3, J4, J6 and J13) were 
down-regulated in PPARa (+/+) mice after treatment with Wy-14,643 for two weeks. In 
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Figure 33. Gel H (part 1): Fluorescent differential display of liver RNAs from PPARa 
(+/+) and PPARa (-/-) mice treated with control (CTL) or 0.1% Wy-14,643 (WY) diet 
for 2 weeks. Total R N A was reverse transcribed using the AP9 primer. PCR reactions 
were performed in duplicate for each mouse in the presence of 3'-TMR-labeled AP9 and 
5’-ARP3 primers. The TMR-labeled fluorescent PCR products were run on a 5.6% 
denaturing polyacrylamide gel. Each lane represents one PCR reaction. A total of 2 
mice (i.e. 4 PCR reactions) were used for each treatment group. Arrows indicate the 
fragments were excised from the gel for reamplification. M , TMR-labeled molecular 
weight D N A marker. 
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Figure 34. Gel H (part 2): Fluorescent differential display of liver RNAs from PPARa 
(+/+) and PPARa (-/-) mice treated with control (CTL) or 0.1% Wy-14,643 (WY) diet 
for 2 weeks. Total R N A was reverse transcribed using the AP9 primer. PGR reactions 
were performed in duplicate for each mouse in the presence of 3’-TMR-labeled AP9 and 
5'-ARP4 primers. The TMR-labeled fluorescent PGR products were run on a 5.6% 
denaturing polyacrylamide gel. Each lane represents one PGR reaction. A total of 2 
mice (i.e. 4 PGR reactions) were used for each treatment group. Arrows indicate the 
fragments were excised from the gel for reamplification. M , TMR-labeled molecular 
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Figure 35. Gel J (part 1): Fluorescent differential display of liver RNAs from PPARa 
(+/+) and PPARa (-/-) mice treated with control (CTL) or 0.1% Wy-14,643 (WY) diet 
for 2 weeks. Total R N A was reverse transcribed using the AP4 primer. PGR reactions 
were performed in duplicate for each mouse in the presence of 3'-TMR-labeled AP4 and 
5'-ARPl primers. The TMR-labeled fluorescent PGR products were run on a 5.6% 
denaturing polyacrylamide gel. Each lane represents one PGR reaction. A total of 2 
mice (i.e. 4 PGR reactions) were used for each treatment group. Arrows indicate the 
fragments were excised from the gel for reamplification. M , TMR-labeled molecular 
weight D N A marker. 
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Figure 36. Gel J (part 2): Fluorescent differential display of liver RNAs from PPARa 
(+/+) and PPARa (-/-) mice treated with control (CTL) or 0.1% Wy-14,643 (WY) diet 
for 2 weeks. Total R N A was reverse transcribed using the AP4 primer. PCR reactions 
were performed in duplicate for each mouse in the presence of 3,-TMR-labeled AP4 and 
5'-ARP2 primers. The TMR-labeled fluorescent PCR products were run on a 5.6% 
denaturing polyacrylamide gel. Each lane represents one PCR reaction. A total of 2 
mice (i.e. 4 PCR reactions) were used for each treatment group. Arrows indicate the 
fragments were excised from the gel for reamplification. M , TMR-labeled molecular 

















































































































































































































































































































































































































































































































































































































PPARa (-/-) mice receiving the same treatment indicating that PPARa mediates the 
transcriptional regulation of these c D N A fragments upon short-term Wy-14,643 
treatment. 
- 'V 
5.7 Reamplification of excised cDNA fragments 
All of the fifty PPARa-dependent and Wy-14,643 responsive c D N A fragments 
excised from the fluoroDD gels were tried for PGR reamplification in the presence of 
Ml3 reverse (-48) 24 mer and T7 promoter 22-mer primers. Several rounds of PGR 
reamplification were performed on each excised c D N A fragment in order to obtain 
enough material for subsequent subcloning. As discussed earlier in section 4.10, the 
reamplified P G R products were expected to have 13 nucleotides longer than the size of 
the fragments estimated from the fluoroDD gels. 
Figure 37 illustrated the PGR products reamplified from the excised c D N A 
fragments from Gel B. All of the fourteen fragments excised from Gel B were 
successfully reamplified and more or less agreed with the expected fragment sizes (Table : 
il 
III! 
12). However, there were a few other faint bands reamplified in fragments B4, B5 and 
B8. These faint bands could be artifacts generated during reamplification. Alternatively, 
these extra minor bands might be due to the reamplification of neighboring bands 
comigrated on the fluoroDD gel. 
All of the nine cDNA fragments excised from Gel F were tried for PGR 
reamplification (Figure 38). Among them, only six cDNA fragments (Fl，F2, F5, F7, F8 
and F9) were successfully reamplified and more or less agreed with the expected 
fragment sizes (Table 13). The other two fragments (F3 and F6) were successfully 
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Figure 37. Reamplification of cDNA fragments excised from Gel B. The cDNA 
fragments were excised from the fluoroDD gel, eluted in TE buffer and amplified by 
PGR using Ml3 reverse (-48) and T7 promoter primers. The PGR products were loaded 
on 2% agarose, 0.5X TBE gels with ethidium bromide staining. 100 bp, 100 bp D N A 
marker. 
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Figure 38. Reamplification of cDNA fragments excised from Gel F. The cDNA 
fragments were excised from the fluoroDD gel, eluted in TE buffer and amplified by 
PCR using Ml3 reverse (-48) and T7 promoter primers. The PCR products were loaded 


























































































































































































































































































































































































































































































































































































































could not be reamplified and this might be due to the inadequate amount ofcDNA eluted 
out from the gel slices for the PCR reamplification. 
Figure 39 illustrated the PCR products reamplifed from the fourteen excised 
cDNA fragments from Gel H. Among them, only ten cDNA fragments (HI, H3，H4, H5, 
H6，H7, H8, H9, Hll 油d H12) were successfully ramplified and more or less agreed 
with the expected fragment sizes (Table 14). However, there were a few other faint 
bands showed up on the reamplified PCR products from fragments HI, H2, H5 and H7. 
Ill 
I i 
These might be. due to the reamplification of neighboring bands comigrated Qn the 
fluoroDD gel. Alternatively, these extra minor bands could be due to artifacts generated 
during reamplificaiton. One cDNA fragment (HI4) could not be reamplified and this 
might be due to the inadequate amount of cDNA eluted out from the gel slices for the 
PCR reamplification. The other three cDNA fragments (H2, HIO and HI3) were 
successfully reamplified but with the wrong fragment sizes. 
All of the thirteen cDNA fragments excised from Gel J were tried for PCR 
！'' 
reamplification (Figure 40). Among them, twelve (J2-J13) cDNA fragments were i 
li' 
III" 
successfully reamplified and more or less agreed with the expected fragment sizes (Table 
15). However, there were a few faint bands showed up on the reamplified PCR products 
from fragments (J2, J3, J5, J6 and J7). These might be due to the reamplification of 
neighboring bands comigrated on the fluoroDD gel. Alternatively, these extra minor 
bands could be due to artifacts generated during reamplification. Only one (Jl) cDNA 
fragment failed to reamplify and this could be due to inadequate cDNA eluted out from 
gel slices for PCR reamplification. 
In conclusion, only forty-two excised cDNA fragments (84%) were successfully 
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Figure 39. Reamplification of cDNA fragments excised from Gel H. The cDNA 
fragments were excised from the fluoroDD gel, eluted in TE buffer and amplified by 
PCR using Ml3 reverse (-48) and T7 promoter primers. The PGR products were loaded 














































































































































































































































































































































































































































































































































































































































































































































L M J1 J2 J3 J4 J5 J6 J7 J8 J9 JIO Jll J12 J13Mix 
-、 l l l ^ ^ ^ j f f B l f f W M l i i — — — 
— • b p 
1000 bp 一 ~ n ^ y m n u m ^ i ^ m ^ ^ ^ ^ ‘ ~ 一 io3i bp 
800 bp — • l ^ ^ . j ^ ^ W B f c a l B i E U i i i i J — 800 bp 
600 bp 600 bp 
400 bp 400 bp 
200 bp _ M S i i i l i l M i l i M l i l i i l l M I B H I H M I ^ B B B 
I H H i i i P W — ^ ― 4 ~ 200 bp 
H k H U H ^ H 
Figure 40. Reamplification of cDNA fragments excised from Gel J. The cDNA 
fragments were excised from the fluoroDD gel, eluted in TE buffer and amplified by 
:ti 
PCR using Ml3 reverse (-48) and T7 promoter primers. The PCR products were loaded 
on a 2% agarose, 0.5X TBE gel with ethidium bromide staining. L M , Generuler™ 100 






















































































































































































































































































































































































































































































































































































































































































c D N A fragments were successfully reamplified but with the wrong fragment sizes. 
Three excised c D N A fragments could not be reamplified and this might be due to the 
inadequate amount of D N A eluted out from the excised gel slices for PCR 
re^plification. 
5.8 Subcloning of reamplified cDNA fragments 
PCR-TRAP® and AdvaTAge cloning systems were used to subclone the 
reamplified c D N A fragments. After subcloning, high quality plasmid DNA-from each 
recombinant clone was prepared using Wizard™ Plus Minipreps D N A purification 
system. Then the size of D N A inserts was checked by colony-PCR or EcoRI restriction 
enzyme digestion for recombinant clones subcloned in PCR-TRAP® or pT-Adv vectors 
respectively. 
Figure 41 illustrated colony-PCR products obtained from recombinant clones 
containing c D N A fragments B14, H4, JIO and J12. All of the colony-PCR reactions 
were performed in the presence of T7 promoter and Ml3 reverse (-48) primers. All of 
h 
II 
the four recombinant clones of B14 (350 bp), JIO (760 bp) and J12 (670 bp) were found 
to contain the correct inserts. For recombinant clones of H4, only five (1, 3, 4, 7 and 8) 
out of six clones contained the right insert (730 bp). 
The EcoRI digested D N A fragments from recombinant clones B2, B7, B8, H5, J2, 
J5 and J6 were illustrated in Figure 42. All of the recombinant clones of B2 (800 bp), B7 
(550 bp), B8 (550 bp), H5 (730 bp) and J2 (1000 bp) contained the correct inserts. Three 
recombinant clones of J5 (19, 5 and 8) contained the right insert size (700 bp), while only 
two recombinant clones (14 and 28) of J6 contained their expected insert size at 600 bp. 
121 
. B 14 H 4 
I 1 I 1 
: 3 5 0 bp 
J 10 J12 
I 1 I 1 
bp 1 2 3 5 7 1 4 5 6 7 8 9 10 11 
900 bp —Jm I H H H I M I H ^ ^ B I H ^ H 
(insert) 760 bp 670 bp 
600 bp ~ ~ ^ ^ ^ ^ ^ ^ g ^ l l g l g l l ^ l ^ l l l ^ l l l l l l 
Figure 41. Colony-PCR screening of recombinant clones containing cDNA fragments 
B14 and H4 (upper panel) and JIO and J12 (lower panel). Plasmid DNAs were isolated 
from the recombinant clones based on the protocol of Promega Miniprep method. The 
purity and size of inserts were checked by colony-PCR reaction in the presence of T7 
promoter and Ml3 reverse (-48) primers. Then, 10 f^l of colony-PCR product was 
resolved on 1% agarose, 0.5X TBE gels with ethidium bromide staining. The (Z) 
represented the recombinant clones containing the correct insert size. lOObp, 100 bp 
D N A marker. 
122 
‘ B 2 B 7 B 8 H 5 
I 1 I 1 I 1 ( 1 
bp 8 10 12 18 22 27 6 9 12 14 23 24 25 Ikb 
：： 3900 bp (vector) 
me hp 
(insert) 800 bp 1018 bp 
(insert) 550 bp 一 ~ • E H H I ^ ^ Q Q ^ Q S i m ^ H I ^ ^ ~ 一 730 bp (insert) 
~ ~ 506 bp 
J2 J5 J6 
I 11 11 1 
bp 5 11 13 17 19 1 5 8 14 27 28 Ikb 
m i n 
1 L X . , 3900 bp (vector) 
~ 1636 bp 
l l ^ l U l U P ^ ^ I I I ^ ^ O I ‘ _ 700 bp (insert) 
B l ^ m ^ ^ l l l i m i m ^ l ^ ^ ^ 600 bp (insert)' 
I H r 
Figure 42. EcoRI restriction enzyme digestion of recombinant clones containing cDNA 
fragments B2, B7，B8 and H5 (upper panel) and J2, J5 and J6 (lower panel). Plasmid 
DNAs were isolated from the recombinant clones based on the protocol of Promega 
Miniprep method. The purity and size of inserts were checked by EcoRJ restriction 
enzyme digestion. EcoRI digested D N A fragments were then resolved on 1% agarose, 
0.5X TBE gels with ethidium bromide staining. The ⑷ represented the recombinant 




Figure 43 showed the EcoRI digested D N A fragments from recombinant clones 
HI, H3 and H6. Three recombinant clones of HI (1, 5 and 7) contained the right insert 
size (900 bp), while the other three recombinant clones of H6 (8，10 and 11) contained 
the： expected insert size at 640 bp. All of the two recombinant clones H3 (9 and 10) 
contained the correct insert size (700 bp). 
The EcoRI digested D N A fragments from recombinant clones H8 and HI2 were 
indicated in Figure 44. Two recombinant clones of H8 (1 and 5) contained D N A inserts 
and more or less agreed with the expected size (580 bp). Three recombinant clones of 
H12 (1, 2 and 6) contained the expected insert size (1150 bp). 
Figure 45 illustrated the EcoRI digested D N A fragments from recombinant clones 
J7 and Jl 1. Two recombinant clones of J7 (1 and 3) contained D N A inserts and more or 
less agreed with the expected size (570 bp), whereas all recombinant clones of Jll 
contained the correct insert size (700 bp). 
In summary, a total of eighteen cDNA fragments were successfully subcloned 
from forty-two c D N A fragments (Table 16). Four (B14，H4，JIO and J12) out of them 
i! 
were successfully subcloned into PCH-丁RAP® vector and the remaining c D N A 
fragments (B2, B7, B8, HI, H3, H5, H6, H8, H12, J2, J5, J6, J7 and Jll) were 
successfully subcloned into pT-Adv vector. High quality plasmid D N A s were purified 
from all of these eighteen recombinant clones for D N A sequencing and for probes for 
Northern blot analyses. 
5.9 DNA sequencing of subcloned cDNA fragments 
Eleven subcloned cDNA fragments (B14, HI, H3, H4, H5, H6, H8, H12, J7, JIO 
and Jll) were successfully sequenced (Tables 17-19). However, only three c D N A 
124 
^ . . ^ 
H I H 6 
I 1 r 1 
V ^ ^ ^ V ^ 1 0 0 
Ikb 1 CI 2 C2 5 C5 7 C7 8 C8 10 CIO 11 Cll bp 
^ • B B B E H ^ ^ ^ ^ ^ ^ W K l — 3900 bp (vector) 
1636 bp _ 
1018 bp _ f c j u m m i i p ^ p i ^ ^ ^ ^ ^ ^ i m i m 
(insert) 900 bp ~ _ 800 bp 
506 bp ‘ M B M H B B H f f l i ^ ^ M E ^ m i i g ^ ^ ~ 640 bp (insert) 
^ I m m m i ^ j ^ ^ m ^ j ^ ^ ^ j ^ _ _ 400 bp 
l i i i i i l l l l i H B 
H 3 
I 1 
1 kb 9 10 
3900 bp (vector) 
1636 bp ~ ~ 
1018 bp _ • J J J U U J I 
506 bp _ ~ ~ 700 bp (insert) 
Figure 43. EcoRI restriction enzyme digestion of recombinant clones containing cDNA 
fragments HI and H6 (upper panel) and H3 (lower panel). Plasmid DNAs were isolated 
from the recombinant clones based on the protocol of Promega Miniprep method. The 
purity and size of inserts were checked by EcoRI restriction enzyme digestion. EcoRI 
digested D N A fragments were then resolved on 1% agarose, 0.5X TBE gels with 
ethidium bromide staining. The (V) represented the recombinant clones containing the 
correct insert size. C，EcoRI restiction enzyme digested plasmid DNA; Ikb, 1 kb D N A 






Z Z 100 
Ikb 1 CI 3 C3 5 C5 bp 
~ 3900 bp (vector) 
1636 bp 
1018 bp —— 
~ 800 bp 
506 bp _ • ^ ^ B H B I H ^ B i m m i ^ ~ 580 bp (insert) 
j m i j j j l ^ ^ ^ l l ^ l l , ~ ~ 400 bp 
H 1 2 
I 1 
Z Z 100 
Ikb 1 CI 2 C2 6 C6 bp 
• � I ” 國 
^ ~ 3900 bp (vector) 
M ^ ^ ^ B J f * " 2072 bp 
Figure 44. EcoRJ restriction enzyme digestion of recombinant clones containing cDNA 
fragments H8 (upper panel) and HI2 (lower panel). Plasmid DNAs were isolated from 
the recombinant clones based on the protocol of Promega Miniprep method. The purity 
and size of inserts were checked by EcoRI restriction enzyme digestion. EcoRI digested 
D N A fragments were then resolved on 1% agarose, 0.5X TBE gels with ethidium 
bromide staining. The (^) represented the recombinant clones containing the correct 
insert size. C, EcoRI restiction enzyme digested plasmid DNA; Ikb, 1 kb D N A marker; 




100 z V 
bp 1 CI 2 C2 3 C3 8 C8 
一 570 bp (insert) 
J 11 
I 1 
Z Z Z 
1 kb 1 CI 5 C5 7 C7 9 C9 
P U I P P I ^ P I I 
. f ^ T n l i J ^ 3 9 0 0 bp (vector) 
1636 bp ~ • R I ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ M H H I 
1018 bp ~ • i m i i i m i ^ ^ ^ ^ j ^ u 
506 bp — 7 0 0 bp (insert) 
Figure 45. EcoRI restriction enzyme digestion of recombinant clones containing cDNA 
fragments J7 (upper panel) and Jll (lower panel). Plasmid DNAs were isolated from the 
recombinant clones based on the protocol of Promega Miniprep method. The purity and 
size of inserts were checked by EcoRI restriction enzyme digestion. EcoRI digested 
D N A fragments were then resolved on 1% agarose, 0.5X TBE gels with ethidium 
bromide staining. The (Z) represented the recombinant clones containing the correct 
insert size. C, EcoRI restiction enzyme digested plasmid DNA; Ikb, 1 kb D N A marker; 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































fragments [B14 (Figures 46 and 47)，H4 (Figures 50 and 51) and H5 (Figures 52 and 53)] 
were successfully sequenced from both the sense and anti-sense regions. Eight c D N A 
fragments [HI (Figure 48)，H3 (Figure 49)，H6 (Figure 54), H8 (Figure 55), H12 (Figure 
56); J7 (Figure 57), JIO (Figure 58) and J11 (Figure 59)] were derived from seven known 
genes encoding mouse Cyp4al0 (B14 and JIO), mouse Cyp4al4 (H3 and H4), mouse L-
specific multifunctional beta-oxidation protein, partial c D N A (L-MFP) (HI), mouse 
alpha-1 protease inhibitor 1 (a-l-PIl) (H5), mouse farnesyl diphosphate farnesyl 
II 
transferase (Fdftl)/squalene synthase (J7), mouse 2-hydroxyphytanoyl-CoA lyase (2-
HPCL) (H8) and mouse 16s ribosomal R N A of mitochondrion complete genome (J11). 
It is interesting to note that c D N A fragments H3 and H4 encoding the same mouse 
Cyp4al4 gene and c D N A fragments B14 and JIO encoding the same mouse Cyp4al0 
gene. Also, c D N A fragments H6 and H12 did not show sequence homology to known 
genes but showed remarkable homology to mouse ESTs (Figures 54 and 56). 




Northern blot analysis was applied to confirm the differentially expression pattern 
of c D N A fragments B14，HI, H3, H4, H5, H8 and JIO shown on fluoroDD gels. Since 
both c D N A fragments B14 and JIO encoded for the same mouse Cyp4al0 gene, only 
c D N A fragment B14 was used as a probe for Northern blot analysis. Similarly, cDNA 
fragments H3 and H4 encoded for the same mouse Cyp4al4 gene and only cDNA 
fragment H4 was selected as a probe for Northern blot analysis. For normalization, a 
partial mouse G A P D H cDNA probe was synthesized and used to assess R N A loading on 




cDNA clone ‘ 
(Fragment size I Primer 丨‘对日自广日^^ homology 丨 Transc^j^t 丨 ( identities 
on FDD gel) 丨（ N u c l e o t i d e sequence) ： size (bp)丨 value ； 
、 ] " " " " " “ 1 M^"e""Cyp4aTo I : : I 7771—"""2767278' 
(320 bp) 丨 Lseq 丨 （ 1 8 0 0 - 2 0 7 7 bp) : 卻 1 | e-150 : (99务） 
B14: 111 ctccaagatagttttcccatctaaatgtatcttattcaatctaacctactaagttccttc 170 
丨 I 丨丨 I I I 丨丨 M I M M M I M I M M 丨 M I M I I III I I I M M I 丨 I M M I I 丨 I I 丨 I M 
Sbjct: 1800 ctccaagatagttttcccatctaaatgtatcttattcaatctaacctactaagttccttc 1859 
B14: 171 tgagttatgaggaatcattcaatatgtaccatggtctccaaaatccaaggcctgaacatc 230 “ 
I 1 I 丨丨丨 I 丨 I I I M I 丨 U I I M M M M M I M M M M I I I 丨 I M 丨 M I M M M I M I 
Sbjct: 1860 tgaattatgaggaatcattcaatatgtaccatggtctccaaaatccaaggcctgaacatc 1919 
( 
B14: 231 attgtgaagacattattcagcttagtatcattttcacatgacagttacctaatgtgttca 290 
丨 I M I M I I M M 丨 M I I M M I M M 丨 I M M I I M M m I M M I I m I I M M I I 
Sbjct: 1920 attgtgaagacattattcagcttagtatcattttcacatgacagttacctaatgtgttca 1979 
B14: 291 tctaaatctaccctgcatagtctctttctacctgattaatcctcacacgagtttctccat 350 
丨 I I I I I M I I M I I M I M I M 丨 M I I M I M 丨 M 丨 M I II I I M M m 丨 M m M M 
Sbjct: 1980 tctaaatctaccctgcatagtctctttctacctgattaatcctcacacgagtttctccat 2039 
！: 
I 
B14: 351 cttccctcctttctgcaataaagttcccagtgtcatgc 388 
M I M I m 11 丨 I m 11II 丨 11111 m 丨 11 m M I : 






Figure 46. Sequencing comparison between the cDNA fragments B14 isolated from differentially 
display gel and mouse Cyp4al0. The insert was sequenced using CEQ 2000 dye terminator cycle 
sequencing system in the presence of Lseq primer. The sequence of fragment B14 was compared 





cDNA clone i 1 '""""" 
(Fragment size I Primer 丨'wSe^enc^ homology 丨 Transcript 丨 E - 丨 identities 
on FDD gel) I 1 (Nucleotide sequence)丨 size (bp)丨 value 丨 identities 
I 'Z I I I7Z 二-1 J^^Tf^— 
(320 bp) I 丄 , 丨 (1800-2064 bp) ： 2077 丨 e-127 丨 （今？务） 
- 'V 
B14: 7 aactttattgcagaaaggagggaagatggagaaactcgtgtgaggattaatcaggtagaa 66 
, I丨丨丨丨丨丨丨丨丨丨丨丨丨丨M丨丨丨M丨丨丨丨丨丨丨丨M丨丨M丨丨丨M丨丨丨I M 丨 M 丨 丨 丨 M M 丨 M 
Sbjct: 2064 aactttattgcagaaaggagggaagatggagaaactcgtgtgaggattaatcaggtagaa 2005 
B14: 67 agagactatgcagggtagatttagatgaacacattaggtaactgtcatgtgaaaatgata 126 
丨丨丨丨丨丨I丨丨丨丨I I丨I I丨I I I丨M M M M M I M I I I M M I M I I M I I丨I III I M I I 
Sbjct: 2004 agagactatgcagggtagatttagatgaacacattaggtaactgtcatgtgaaaatgata 1946 
. • I 
B14: 127 ctaagctgaataatgtcttcacaatgatgttcaggccttggattttggagaccatggtac 186 
丨丨丨 I I I I M 丨 I M I M I I m I M M III I 丨丨 I 丨 M M I M I I M I M m I I I M I I M 
Sbjct: 1945 ctaagctgaataatgtcttcacaatgatgttcaggccttggattttggagaccatggtac 1888 
B14: 187 atattgaatgattcctcataactcagaaggaacttagtaggttagattgaataagataca 246 
I 丨丨 I I 丨丨 I I I m I M I M M I I M M M M M I M I I M 丨 m I I I I 丨 I I I M M 丨 M 
Sbjct: 1887 atattgaatgattcctcataattcagaaggaacttagtaggttagattgaataagataca 1828 
B14: 247 tttagatgggaaaactatcttggag 271 | 
II 丨 m M I I I M M I m I M I I I 
Sbjct: 1827 tttagatgggaaaactatcttggag 1800 
,1 





Figure 47. Sequencing comparison between the cDNA fragments of B14 isolated from "” 
differentially display gel and mouse Cyp4al0. The insert was sequenced using CEQ 2000 dye 
terminator cycle sequencing system in the presence of T7 promoter primer. The sequence of 
fragment B14 was compared to entire non-redundant sequence database at the National Library of 






cDNA clone 1 ； “ ^ 一‘ 
(Fragment size I Primer 丨 Se^ence homology Transcript E- identities 
on FDD gel) (Nucleotide sequence) size (bp) value 丄aentities 
I Mouse L-specific 
I multifunctional beta , 
1 oxidation protein, 1649 0 二？ ? 
7 I partial cDNA ( ) 
HI I (837-1373 bp) 
bp) • i Rat peroxisomal enoyl- ！ 
CoA: hydrotase-3-
hydroxyacyl-CoA 3097 丨 le—40 ： 
I bifunctional enzyme 
i 」 (2177-2307 bp) | 
HI: 106 ccattgcagcaaactgtgattcagccttctgcattttgccatgtatggtggcatctaatt 165 "" 
丨丨丨 I I I 丨丨 M M I I 丨 M M M M 丨 M M I I I M 丨 M M I I M M I'M 丨 M 丨 I I I M M I ：  
.Sbjct: 837 ccatagcagcaaactgtgattcagccttctgcattttgccatgtatggtggcatctaatt 896 , 
• :i 
1 
HI: 166 tcagcgtgattcattcctaaaatccaaacagatttctctgaagtacaaatgatgattgct 225 : 
丨 I 丨 I 丨丨 I I M M I I M III I I I I I I M I I I I I I I M M III I M I I m M I I I Ml 丨 I 
Sbjct: 897 tcagtgtgattcattcctaaaatccaaacagatttctctgaagtacaaatgatgattgct 956 : 
HI: 226 gctgttgctgctgctgctggtggtggtggtgctaaatggtcagcaaaagcccctctctgt 285 
1111 m 丨丨丨 M 丨 I M I M I M I M M 丨丨 I 丨 m 丨 I I I I I I I M I I I M I I m I I I I 丨 I 
Sbjct: 957 gctgttgctgctgctgctggtggtggtggtgctaaatggtcagcaaaagcccctctctgt 1016 
HI: 286 atcttcctacctcataattctaacggccagatttcaggaatgtgttttctatacctctga 345 • 
I I I I I I I I I I M I I I I I I I M I I I I I I M I M I M 丨 I I I 丨 I I M I I I I I M I I I I m I 
Sbjct: 1017 atcttcctacctcataattctaatggccagatttcaggaatgtgttttctatacctctga 1076 : 
HI: 346 cggtacttctatcagaaaaattcagcaaatatgtatttactactgcaagcgttcttctct 405 
I I M I I M I I M I I 丨 N M I I 丨丨 I I M I I m I m M I M 丨丨丨 I M M I M I I M 丨 I II ；： 
Sbjct: 1077 cggtacttctatcagaaaaattcagcaaatatgtatttactactgcaagcgttcttctct 1136 
/丨 
ii 
HI: 406 tttgactgtttgcttggtatagccataacttatacaaaatgttgctaagagaataattca 465 J 
I I I I I I I I M I I M I M I I M I III I m I I I I I I I I M M I I M I I M M I I I I 丨 M I I 、 
Sbjct: 1137 tttgactgtttgcttggtatagccataacttatacaaaatgttgctaagagaataattca 1196 
HI: 4 66 taactccagttgacaacccagatataccttttagcaaatcaacaaaagtggcatggacat 525 
11111 丨 I M m I 丨 111 M I M I m I m I M I 丨 I 丨 1111 M m 11 m M 1111111 
Sbjct: 1197 taactccagttgacaacccagatataccttttagcaaatcaacaaaagtggcatggacat 1256 
HI: 526 acaagtcacacatttcagctgtgtgaccgaccatgatgcaccatggtgctgtgttgcagc 585 
丨 1111111 丨 m I m 11 m 111111 11 1111111111111111 i 丨 11 m 丨 111 
Sbjct: 1257 acaagtcacacatttcagctgtgtgacggaacatgatgcaccatggtcgtgtgttgcagc 1316 
HI: 586 attgctctgactaagaggaggcagccaaagaagggcccttgtcatatgggatgtggat 643 
I I I I I I I I I I I I I I I I I I I I I I M I I I I I I I I I I I I M I I I I I I I I I I I I i I I I 
Sbjct: 1317 attgctctgactaagaggaggcagccaaagaaggccacatgtcatat-ggatgtggat 1373 
Figure 48. Sequencing comparison between the cDNA fragments of HI isolated from differentially display 
gel and mouse L-specific multifunctional beta-oxidation protein, partial cDNA. The insert was sequenced 
using CEQ 2000 dye terminator cycle sequencing system in the presence of Ml3 sequencing primer. The 
sequence of fragment HI was compared to entire non-redundant sequence database at the National Library 





(Fragment size j Primer 丨 , S e ^ e n c e homology 丨 Transcript 丨 E_ 丨 identities 
on FDD gel) (Nucleotide sequence)丨 size (bp)丨 value j identities 
H 3 M o u s e C y p ^ i l l ""l ^ 7 7 7 i : i “ J l e T T s F ' ' " 
(715 bp) i 丨 (2031-2488 bp) : 2547 : 0 丨 （ ^ ^ 赛 ） 
H3: 108 gtcatgtgattttaataggaattctccaaatcactaaagtgaataatcagagtactct-a 166 
丨丨丨丨丨丨丨丨丨丨丨I丨丨丨丨丨1丨丨丨丨I III I丨丨丨丨III I mil丨丨丨1丨丨I I丨丨 
Sbjct: 2488 gtcatgggattttaatgggaattctccaaatcattaaggggaatattc-gagtaatttta 2430 
H3: 167 aacaaataagaccgggttaaagtcagaaaactccttagcttcacaaaaaacgccaacctg 226 
. I I I I M I I I I I I I I I I I I M I I I I I I I M I M I I I M ,„ 
Sbjct: 2 4 2 9 aacaaataagaccgggttaaattcagaaaattctttaggttcacaaaaaacgccaacttg 2370 ：丨 
H3: 227 catttctacacaaccagctcaggagtcaaaagcagagaacaacctctcaggagctgagaa 286 f 
, I I I I I I 丨丨丨丨 M 丨丨丨丨 I M I I 丨 M M I M M M I m I m I 丨 M I M M I I I I I I M ；  
Sbjct: 2369 cattttaacacaaccagctcaggagtcaaaagcagagaacaacctctcaggagctgagaa 2310 〔 
H3: 287 ttctaccacattctaacagtagggaccagatggcaacatgcttccctggattgccaaaac 346 
I丨丨丨I I丨丨M丨丨丨丨I丨丨I I M M I M I I M I M I I I I I I I m M m丨丨 I M m I M丨 
Sbjct: 2309 ttctaccacattctaacagtagggaccagatggcaacatgcttccctggattgccaaaac 2250 
I 
H3: 347 tgctctggctccccaaagttcatgctgagtagttttcctgtgtcttaaatgaaattggga 406 
I I I I I I I I M I I I I I I I I I I I I I I I I I I I I I I I I I I I M I I I I I I I I I I I I M I I I I I I I 
Sbjct: 2249 tgctctggctccccaaagttcatgctgagtagttttcctgtgtcttaaatgaaattggga 2190 
H3: 407 aacagaaattgatgaaataaaatggattttttcacagtttggcccaaagtagcaaaaact 466 , 
I 丨 I I I I 丨丨丨丨 I I I 丨 I I 丨 I M M I I M M I I I m 丨 I I M I III I I I I M I I I 丨 M M I M ： 
Sbjct: 2189 aacagaaattgatgaaataaaatggattttttcacagtttggcccaaagtagcaaaaact 2130 ：丨 
：‘丨丨 
H3 ： 467 attcatttctctctaaccttctgtatcagtattactacttcatagaaaagatgaggcata 526 
丨丨丨丨丨丨丨丨丨丨丨M丨丨丨丨丨丨丨丨丨丨丨丨丨丨I丨丨丨丨丨丨I丨丨I丨I丨I丨丨丨丨丨丨丨丨丨丨II丨丨丨 丨: 
Sbjct: 2129 attcatttctctctacctttctgtatcagtattactacttcatagaaaagatgaggcata 2070 "“ 
H3: 527 tgccaagaagcaggaaaacattattttt-actatgagac 564 
丨丨丨丨丨 I I M I I I I I I I I 11 I I Mil I I I I I I I I I I 
Sbjct: 2069 tgccagaaagcaggaaaacattaattttaactatgagac 2031 
Figure 49. Sequencing comparison between the cDNA fragments H3 isolated from differentially 
display gel and mouse Cyp4al4. The insert was sequenced using CEQ 2000 dye terminator cycle 
sequencing system in the presence of M l 3 sequencing primer. The sequence of fragment H3 was 




cDNA clone i ： ~ ^一"""""""""" 
(Fragment size 丨 Primer 丨丨^日^^抑。^ homology Transcript E _ identities on FDD gel) ： (Nucleotide sequence) ： size (bp) j value ；丄a抑titles 
H4 I - i M^si^'^IiTi ] ！ :—f—^87578 — 
(700 bp) I i (1904-2481 bp) 丨 2547 丨 0 丨 （ 9 6 务 ） 
H4： 1 gattttaataggaattctccaaatcactaaagtgaataatcgagtactct-aaacaaata 59 
丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨11丨丨丨丨I 1 1 1 1 1 I I M I M 丨 丨 丨 丨 丨 I 丨 丨 N 丨 
Sbjct: 2481 gattttaatgggaattctccaaatcattaaggggaatattcgagtaattttaaacaaata 2422 
H4: 60 agaccgggttaaagtcagaaaactccttagcttcacaaaaaacgccaacctgcatttcta 119 
, I M M I I I I I I I I I I I I I I I I I I M M M I I I I I I I I I M M I I I 
Sbjct: 2421 agaccgggttaaattcagaaaattctttaggttcacaaaaaacgccaacttgcattttaa 2362 "丨 
"I 
H4: 120 cacaaccagctcaggagtcaaaagcagagagcaacctctcaggagctgagaattctacca 179 
. I丨丨M丨I I I m M I M M M丨M丨m M I I III M M M丨丨丨M丨I M I M M I I I I 丨  
Sbjct: 2361 cacaaccagctcaggagtcaaaagcagagaacaacctctcaggagctgagaattctacca 2302 
H4: 180 cattctaacagtagggaccagatggcaacatgcttccctggattgccaaaactgctctgg 239 : 
丨丨I丨丨丨I丨丨丨I丨M M I M I I M 丨 M M M I M M I I I M M M M M I M I I I M丨 I M 
Sbjct: 2301 cattctaacagtagggaccagatggcaacatgcttccctggattgccaaaactgctctgg 2242 
H4: 240 ctccccaaagttcatgctgagtagttttcctgtgtcttaaatgaaattgggaaacagaaa 299 
I 丨丨丨丨丨 I I I 丨丨 I I M M I M M 丨 I M I M M M I M I M I M I I I I M I 丨 M I M M M I 
Sbjct: 2241 ctccccaaagttcatgctgagtagttttcctgtgtcttaaatgaaattgggaaacagaaa 2182 
H4: 300 ttgatgaaataaaatggattttttcacagtttggcccaaagtagcaaaaactattcattt 359 
丨丨丨丨M丨丨丨I丨I I丨M M丨M I M I丨I M I M M M I丨I I II I I I I M I丨I I I M丨I I丨I ‘ 
Sbjct: 2181 ttgatgaaataaaatggattttttcacagtttggcccaaagtagcaaaaactattcattt 2122 :: 
H4: 360 ctctctacctttctgtatcagtattactacttcatagaaaagatgaggcatatgccagaa 419 ] 
I I I I I 丨 I I I I 丨 I I I M I M 丨 I M 丨 M M I I I M I I I M I I I I I I I m I m m M M I ；； 
Sbjct: 2121 ctctctacctttctgtatcagtattactacttcatagaaaagatgaggcatatgccagaa 2062 J 
H4: 420 agcaggaaaacattaattttaactatgagacagacagaaatatctaaaaatctcttattt 479 
丨 I I I 丨 I N M I M M M M 丨 I I M M 丨 M I M 丨 M I m M I M I I I m M I 丨 I M m 
Sbjct: 2061 agcaggaaaacattaattttaactatgagacagacagaaatatctaaaaatctcttattt 2002 
H4: 480 tgagtcaagttccttcctctggctggtaccagattttagtgttaatttcctcccagcatg 539 
I I I I I M I M M M M M I 丨 M I M I I M I M M M M M I 丨丨 M 丨 M M 丨 I I I M I 丨丨 
Sbjct: 2001 tgagtcaagttccttcctctggctggtaccagattttagtgttaattttctcccagcatg 1942 
H4: 540 tga-tcctaagaacgttttaattcatgatgttcattgt 576 
I I 丨 I I I I I I I I M I I I I I I i M I I I I I I I I I I I I I 
Sbjct: 1941 tgatttctaagaacgttttaatteatgatgtccattgt 1904 
Figure 50. Sequencing comparison between the cDNA fragments H4 isolated from differentially 
display gel and mouse Cyp4al4. The insert was sequenced using CEQ 2000 dye terminator cycle 
sequencing system in the presence of T7 promoter primer. The sequence of fragment H4 was 







(Fragment size ！ Primer Se^ence homology 丨 Transcript | E -丨 identities 
on FDD gel) 丨（ N u c l e o t i d e sequence) size (bp) ； value j 丄aenx^ iT^ ies 
r Lsea I I 1 "一 " . T — I W I ^ — 
(700 bp) i Lseq 丨 （1823-2287 bp) 1 2547 丨 • 丨 (93%) 
H4: 105 accattgcactgacagaggaagatatattttagagggagacacttgtacctttctctccc 164 
丨丨丨丨丨丨丨丨 M M M I M I I I I M M I I I I I M M M I I M 丨 I I I 丨 I I I 丨 I I M M I I M I 
Sbjct: 1823 accattgcactgacagaggaagatatattttagagggagacacttgtacctttctctccc 1882 
H4: 165 ttcagttattagactcttgggacaatggacatcatgaattaaaacgttcttagagatcac 224 
丨 I 丨 N I 丨 I I I I 丨 I M M I I II I I M M M M M I 丨 m M M I 丨 M I I I I I m I I M 丨 ,, 
Sbjct: 1883 ttcagttattagactcttgggacaatggacatcatgaattaaaacgttcttagaaatcac 1942 
�� 
H4: 225 atgctgggagaaaattaacactaaaatctggtaccagccagaggaaggaacttgactcaa 284 丨; 
I 丨 I I I I I I 丨 I 丨 m 丨 M M I I I I I I I I M m M I M I M III I I I I I I M I M M M I 丨 丨: 
Sbjct: 1943 atgctgggagaaaattaacactaaaatctggtaccagccagaggaaggaacttgactcaa 2002 ：! 
H4: 285 aataagagatttttagatatttctgtctgtctcatagttaaaattaatgttttcctgctt 344 
M I M I M 丨 I I M I I I I M M I I I M M I I I M M I I M M I I M I M I I 丨丨 I M m I I ！ 
Sbjct: 2003 aataagagatttttagatatttctgtctgtctcatagttaaaattaatgttttcctgctt 2062 
H4: 345 tctggcatatgcctcatcttttctatgaagtagtaatactgatacagaaaggtagagaga 404 
丨丨 M I M M M I I I I M M I M I M I I 丨 I I M M I M I I I I M I I I I M I I I I I M M 丨丨 ： 
Sbjct: 2063 tctggcatatgcctcatcttttctatgaagtagtaatactgatacagaaaggtagagaga 2122 “ 
H4： 405 aatgaatagtttttgctactttgggccaaactgtgaaaaaatccattttatttcatcaat 464 
I I I I i I I I i I I I I I I I I I I M i I I I I I I M I I I I I I I I I I I I I I I I I I I I I I I I I I I I i I :  
Sbjct: 2123 aatgaatagtttttgctactttgggccaaactgtgaaaaaatccattttatttcatcaat 2182 : 
•I, 
H4: 465 ttctgtttcccaatttcattaaagacacaggaaaactactcagcatgaac-ttggggagc 523 i' 
M I I I I I I M I I I I I I I I I I I m I I I M III m M M I M I I M I M I I M I I M I 丨: 
Sbjct: 2183 ttctgtttcccaatttcatttaagacacaggaaaactactcagcatgaactttggggagc 2242 
H4: 524 cgaagcagtttgggcaatccagggaagcatgttgccatctggtcc 568 
I I M M M I I I M I I I M I I I I I I 丨 I 丨 I I I M I I I I M M I I 
Sbjct: 2243 cagagcagttttggcaatccagggaagcatgttgccatctggtcc 2287 
Figure 51. Sequencing comparison between cDNA fragments of H4 isolated from differentially 
display gel and mouse Cyp4al4. The insert was sequenced using C E Q 2000 dye terminator cycle 
sequencing system in the presence of Lseq primer. The sequence of fragment H4 was compared 




(Fragment size | Primer 丨 h o m o l o g y Transcript 丨 identities 
on FDD gel) (Nucleotide sequence) size (bp) value 
i ： Mouse serine protease ； 412/41A 
I ： inhibitor 1-1 (Spil-1) ； 1366 0 YJ^o： 
H5 I (949-1366 bp) (州名） 
(640 bp) I Mi:3seq ： Mouse alpha-1 ： “——I I 
I I protease inhibitor 1 ; 丨 门 丨 412/418 
I (alpha-1 PI-1) 1366 • (98%) 
j i (949-1366 bp) ； ! _欲 j 
H5: 99 tttttttactgtagcatcaggcacgagccaggccagcctgtgtttaatggaaggaaccca 158 
丨I丨丨丨丨I丨丨丨丨丨丨丨丨丨丨M丨丨丨III丨丨丨丨丨M M丨丨 M丨丨丨丨丨丨 m M I丨丨丨丨丨丨I M ‘：: 
Sbjct ： 1366 tttttttgctgtagcatcaggcacgagccaggccagcctgtgtttaatggaaggaaccca 1307 
I•‘ 
ill 小 
H5： 159 attcagaaggaaggatgacatcttagggtggtcatttatgtgtgggatctaccacttttc 218 1 
丨M I丨I丨I丨I丨丨I丨丨丨M M I丨M I I I M I M M M丨II I I I丨m丨I M丨M M M丨I I 
Sbjct: 1306 attcagaaggaaggatgacatcttagggtggtcatttatgtgtgggatctaccacttttc 1247 j 
I 
H5: 219 ccacaaagatggggctctgagtgtgttcttcaaatattatgaaaaggaaagggtggtcga 278 
III I 丨 M M I I M m M M M I I m M M m 丨 I M I M I I 丨 I M I I I I 丨 I I I I I I 丨 ：: 
Sbjct: 1246 ccaaaaagatggggctctgagtgtgttcttcaaatattatgaaaaggaaagggtggtcga 1187 , 
'I 
H5: 279 agcgcaggatagggggcatagacatgggaaccatttgtaagactgtaactgctgcagctt 338 
I I M M I I M M I I M M I I M M I I I I I I III I M I M 丨 M I I M I M I I I 丨丨 III M :  
Sbjct: 1186 agcgcaggatagggggcatagacataggaaccatttgtaagactgtaactgctgcagctt 1127 : 
：丨  
H5: 339 ctgttcctgtctcaccgatggtcagcacagccttatgcacagcctggctgagcttcaggg 398 ; 
I I I I I I i I I I I I I I I M 丨 I M M m I M I 丨 M M I M M M 丨 M M M M I M M I 丨 I if 
Sbjct: 1126 ctgttcctgtctcatcgatggtcagcacagccttatgcacagcctggctgagcttcaggg 1067 ,丨丨丨 
H5: 399 gagcattctcctctgtgattccggagaggtcagccccattgttgaagatccgggtgatgc 458 
I I i I M I I M I I M M 丨 I I I M I I M I I M I M M I I 丨 I 丨 M I M M M I I I M M I I I 
Sbjct: 1066 gagcattttcctctgtgattccggagaggtcagccccattgttgaagatccgggtgatgc 1007 
H5: 459 ccagtggactcatgagtgtctacaagttatattctccagagatggacagtctggggaa 516 
I M I M M I I I I I I I I I I M I I I i I I I I i I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1006 ccagtggactcatgagtgtcttcaagttatattctccagagatggacagtctggggaa 949 
Figure 52. Sequencing comparison between the cDNA fragments of H5 isolated from 
differentially display gel and mouse serine protease inhibitor 1-1/mouse alpha-1 protease inhibitor 
1. The insert was sequenced using CEQ 2000 dye terminator cycle sequencing system in the 
presence of Ml3 sequencing primer. The sequence of fragment H5 was compared to entire non-





cDNA clone 臺 ‘ ^ T ™ " • 
(Fragment size | Primer 丨 h o m o l o g y | Transcript 丨 丨 identities 
on FDD gel) ： (Nucleotide sequence)丨 size (bp) ; value j 
'' I : Mouse serine protease i /rco 
！ ： inhibitor 1-1 (Spil-1) I 1366 0 i tlno / 
O. I (949-1366 bp) (…） 
XX -；-
( 6 4 0 b p ) i M 1 3 r e v ； M o u s e a l p h a - 1 -
j protease inhibitor I 548/562 
I (alpha—1一PI—1) 1366 〇 (97%) 
i 丨 （776-1254 bp) ： ； ： 
丨I 
‘ It 
H5: 7 4 accattgcagcacgctgtccagctgggtgctgctgatggattatgcaggcaatgccactg 133 
‘ .M M I I M M I I M I m M M I I M I I I 丨 I I I M I I M M I M M I I 丨 I M M I M I 丨 I | 
Sbjct: 776 accattgcagcacgctgtccagctgggtgctgctgatggattatgcaggcaatgccactg 835 ；丨 
H5: 134 ctgtcttccttctgcccgatgatgggaagatgcagcatctggagcaaactctcagcaagg 193 : 
丨丨 I M M I I I I M m M M M I I 丨 M I 丨 M I I I I M M I M I M I M M I 丨 M M I I M 
Sbjct: 836 ctgtcttccttctgcccgatgatgggaagatgcagcatctggagcaaactctcagcaagg 895 
H5: 194 agctcatctctaagttcctgctaaacaggcgcagaaggttagcccagatccacttcccca 253 丨 
I 丨 I M 丨 M I M M M M M I I M M 丨丨丨 I I M I M I M I I M 丨 M I M M M I I I M I M 
Sbjct: 896 agctcatctctaagttcctgctaaacaggcgcagaaggttagcccagatccacttcccca 955 
H5: 254 gactgtccatctctggagaatataacttgaagacactcatgagtccactgggcatcaccc 313 ：  
• I M M I 丨 I M M M I M I M M I I m I 丨 M m 丨 I I I I I I m III I I I I 丨 I M III I I , 
Sbjct: 956 gactgtccatctctggagaatataacttgaagacactcatgagtccactgggcatcaccc 1015 : 
H5: 314 ggatcttc-acaatggggctgacctctccggaatcacagaggagaatgctcccctgaagc 372 j 
• I I I I I i M I I I I I I I M I I I I I I I I I I I I I I I I I I I M I I I I I I I I M I I I M 丨 M I I I: 
Sbjct: 1016 ggatcttcaacaatggggctgacctctccggaatcacagaggaaaatgctcccctgaagc 1075 丨丨 
丨丨丨 
H5: 373 tcaagccaggctgtgcataaggctgtgctgaccatcggtgagacaggaacagaagctgca 432 
I I M I I i I I M I I I I M I I I I I I I I I I i I I I I I M I I I I I I M I M I I 丨 I I M I I M I 
Sbjct: 1076 tc-agccaggctgtgcataaggctgtgctgaccatcgatgagacaggaacagaagctgca 1134 
H5: 433 gcagttacagtcttacaaatggttcccatgtctatgccccctatcctgcgcttcga-cac 491 
I I i I M i I I I M I I I I I I I I I I I I I I i I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1135 gcagttacagtcttacaaatggttcctatgtctatgccccctatcctgcgcttcgaccac 1194 
H5: 492 cctttccttttcataatatttgaagaacacactcagagccccatcttggtgggaaaagtg 551 
丨丨丨 M I I M I M m 丨 M M M I M m I I I 丨 M I I m I 丨 M 丨丨 I I I I M M M I I 丨 
Sbjct: 1195 cctttccttttcataatatttgaagaacacactcagagccccatctttttgggaaaagtg 1254 
Figure 53. Sequencing comparison between the cDNA fragments of H5 isolated from 
differentially display gel and mouse serine protease inhibitor 1-1/mouse alpha-1 protease inhibitor 
1. The insert was sequenced using CEQ 2000 dye terminator cycle sequencing system in the 
presence of Ml3 reverse primer. The sequence of fragment H5 was compared to entire non-




cDNA clone "“ ‘""“"" 
^^  丨 Sequence homology Transcript E- ： ^^ ^. ^ . 
(Fragment size ； Primer ？ ^ . , 、 , , Identities 
on FDD gel) (Nucleotide sequence) size (bp) value 
M o u s e E 7 . 5 e x t r a -
j 丨 e m b r y o n i c p o r t i o n c D N A 丨 / R a n 
I l i b r a r y m o u s e c D N A 5 7 7 0 
I c l o n e C 0 1 7 0 H 0 6 3 ' ( ) 
_� I I ( 2 1 - 5 5 7 b p ) j 
H 6 i M 1 3 r e v I S i m i l a r t o ： I 
( 6 0 0 b p ) J . a d e n y l o s u c c i a t e 
•f -. i ； 
I s y n t h e t a s e ( H u m a n ) ： 丨 I f 5 4 3 / 5 8 3 
1 I m o u s e g r o w t h h o r m o n e - 丨 8 3 1 0 
j r e l e a s i n g h o r m o n e 丨 丨 ° 
！ m R N A , c o m p l e t e 
i 丨 （ 1 3 - 5 7 8 b p ) ： i I 
III 
H6: 72 accattgcaaaattgagctttggtagggtagggggagtatgttcatgagacttttaattt 131 
丨I I I I I m I I I I I I丨丨I I丨I I I丨I I丨I丨I丨I I I丨I丨I I M I I丨I丨I M丨丨I丨I I I丨丨丨丨 I' 
Sbjct: 557 accattgcaaaattgagctttggtagggtagggggagtatgttcatgagacttttaattt 498 丨; 
！I; 
H6 ： 132 gtataaaacacagaacttagttctctctgcaatttatttaatacagtcaacattaaattg 191 ,丨 
11丨丨i I丨M I丨丨丨I丨I丨丨丨丨丨I丨I丨丨I III丨I丨I丨丨丨丨丨III丨丨丨m丨m丨丨11丨丨I丨 ：: 
Sbjct: 497 gtataaaacacagaacttagttctctctgcaatttatttaatacagtcaacattaaattg 438 ,丨 
H6： 192 agtgttcaaaaagaagagatgtttccctacaataacaaccttaatgtgagaaaataatta 251 
I丨II丨I 11丨丨丨丨I丨I I丨丨丨1丨丨丨丨丨III丨I丨丨丨1丨丨丨丨I丨丨丨I丨丨丨丨I丨I丨丨丨丨丨I丨丨丨I ： 
Sbjct： 437 agtgttcaaaaagaagagatgtttccctacaataacaaccttaatgtgagaaaataatta 378 ： 
H6： 252 ttaaaaaaaaatctgttgtgatatttgatggatatttttccttgttttcagatatgatct 311 
I I丨丨丨丨丨丨丨丨丨I丨丨丨丨丨丨I丨1 I丨丨丨丨丨丨丨丨丨IN丨I丨1丨丨丨I丨I丨丨丨丨丨丨丨丨丨III丨I丨 ’： 
Sbjct: 377 ttaaaaaaaaatctgttgtgatatttgatggatatttttctttgttttcagatatgatct 318 
H6 ： 312 caaatgtttgtcttttctttttcttttttaagcatactgttgtttctaagaacagtgggt 371 •.丨 
I丨I I丨丨I丨I I I丨I丨丨丨丨I丨I丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨I丨丨丨丨丨丨丨丨丨丨丨I丨丨丨丨丨丨丨I ：： 
Sbjct: 317 caaatgtttgtcttttctttttcttttttaagcatactgttgtttctaagaacagtgggt 258 • 
•丨丨 
. '1 
H6： 372 ttgcttacatttcgcctgccagtatacctacaaaatgaccccccaagtaacccgcatgag 431 丨, 1111 I I i I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 丨丨 I 丨 I 丨 I I 丨丨丨丨丨丨丨 I 丨 丨: 
Sbjct： 257 ttgcccacatttcgcctgccagtatacctacaaaatgac-ccacaagtaacccgcatgag 199 丨” 
H6： 432 ttccaagttgttcagccatattttgatcatgccctcatccctcctttcttgaaaaagcaa 4 91 
I I I I I I I I I I M I I I I I I I I I I I I I I I I I I I I M I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 198 -tccaagttg-tcagccatattttgatcatgccctcatccctcctttcttgaaaaagcaa 141 
H6: 4 92 agagggatcacctggcccttggctttacattgtgctgagattagccccccctggaccatt 551 
I I I I I I I I I I I I I I I I I I I I I M I I I I I I I I M I I I I I I I I I I I I I I 丨 I I I I I I I I M 
Sbjct: 140 agagggatcacctggcccttggctttacattgtgctgagattagccttccctggaccatt 81 
H6: 552 -aatgtttaaattaggcatcacctgaaattattttatattaccacc-acagctgattaaa 609 
丨丨丨 I 丨 11 丨 III m I 丨 11111 丨 11 丨 1111111 m 11 1111111 丨丨 1111 丨 m m 
Sbjct: 80 aaatgtttaaattaggcatcacctgaaattattttataataccaccaacagctgattaaa 21 
Figure 54. Sequencing comparison between the cDNA fragment of H6 isolated from differentially 
display gel and mouse E7.5 extraembryonic portion cDNA library mouse cDNA clone C0170H06 
37 Sugano mouse kidney mkia mouse cDNA clone IMAGE:2192373 3’ similar to 
adenylosucciate synthetase (Human): mouse growth hormone-releasing hormone m R N A , 
complete (EST). The insert was sequenced using CEQ 2000 dye terminator cycle sequencing 
system in the presence of Ml3 reverse primer. The sequence of fragment H6 was compared to 




(Fragment size 丨 Primer Sequence homology Transcript E- identities 
on roD gel) (Nucleotide sequence) size (bp) value l^^^tities 
i M o u s e 2 -
� H 8 丨 M 1 3 s e a h y d r o x y p h y t a n o y l - 3 5 6 / 3 6 0 
( . 5 1 0 b p ) 丨 M i j s e q c o A l y a s e 1 9 8 2 • ( 9 9 % ) 
. (1489-1847 bp) 
H8: 94 ggagaccat-tgcaggtacaacttgccaatcatactcttggtagtaaacaataatggaat 152 
丨丨丨丨丨丨丨丨丨丨丨丨丨M丨丨丨丨M丨丨丨m丨丨丨丨丨M丨丨丨丨丨I I M I丨丨丨I I丨丨丨M M I丨丨 
Sbjct: 1489 ggagaccatctgcaggtacaacttgccaatcatactcttggtagtaaacaataatggaat 1548 
‘ ,1 
H8: 153 ttaccaaggttttgacgctgacacctgggaaaaaatgctacattttcaagaagctgctac 212 
, I丨丨丨丨M M M m I丨I m I丨丨丨丨I丨I丨丨丨I丨丨丨I M II丨丨丨I M M M I I M I丨丨丨丨 
Sbjct: 1549 ttaccaaggttttgacgctgacacctgggaaaaaatgctacattttcaagaagctgctac 1608 
H8： 213 aactgtccctccaatgtgcctcttgccaaactcgcattatgagcaggtcatgactgcatt 272 
I丨M丨丨丨丨丨丨丨丨丨I丨M I I丨丨丨丨丨丨丨M丨丨M丨丨丨丨丨丨I M丨丨丨丨丨丨丨丨丨II丨M丨丨丨M 
Sbjct: 1609 aactgtccctccaatgtgcctcttgccaaactcgcattatgagcaggtcatgactgcatt 1668 
H8： 273 tggaggcaaagggtattttgtacgaacaccagaagagctccaacactcgctgaggcaggc 332 
丨丨丨丨丨丨丨丨丨M丨I I丨丨丨M I I M丨M丨丨M M丨丨丨M M M丨丨III丨丨I M M丨丨丨丨丨丨丨 
Sbjct: 1669 tggaggcaaagggtattttgtacgaacaccagaagagctccaacactcgctgaggcaggc 1728 
H8： 333 tctgcaagacacaaagtaaaccctgccttctcaacattatgattgagccac-aagtacgc 391 
丨丨M M I m丨丨丨M丨丨M M丨I M丨I丨丨II I丨丨丨丨M I M I丨丨丨丨丨丨丨丨丨丨丨I丨I I 
Sbjct: 1729 tctgcaagacac-aagtaaaccctgccttctcaacattatgattgagccacaaagtacgc 1787 ,j 
f.i 
H8: 392 gcaaggcccaggattttcactggctcacccgttctaacatgtgaataaactactggatgg 451 
丨丨丨丨丨M I I I丨丨I M I I I丨M M I I M M I I I m M丨I I M I M M I I I M I丨丨丨丨M 
Sbjct: 1788 gcaaggcccaggattttcactggctcacccgttctaacatgtgaataaactacttgatgg 1847 
Figure 55. Sequencing comparison between the cDNA fragments of H8 isolated from 
differentially display gel and mouse 2-hydroxyphytanoly-CoA lyase. The insert was sequenced 
using CEQ 2000 dye terminator cycle sequencing system in the presence of Ml3 sequencing 
primer. The sequence of fragment H8 was compared to entire non-redundant sequence database at 





QI5NA clone I ^ ~ r ~ : “ “ ~ ~ ~ 
(Fragment size | Primer 丨 h o m o l o g y 丨 Transc^I^t | E- | identities 
on FDD gel) 丨 丨（Nucleotide sequence)丨 size (bp)丨 value | 
1 i 1 i i 
I Mouse kidney mkia 
I mouse cDNA clone 
--H12 I ； 1480995 3'similar to … …； 2 8 1 / 2 8 4 
(1100 bp) i Ml北ev 丨 liver carboxylesterase ： 469 丨 e-151 丨 ( 9 3 % ) 
j . precursor (Human) 
1 J (5-288 bp) : ： 身 i 
H12: 78 tttttttttttaaccatataaagaacatttattctctaaattaaagacataaatacaaca 137 
, I M I M 丨 III I M 丨 M M M I 丨 M M I I M I M I M M I I I 丨丨 I M I I 丨丨 I I I I M I I 
Sbjct: 5 tttttttatttgaccatataaagaacatttattctctaaattaaagacataaatacaaca 64 ‘ 
H12: 138 tttcccttccctgggctctgcctatatctatgacaaagttcttcaggatcctccaagatc 197 
丨丨丨丨丨丨丨丨丨M丨丨丨M I丨丨丨丨丨丨丨丨丨丨丨I丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨I丨I M I丨丨丨I丨丨丨丨 
Sbjct: 65 tttcccttccctgggctctgcctatatctatgacaaagttcttcaggatcctccaagatc 124 
H12: 198 catcttggatttacatacactgttagtggaagaaccatatcttggcttctctggtataag 257 
丨丨I丨丨I丨丨M III M M I丨丨I丨I丨丨丨丨丨M m I I M I丨丨丨I丨丨丨丨丨丨丨丨丨丨I丨M M丨丨 
Sbjct: 125 catcttggatttacatacactgttagtggaagaaccatatcttggcttctctggtataag 184 
H12: 258 cctggcagagctttgcattcacagctcattgtggtatggctggggttgtttcttggcaaa 317 
I I I I I I I I I I I I I I I I I I I I I I I I I I I M I I I I I I I I I I I I I I I I I I I I I M I I I I I I I 
Sbjct: 185 cctggcagagctttgcattcacagctcattgtggtatggctggggttgtttcttggcaag 244 
H12: 318 ggactgtgtccagaaagtcacttcctcttccttcagtctctggg 361 : 
I I I I M I I m M M M I M I I I I M 丨 M I I 丨 M I I I I I I m I :: 
Sbjct: 245 ggactgtgtccagaaagtcacttcctcttccttcagtctctggg 288 
Figure 56. Sequencing comparison between the c D N A fragment of HI2 isolated from 
differentially display gel and mouse kidney mkia mouse c D N A clone 1480995 3’ similar to liver 
carboxylesterase precursor (Human) (EST). The insert was sequenced using C E Q 2000 dye 
terminator cycle sequencing system in the presence of Ml3 reverse primer. The sequence of 






cDNA clone 丨 "i 
(Fragment size | Primer I homology 丨 Transc^I^t 丨 丨 identities 
on FDD gel) 丨 (Nucleotide sequence) size (bp) \ value ； 
I Mouse famesyl 
、 I 丨 diphosphate f a m e s y l 丨 丨 204/207 
j7 I 1 transferase 1 (Fdftl) I 丄 1 e 一 丄 j (93%) 
( 5 4 0 b p ) 1 M 1 3 r e v ( 1 1 0 9 - 1 3 1 4 b p ) j | 
I • M o u s e s q u a l e n e | ( 。 � 力 / � � ？ 
I synthase 1634 I e-103 I ^04/207 
i ！ (1109-1314 bp) ； I I ( 州 ” 
J7: 88 ctccaagatcaggacacagaaccttcccaactgccagctcatctcccgaagaccactact 147 
I I I I I I M I I I I I I I I I I I i I I I I I I I I I I I I I i I I I I I I M I I I I 1 I I I I I I I I 丨 m 
Sbjct: 1109 ctccaagatcaggacacagaaccttcccaactgccagctcatctcccgaag-ccactact 1167 
J7: 148 cccccatttacctgtcatttatcatgctcttggctgccctgagctggcagtacctgagca 207 
I 丨丨 m I I I I M I M M M M I M M m M I m I M M I M I M I m I 丨 I 丨 M I 丨 I 
Sbjct: 1168 cgcccatttacctgtcatttatcatgctcttggctgccctgagctggcagtacctgagca 1227 
J7: 208 ccctgtcccaggtcacagaagactatgtccagagagaacactgattttgtttagccggag 267 
I I 丨 I 丨 I I I M M M I I M M M M I I m I M M M I I I M 丨 I I I M I M m I I I I M 
Sbjct: 1228 ccctgtcccaggtcacagaagactatgtccagagagaacactgattttgtttagccggaa 1287 
J7: 268 gtggaagttcccgtggagtgggttttt 294 
I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1288 gtggaagttcccgtggagtgggttttt 1314 
1 
I 
Figure 57. Sequencing comparison between the cDNA fragments of J7 isolated from ’ 
differentially display gel and mouse famesyl diphosphate famesyl transferase 1/mouse squalene 
synthase. The insert was sequenced using CEQ 2000 dye terminator cycle sequencing system in 
the presence of Ml3 reverse primer. The sequence of fragment J7 was compared to entire non-





cDNA clone i ~ ； ^ 
(Fragment size | Printer 二 二 Transcript E- id^tities 
on FDD gel) (Nucleotide sequence) size (bp) value 
JIO I Mouse Cyp4alO ::二 “； “"""""""—“―““— 
(730 bp) i ： (1438-2070 bp) � 2。" ： • 丨 (97%) 
Ji-0: 14 actgggaactttattgcagaaaaggagggaagatggagaaactcgtgtgaggattaatca 73 
. I丨丨丨丨丨I丨丨丨丨II M M M丨丨I丨m丨丨丨丨丨丨丨丨丨丨丨丨丨M M M丨丨丨丨丨丨M丨m丨 
Sbjct: 2070 actgggaaetttattgcagaaa-ggagggaagatggagaaactcgtgtgaggattaatca 2012 
JIO: 74 ggtagaaagagactatgcagggtagatctagatgaacacattaggtaactgtcatgtgaa 133 
. 丨I丨丨M I丨丨丨M M I I丨丨丨丨I丨丨I丨M I I I I I M M I丨m I M I M M M I I I I I I M 
Sbjct: 2011 ggtagaaagagactatgcagggtagatttagatgaacacattaggtaactgtcatgtgaa 1952 
JIO: 134 aatgatactaagctcgaataatgtcttcacaatgatgttcaggccttggattttggagac 193 
M I I I I I I I I I I I I I M I 丨 M M M I I I M I I I 丨 I I M M M 丨丨丨'1 M I M M I I 丨 I I 丨 
Sbjct: 1951 aatgatactaagct-gaataatgtcttcacaatgatgttcaggccttggattttggagac 1893 
JIO: 194 catggtacatactgaatgattcctcataattcagaaggaacttagtaggttagattgaat 253 
I I I M I I M I I M M I I M M M m I M M I M I I M I I I I 丨丨 M I I I I I 丨 M I I I M 
Sbjct: 1892 catggtacatattgaatgattcctcataattcagaaggaacttagtaggttagattgaat 1833 
JIO: 254 aagatacatttagatgggaaaactatcttggagcttttagggatcttaatgatgtcataa 313 
M M M M I I I I I M M M M I I I M m I M II III I I M M I I 丨 M I 丨 I M m I I I I 
Sbjct: 1832 aagatacatttagatgggaaaactatcttggagcttttagggatcttaatgatgtcataa 1773 
JIO: 314 gcatctgtaaaaggtaaggacattaagaagagaggggatgaggagggtgctggctttgaa 373 
I I I I M M I I I I I I I I I M I I I I M M M M I I I 丨 I M M I M I I M I I I I M I I 丨 m 
Sbjct: 1772 gcatctgtaaaaggtaaggacatta-gaagagaggggatgaggagggtgctggctttgaa 1714 
JIO: 374 gcaggggaatattccagtgccaaggaatgatgatctatactgaacagaggatgagaggac 433 
M I I M M M M I I M M M 丨 M I I M M M I 丨 I I I M I M M I M I I M M 丨 m I 丨 M 
Sbjct: 1713 gcaggggaatattccagtgccaaggaatgatgatctatactgaacagaggatgagaggac 1654 
JIO: 434 tctctggagtattcttctgaaaaaggtaggtcacaccaacaacttagctttctccagtga 493 ： 
I M I I I I I I I 丨 m M I M I M I I I III I I I I M M I I I M M M M I M M I M M M I “ 
Sbjct: 1653 tctctggagtattcttctgaaaaaggtaggtcacaccaacaacttagctttctccagtga 1594 
JIO: 4 94 aactcttctctgacattggagctccacaacagaatcagtggagcttcttgagatgtaggt 553 
丨 M 丨 I M I I I I M I I I I I M I m m M M I I I I I I I I I I M I I I I I M I I I I I I I I 
Sbjct: 1593 aactcttctcagacattggagctccacaacagtatcagtggagcttcttgagatgtaggt 1534 
JIO: 554 agattccatttttggacttcagcacaagtcgggctaagggcatggggaccctggtaggat 613 
1111 I M 111 M 11111 M M M 1111 m 111111 M I M I m m I M I III I m 
Sbjct: 1533 agatcccatttttggacttcagcacaagtcgggctaagggcatggggaccctggtaggat 1474 
JIO: 614 ctggcatta-ttccaaacggaccaatgtcagggcca 648 
I I I I I I II III I I 丨丨 I I 11 I M M I I 丨 M I 
Sbjct: 1473 ctggcagtagttcgaagcggagcagtgtcagggcca 1438 
Figure 58. Sequencing comparison between the cDNA fragments of JIO isolated from 
differentially display gel and mouse Cyp4al0. The insert was sequenced using ABI PRISM™ 
dRhodamine terminator cycle sequencing system in the presence of T7 promoter primer. The 
sequence of fragment JIO was compared to entire non-redundant sequence database at the 
National Library of Medicine using BLAST. 
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cDNA clone ； ~^赠 ” 
(Fragment size | Primer 丨 口 = homology Transcript 丨 E -丨 identities 
on FDD gel) ! i (Nucleotide sequence) size (bp) ； value 丄aeni^ixiies 
•从.•…… vv��,•_,.‘、， ！ ； i • 
i • ^..^：.. ....... ，..、..,, 
I Mouse mitochondrion i 
I complete genome 16295 0 565/568 
J l l i M 1 3 s e a i......... ( 2 0 6 2 - 2 6 2 9 b p ) 丨 — （ 9 9 % ) 
f 广 ^ y^ 、 $ JL J 丄••J O V j 
(67〇 bp) i ^ : Mouse chimeric 16S 
•: I r i b o s o m a l R N A 1 6 8 5 0 5 6 5 / 严 
i i (1090-1657 bp) i ； (99%) 
Jll: 117 tagcatggacggctaaacgagggtccaactgtctcttatctttaatcagtgaaattgacc 176 
. I丨 I丨丨丨丨M I I I I I I I I丨丨丨 I M I 丨 M I I M I m I I M 丨 M I m M I 
Sbjct: 2062 tagcatgaacggctaaacgagggtccaactgtctcttatctttaatcagtgaaattgacc 2121 
J l l : 177 t t t c a g t g a a g a g g c t g a a a t a t a a t a a t a a g a c g a g a a g a c c c t a t g g a g c t t a a a t t a 236 
I I I I I I I I I I I I M I I I I M I I M I I I I I I I I I M I I I I I M I I I M I I I I I M 
Sbjct: 2122 tttcagtgaagaggctgaaatataataataagacgagaagaccctatggagcttaaatta 2181 
Jll: 237 tataacttatctatttaatttattaaacctaatggcccaaaaactatagtataagtttga 296 
. M I I I M i i I I M I M I I I I I I I I I M I I I I I M I I I I I M I I I I I I I I I I I I I I I I I I I 
Sbjct: 2182 tataacttatctatttaatttattaaacctaatggcccaaaaactatagtataagtttga 2241 
Jll: 297 aatttcggttggggtgacctcggagtataaaaaatcctccgaatgattataacctagact 356 
I I M M I I I I I I I I I I I I I I I I I I I I I I I M M M III M M I I M M M I I 丨 M M M 
Sbjct: 2242 aatttcggttggggtgacctcggagaataaaaaatcctccgaatgattataacctagact 2301 
Jll: 357 tacaagtcaaagtaaaatcaacatatcttattgacccagatatattttgatcaacggacc 416 
丨丨丨丨I丨丨I I丨丨丨丨M丨I I丨I I I M丨I I I I I I I I I m M I M I I I丨I M M M M M M丨 
Sbjct: 2302 tacaagtcaaagtaaaatcaacatatcttattgacccagatatattttgatcaacggacc 2361 
J l l : 417 a a g t t a c c c t a g g g a t a a c a g c g c a a t c c t a t t t a a g a g t t c a t a t c g a c a a t t a g g g t t 476 
丨丨丨丨 I I I 丨 I I 丨 I 丨 I M 丨 M I I I 丨 I M M I I M I I M M M I I I M I M I I I I M I m I I 
Sbjct: 2362 aagttaccctagggataacagcgcaatcctatttaagagttcatatcgacaattagggtt 2421 
Jll: 477 tacgacctcgatgttggatcaggacatcccaatggtgtagaagctattaatggttcgttt 536 
丨 I I 丨丨 I M I I 丨丨丨丨 M I M M I m M I M M I I I M I M I M M I I M 丨 I I I I I M m ； 
S b j c t : 2422 t a c g a c c t c g a t g t t g g a t c a g g a c a t c c c a a t g g t g t a g a a g c t a t t a a t g g t t c g t t t 2481 
Jll: 537 gttcaacgattaaagtcctacgtgatctgagttcagaccggagcaatccaggtcggtttc 596 
I M I I I 丨 I 丨 I I I 丨 M I I M I I I I m I I I M M M I M I M I I I M 丨 I I M I M M M I I 
Sbjct: 2482 gttcaacgattaaagtcctacgtgatctgagttcagaccggagcaatccaggtcggtttc 2541 
Jll: 597 tatctatttacgatttct-ccagtacgaaaggacaagagaaatagagccaccttacaaat 655 
I I I I I I I I I I I I I I I I I I 丨 M I I M 丨 I I I M I M M I I I III 丨 I 丨丨 m 丨 M M M I I I 
Sbjct: 2542 tatctatttacgatttctcccagtacgaaaggacaagagaaatagagccaccttacaaat 2601 
Jll: 656 aagcgctctcaacttaatttatgaataa 683 
I I I I I I 丨 I I 丨 I I I I I 丨 M M I I 丨 I I I I I 
Sbjct: 2602 aagcgctctcaacttaatttatgaataa 2629 
Figure 59. Sequencing comparison between the cDNA fragments of Jll isolated from 
differentially display gel and mouse mitochondrion complete genome/mouse chimeric 16s 
ribosomal RNA. The insert was sequenced using CEQ 2000 dye terminator cycle sequencing 
system in the presence of Ml 3 sequencing primer. The sequence of fragment Jll was compared 




confirmed with the published mouse G A P D H cDNA sequence (Figures 60-61). DIG-
labeled R N A molecular weight marker I was used to estimate the size of transcripts. On 
the Northern blots, it was found that the size of transcripts was over-estimated (about 150 
bp longer) in comparison to the expected transcript sizes. This phenomenon might be 
due to the fact that the R N A markers were labeled with digoxigenin. 
The expression pattern of cDNA fragment B14 was shown in Figure 62. There 
was no constitutive expression of cDNA fragment B14 in the livers of both PPARa (+/+) 
and PPARa (-/-) mice fed control diet. In addition, cDNA fragment B14 (2077 bp) was 
dramatically up-regulated in PPARa (+/+) mice after treatment with 0.1% Wy-14,643 
diet for 2 weeks, but no such induction of cDNA fragment B14 was observed in 
PPARa (-/-) mice fed the same diet. This up-regulated expression pattern of cDNA 
fragment B14 shown on the Northern blot was consistent with the same expression 
pattern found on the fluoroDD gel (Figure 30). 
Figure 63 illustrated the expression pattern of cDNA fragment HI. There was 
low level of constitutive expression of cDNA fragment HI (3097 bp) in the livers of both 
I 
PPARa (+/+) and PPARa (-/-) mice fed control diet. After treatment with 0.1% Wy-
14,643 for 2 weeks, cDNA fragment HI was up-regulated in PPARa (+/+) but not in 
PPARa (-/-) mice fed the same diet. This up-regulated expression pattern of cDNA 
fragment HI agreed with the expression pattern shown on the fluoroDD gel (Figure 33). 
The expression pattern of cDNA fragment H4 was indicated in Figure 64. There 
was constitutive expression of cDNA fragment H4 (2547 bp) in the livers of PPARa (+/+) 
mice fed control diet, whereas no constitutive expression was observed in PPARa (-/-) 




Reamplified j — """ 
fragment j _ . Sequence homology Transcript i E- 丨 … ^ . ^ . 
； Primer ？ ^. , 、 , ， ； Identities 
(Fragment (Nucleotide sequence) size (bp) value I 
size) 
4 ； j 1 
I 丨 Mouse glyceraldehyde-3-丨 | 
GAPDH 丨 丨 phosphate dehydrogenase 丨 丨 n I 566/580 
(827 bp) I M丄北 e v 丨 （GAPDH) 。 ] (97%) 
•- [ I (191-769 bp) I I J^ 
Query: 47 tccactcacggcaaattcaacggcacaqtcaaqqccqaqaatqqqaaqcttqtcatcaac 106 
I 丨丨 M I M I I M I M I 丨 I M M I I I I M M M I 丨 M I M M I I m I I M M I M I I I M 
Sbjct: 191 tccactcacggcaaattcaacggcacaqtcaaqqccqaqaatqqqaaqcttqtcatcaac 250 
Query: 107 gggaagcccatcaccatcttccaggagcgagaccccactaacatcaaatggggtgaggcc 166 
M 丨丨丨 I M 丨 I I 丨 I I M I I M I M I I I M 丨 I 丨 M I I I M I M m M M I I 丨 I I I M I I I I ‘ 
Sbjct: 251 gggaagcccatcaccatcttccaggagcgagaccccactaacatcaaatggggtgaggcc 310 ； 
Query: 167 ggtgctgagtatgtcgtggagtctactggtgtcttcaccaccatggagaaggccggggcc 226 I 
I I M I I M M I I I 丨 I M m I I I I I I 丨 I I I I M I I M I M M I I 丨 I M I I I I I I 丨 m I I ； 
Sbjct: 311 ggtgctgagtatgtcgtggagtctactggtgtcttcaccaccatggagaaggccggggcc 370 
Query: 227 cacttgaagggtggagccaaaagggtcatcatctccgccccttctgccgatgcccccatg 286 
丨 I I I I I M m I I I I I M I M 丨 I I M M I M I I I M M I M M I I I 丨 I I M 丨 M M 丨 I 丨 
Sbjct: 371 cacttgaagggtggagccaaacgggtcatcatctccgccccttctgccgatgcccccatg 430 
Query: 287 tttgtgatgggtgtgaaccacgagaaatatgacaactcactcaagattgtcagcaatgca 34 6 
I I I I I I I I M I M I M M M M 丨 M M I I I I 丨 I I M I I I I I 丨 M I M M I I M I M I m 
Sbjct: 431 tttgtgatgggtgtgaaccacgagaaatatgacaactcactcaagattgtcagcaatgca 490 
Query: 347 tcctgcaccaccaactgcttagcccccctggccaaggtcatccatgacaactttggcatt 406 ! 
I M M M m I M I I I I I 丨 M I I I M m M I M I M I M m M 丨 I I M I I 丨 M I 丨 I M ：  
Sbjct: 4 91 tcctgcaccaccaactgcttagcccccctggccaaggtcatccatgacaactttggcatt 550 丨 
Query: 407 gtggaagggctcatgaccacagtccatgccatcactgccacccagaagactgtggatggc 4 66 
丨丨丨 I I I I I I 丨 m I M I I I M I I M I I I I M I I I M 丨 I I I I 丨 M I I I I I M I I m I I I I ； 
Sbjct: 551 gtggaagggctcatgaccacagtccatgccatcactgccacccagaagactgtggatggc 610 
Query: 467 ccctctggaaagctgtggcgtgatggccgt-gggctgcccagaacatcatcactgcattc 525 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I i I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 611 ccctctggaaagctgtggcgtgatggccgtggggctgcccagaacatcatccctgcatcc 670 
Query: 526 actgggtgctgccaaggctgtggggcagggcattccagagctgaac-ggaagctccctgg 584 
I 丨 I M I 丨 I I I I m I III I m I I M I M I I I I M I I i I I I I I I I I I I I I I I I 
Sbjct: 671 act-ggtgctgccaaggctgtgggcaaggtcatcccagagctgaacgggaagctcactgg 729 
Query: 585 catggccttccgtgtt-ctaccccc-atgtgttcgtcgtg 622 
I I I I I I I I I I I I I I I I I I M I I I I I I III I I I 丨 I I I I 
Sbjct: 730 catggccttccgtgttcctacccccaatgtgtccgtcgtg 769 
Figure 60. Sequencing comparison between the reamplified G A P D H fragment and mouse 
glyceraldehyde-3 -phosphate dehydrogenase. The insert was sequenced using CEQ 2000 dye 
terminator cycle sequencing system in the presence of Ml3 reverse primer. The generated 
sequence was compared to entire non-redundant sequence database at the National Library of 
Medicine using BLAST. The sequence of forward primer was underlined. 
148 
V 
Reamplified r"""""‘~"""""" T ‘ i i < 
fragment I Primer 丨 Sequence homology Transcript E-
(Fragment (Nucleotide sequence)丨 size (bp) value | Identities 
— size) 
丨 Mouse glyceraldehyde-3- : j 
GAPDH I ⑷如 ；phosphate dehydrogenase ： . ！ 551/553 
( & 2 7 b p ) 丨 M l ^ i s e q � （ G A P D H ) 1 2 2 8 0 j ( 9 9 � ） 
[ I ( 4 6 5 - 1 0 1 7 b p ) ； ; I 
Query: 77 tccaccaccctgttqctqtaqccqtattcattqtcataccaaaaaataaacttaacaaaa 136 
丨丨丨丨 I 丨 M M 丨 I I M I M m I I m M M I I I I M I M m I I I M M M 丨丨丨 I M I M 
Sbjct: 1017 tccaccaccctgttqctqtaqccqtattcattatcataccaaaaaataaacttaacaaaa 958 
Q u e r y : 1 3 7 ttgtcattgagagcaatgccagccccggcatcgaaggtggaagagtgggagttgctgttg 1 9 6 “ 
, M I N I M I I M M M I I I I I I M I I I I I I I I I I I i M M I M i I M I I ‘ 
Sbjct: 957 ttgtcattgagagcaatgccagccccggcatcgaaggtggaagagtgggagttgctgttg 898 
i： 
i| 
Query: 197 aagtcgcaggagacaacctggtcctcagtgtagcccaagatgcccttcagtgggccctca 256 ； 
丨丨I I丨I I I丨丨丨丨丨丨丨I I丨M丨I m M I M M M I M m I M M I I I M丨I丨M丨I I I I : 
Sbjct: 897 aagtcgcaggagacaacctggtcctcagtgtagcccaagatgcccttcagtgggccctca 838 
i 
Query: 257 gatgcctgcttcaccaccttcttgatgtcatcatacttggcaggtttctccaggcggcac 316 
丨丨丨I丨I I丨丨丨丨丨M丨M M m I丨I I I I I I I M I M I I M I m m丨 I I I I M I I M I I 
Sbjct: 837 gatgcctgcttcaccaccttcttgatgtcatcatacttggcaggtttctccaggcggcac 778 ‘ 
Q u e r y : 3 1 7 gtcagatccacgacggacacattgggggtaggaacacggaaggccatgccagtgagcttc 3 7 6 
M 丨 M I I M 丨 M 丨 M I m M I M M I I I M I m 丨 M I I I I I M I M m I M m I I I 
Sbjct: 777 gtcagatccacgacggacacattgggggtaggaacacggaaggccatgccagtgagcttc 718 ：丨 
Query: 377 ccgttcagctctgggatgaccttgcccacagccttggcagcaccagtggatgcagggatg 436 : 
丨 1111111 M 丨 11 丨 I M m I m M 11 m I 丨 I M 111 m M 11 M I M 11 M 11111 ：丨 
Sbjct: 717 ccgttcagctctgggatgaccttgcccacagccttggcagcaccagtggatgcagggatg 658 
Query: 437 atgttctgggcagccccacggccatcacgccacagctttccagaggggccatccacagtc 496 ：丨 
丨 I I I M M 丨 I 丨 M I M M I I I I I M I M I M M M I I I 丨 I I I I M I I I M 丨 I I I M M I I 
Sbjct: 657 atgttctgggcagccccacggccatcacgccacagctttccagaggggccatccacagtc 598 
Query: 497 ttctgggtggcagtgatggcatggactgtggtcatgagcccttccacaatgccaaagttg 556 
I 丨 I 丨 I I M I 丨 m I M M I I I I I I I I I I 丨 M 丨 M I 丨丨 I 丨 I M 丨 I m I I 丨 I I I I 丨丨 I I I I 
Sbjct: 597 ttctgggtggcagtgatggcatggactgtggtcatgagcccttccacaatgccaaagttg 538 
Query: 557 tcatggatgacctgggccaggggggctaagcagttggtggtgcaggatgcattgctgaca 616 
丨丨丨丨 I I 丨 I 丨 M 丨 I 丨丨丨 I I I I M m m I I I I M I I M I I I M I I I I I I I I I I 丨 M I I I 
Sbjct: 537 tcatggatgaccttggccaggggggctaagcagttggtggtgcaggatgcattgctgaca 478 
Query: 617 atc-tgagtgagt 628 
I I I I I I I I I I I I 
S b j c t : 4 7 7 a t c t t g a g t g a g t 4 6 5 
Figure 61. Sequencing comparison between the reamplified G A P D H fragment and mouse 
glyceraldehyde-3 -phosphate dehydrogenase. The insert was sequenced using C E Q 2000 dye 
terminator cycle sequencing system in the presence of Ml3 sequencing primer. The generated 
sequence was compared to entire non-redundant sequence database at the National Library of 
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Figure 62. Confirmation of fluorescent differential display expression pattern of c D N A 
fragment B14 by Northern blot analysis. Fifteen micrograms of total liver R N A from I 
PPARa (+/+) and PPARa (-/-) mice fed control (CTL) or 0.1% Wy-14,643 (WY) diet 
for 2 weeks were separated on a 1.0% agarose-formaldehyde gel with ethidium bromide 
staining and transferred to nylon membrane. The membrane was hybridized with the 
PCR-DIG-labeled c D N A fragment B14 (320 bp) and the signal was detected by 
colorimetric method with reagents N B T and BCIP. For normalization, the membrane 
was decolorized, stripped and reprobed with the random-primed DIG-labeled partial 
G A P D H c D N A fragment (827 bp). There was no constitutive expression of cDNA 
fragment B14 in the livers of both PPARa (+/+) and PPARa (-/-) mice fed control diet. 
Remarkably, the expression level of cDNA fragment B14 (2077 bp) was dramatically 
increased in PPARa (+/+) mice after treatment with 0.1% Wy-14,643 for 2 weeks, but no 
such induction was observed in PPARa (-/-) mice fed the same diet. M , DIG-labeled 
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Figure 63. Confirmation of fluorescent differential display expression pattern of cDNA 
fragment HI by Northern blot analysis. Fifteen micrograms of total liver R N A from I 
PPARa (+/+) and PPARa (-/-) mice fed control (CTL) or 0.1% Wy-14,643 (WY) diet 
for 2 weeks were separated on a 1.0% agarose-formaldehyde gel with ethidium bromide ‘ 
staining and transferred to nylon membrane. The membrane was hybridized with the 
random-primed DIG-labeled cDNA fragment HI (850 bp) and the signal was detected by 
colorimetric method with reagents N B T and BCIP. For normalization, the membrane 
was decolorized, stripped and reprobed with the random-primed DIG-labeled partial 
G A P D H cDNA fragment (827 bp). There was a low level of constitutive expression of 
cDNA fragment HI 
in the livers of both PPARoc (+/+) and PPARoc (—/—) mice fed control 
diet. Remarkably, the expression level of cDNA fragment HI (3097 bp) was 
dramatically increased in PPARa (+/+) mice after treatment with 0.1% Wy-14,643 for 2 
weeks, but no such induction was observed in PPARa (-/-) mice fed the same diet. M， 
DIG-labeled R N A molecular weight marker I. 
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Figure 64. Confirmation of fluorescent differential display expression pattern of cDNA 
fragment H4 by Northern blot analysis. Fifteen micrograms of total liver R N A from 
li 
PPARa (+/+) and PPARa (-/-) mice fed control (CTL) or 0.1% Wy-14,643 (WY) diet 
for 2 weeks were separated on a 1.0% agarose-formaldehyde gel with ethidium bromide : 
staining and transferred to nylon membrane. The membrane was hybridized with the 
PCR-DIG-labeled cDNA fragment H4 (700 bp) and the signal was detected by 
colorimetric method with reagents N B T and BCIP. For normalization, the membrane 
was decolorized, stripped and reprobed with the random-primed DIG-labeled partial 
G A P D H cDNA fragment (827 bp). There was constitutive expression of cDNA fragment 
H4 in the livers of PPARa (+/+) but not PPARa (-/-) mice fed control diet. 
Remarkably, the expression level of cDNA fragment H4 (2547 bp) was dramatically 
increased in PPARa (+/+) mice after treatment with 0.1% Wy-14,643 for 2 weeks, but no 
such induction was observed in PPARa (-/-) mice fed the same diet. M , DIG-labeled 




mice after treatment with 0.1% Wy-14,643 diet for 2 weeks but no such induction was 
observed in PPARa (-/-) mice fed the same diet. This up-regulated expression pattern 
ofcDNA fragment H4 shown on the Northern blot was in agreement with the expression 、 
pattern observed on the fluoroDD gel (Figure 33). 
The expression pattern of cDNA fragment H5 was shown in Figure 65. There 
was high level of constitutive expression ofcDNA fragment H5 (1366 bp) in the livers of 
both PPARa (+/+) and PPARa (-/-) mice fed control diet. Additionally, cDNA , 
fragment H5 was dramatically down-regulated in PPARa (+/+) mice after administration ；: 
of 0.1% Wy-14,643 diet for 2 weeks, but no such suppression pattern was observed in '： 
•i 
PPARa (-/-) mice fed the same diet. This down-regulated expression pattern of cDNA '； 
fragment H5 shown on the Northern blot was consistent with the expression pattern ,： 
found on the fluoroDD gel (Figure 33). :: 
,1 
Figure 66 illustrated the expression pattern of cDNA fragment H8. There was , 
constitutive expression of cDNA fragment H8 (1982 bp) in the livers of both PPARa I: 
(+/+) and PPARa (-/-) mice fed control diet. Moreover, cDNA fragment H8 was up- ； 
regulated in PPARa (+/+) mice after treatment with 0.1% Wy-14,643 diet for 2 weeks, 
but no such induction was observed in PPARa (-/-) mice fed the same diet. This up-
regulated expression pattern of cDNA fragment H8 shown on the Northern blot was in 
agreement with the expression pattern observed on the fluoroDD gel (Figure 33). 
In summary, the expression patterns of the five PPARa-dependent and Wy-
14,643 responsive differentially expressed cDNA fragments (B14, HI, H4, H5 and H8) 
excised from the fluoroDD gels were confirmed by Northern blot analysis (Table 20). 
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Figure 65. Confirmation of fluorescent differential display expression pattern of cDNA ‘ 
I 
fragment H5 by Northern blot analysis. Fifteen 
micrograms of total liver R N A from 
PPARa (+/+) and PPARa (-/-) mice fed control (CTL) or 0.1% Wy-14,643 (WY) diet :: 
for 2 weeks were separated on a 1.0% agarose-formaldehyde gel with ethidium bromide : 
staining and transferred to nylon membrane. The membrane was hybridized with 
random-primed DIG-labeled cDNA fragment H5 (640 bp) and the signal was detected by 
colorimetric method with reagents N B T and BCIP. For normalization, the membrane 
was decolorized, stripped and reprobed with the random-primed DIG-labeled partial 
G A P D H cDNA fragment (827 bp). There was a high level of constitutive expression of 
cDNA fragment H5 in the livers of both PPARa (+/+) and PPARa (-/-) mice fed control 
diet. However, the expression level of cDNA fragment H5 was decreased to very low 
level in PPARa (+/+) but not in PPARa (-/-) mice after treatment with 0.1% Wy-14,643 
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Figure 66. Confirmation of fluorescent differential display expression pattern of cDNA 
fragment H8 by Northern blot analysis. Thirty micrograms of total liver R N A from 
PPARa (+/+) and PPARa (-/-) mice fed control (CTL) or 0.1% Wy-14,643 (WY) diet 
1 
for 2 weeks were separated on a 1.0% agarose-formaldehyde gel with ethidium bromide • 
staining and transferred to nylon membrane. The membrane was hybridized with 
random-primed DIG-labeled cDNA fragment H8 (510 bp) and the signal was detected by 
colorimetric method with reagents N B T and BCIP. For normalization, the membrane 
was decolorized, stripped and reprobed with the random-primed DIG-labeled partial 
G A P D H cDNA fragment (827 bp). There was constitutive expression of cDNA fragment 
H8 in the livers of both PPARa (+/+) and PPARa (-/-) mice fed control diet. The 
expression level of cDNA fragment H8 was up-regulated in PPARa (+/+) mice after 
treatment with 0.1% Wy-14,643 for 2 weeks, but no such induction was observed in 





































































































































































































































































































































































































































































































































































































































































































multifunctional beta oxidation protein, partial cDNA, Cyp4al4, alpha-1 protease inhibitor 
1 and 2-hydroxyphytanoly-CoA lyase genes respectively. Four of them [B14 (Cyp4al0), 
HI (L-specific multifunctional beta oxidation protein, partial cDNA), H4 (Cyp4al4) and 
'•V 
HS (2-hydroxyphytanoly-CoA lyase)] were up-regulated in PPARa (+/+) mice after 
0.1% Wy-14,643 treatment for 2 weeks while no such up-regulation was observed in 
PPARa (-/-) mice fed the same diet. The H5 (alpha-1 protease inhibitor 1) gene was 
down-regulated in PPARa (+/+) mice after treatment with 0.1% Wy-14,643 for 2 weeks, 
whereas no such down-regulation was observed in PPARa (-/-) mice fed the satae diet. 
These data clearly demonstrated that PPARa is required for the Wy-14,643-induced 
. i 




5.11 Temporal expression pattern of differentially expressed genes 
I 
I 
In order to determine whether the level of induction or suppression of the cDNA 
fragments B14, HI, H4, H5 and H8 after short-term exposure to Wy-14,643 could be 
used as the early marker gene(s) for prediction of Wy-14,643-induced long-term 
hepatocarcinogenesis responses, the expression patterns of these five c D N A fragments at 
24 hours, 1 week, 2 weeks, 6 months and 11 months were investigated by Northern blot 
analyses. The temporal expression studies were investigated in two different phases due 
to the inavailability of R N A samples from the long-term (11 months) Wy-14,643 
treatment. In the first phase of the temporal studies, Northern blot analyses were 
performed when the control- and Wy-14,643-treated liver R N A samples were available 
from both PPARa (+/+) and PPARa (-/-) mice after Wy-14,643 treatment for 24 hours, 
1 week, 2 weeks and 6 months. In the second phase of the temporal studies, Northern 
157 
blot analyses were performed when the R N A sample from all time points (24 hours, 1 
week, 2 weeks, 6 months and 11 months) were available. 
The temporal expression patterns of cDNA fragment B14 in PPARa (+/+) and 
� 
PPARa (-/-) mice after exposure to Wy-14,643 for 24 hours, 1 week, 2 weeks or 6 
months were shown in Figure 67. There was no constitutive expression of cDNA 
fragment B14 in PPARa (+/+) mice fed control diet. In addition, cDNA fragment B14 
was up-regulated in PPARa (+/+) mice after treatment with Wy-14,643 for 24 hours, 1 , 
week, 2 weeks and 6 months, but no such induction was observed in PPARa (-/-) mice 
after exposure to Wy-14,643 at the same time periods. 
Figure 68 illustrated the temporal expression patterns of cDNA fragment HI in 
PPARa (+/+) and PPARa (-/-) mice after exposure to Wy-14,643 for 24 hours, 1 week, : 
) 
2 weeks or 6 months. There was constitutive expression of cDNA fragment HI in both ；丨 
i 
I 
PPARa (+/+) and PPARa (-/-) mice fed control diet for 1 week and 2 weeks. However, 
no constitutive expression of cDNA fragment HI was exhibited in both PPARa (+/+) and : 
ii 
PPARa (-/-) mice injected with control vehicle for 24 hours or fed control diet for 6 : 
months. In addition, cDNA fragment HI was up-regulated in PPARa (+/+) mice after 
exposure to Wy-14,643 for 24 hours, 1 week, 2 weeks and 6 months, but this up-
regulated pattern was not detected in PPARa (-/-) mice after exposure to Wy-14,643 at 
the same time points tested. 
The temporal expression patterns of cDNA fragment H4 in PPARa (+/+) and 
PPARa (-/-) mice after exposure to Wy-14,643 for 24 hours, 1 week, 2 weeks or 6 
months were indicated in Figure 69. There was constitutive expression of cDNA 
fragment H4 in PPARa (+/+) mice injected with control vehicle for 24 hours and fed 
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Figure 67. Temporal expression pattern of cDNA fragment B14 in PPARa (+/+) and 
PPARa (-/-) mice. Fifteen micrograms of total liver R N A from PPARa (+/+) and 
PPARa (-/-) mice injected with control (CTL) vehicle or Wy-14,643 (WY) (50mg/kg), 
or fed control (CTL) or 0.1% Wy-14,643 (WY) diet for 1 week, 2 weeks or 6 months 
were separated on 1.0% agarose-formaldehyde gels with ethidium bromide staining and 
transferred to nylon membranes. The membranes were hybridized with the PCR-DIG-
labeled c D N A fragment B14 (320 bp) and the signal was detected by colorimetric 
method with reagents N B T and BCIP. For normalization, the membranes were 
decolorized, stripped and reprobed with the random-primed DIG-labeled partial G A P D H 
c D N A fragment (827 bp). There was no constitutive expression of cDNA fragment B14 
in the livers of both PPARa (+/+) and PPARa (-/-) mice fed control diet. Remarkably, 
the expression level of cDNA fragment B14 was dramatically increased in PPARa (+/+) 
but not in PPARa (-/-) mice after exposure,to Wy-14,643 for 24 hours, 1 week, 2 weeks 
and 6 months. 
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Figure 68. Temporal expression pattern of cDNA fragment HI in PPARa (+/+) and 
PPARa (-/-) mice. Fifteen micrograms of total liver R N A from PPARa (+/+) and 
PPARa (-/-) mice injected with control (CTL) vehicle or Wy-14,643 (WY) (50mg/kg), 
or fed control (CTL) or 0.1% Wy-14,643 (WY) diet for 1 week, 2 weeks or 6 months 
were separated on 1.0% agarose-formaldehyde gels with ethidium bromide staining and 
transferred to nylon membranes. The membranes were hybridized with the random-
primed DIG-labeled c D N A fragment HI (850 bp) and the signal was detected by 
colorimetric method with reagents N B T and BCIP. For normalization, the membranes 
were decolorized, stripped and reprobed with the random-primed DIG-labeled partial 
G A P D H c D N A fragment (827 bp). There was constitutive expression cDNA fragment 
HI in the livers of both PPARa (+/+) and PPARa (-/-) mice fed control diet for 1 week 
and 2 weeks. Remarkably, the expression level of cDNA fragment HI was dramatically 
increased in PPARa (+/+) but not in PPARa (-/-) mice after exposure to Wy-14,643 for 
24 hours, 1 week, 2 weeks and 6 months. 
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Figure 69. Temporal expression pattern of cDNA fragment H4 in PPARa (+/+) and 
PPARa (-/-) mice. Fifteen micrograms of total liver R N A from PPARa (+/+) and 
PPARa (-/-) mice injected with control (CTL) vehicle or Wy-14,643 (WY) (50mg/kg), 
or fed control (CTL) or 0.1% Wy-14,643 (WY) diet for 1 week, 2 weeks or 6 months 
were separated on 1.0% agarose-formaldehyde gels with ethidium bromide staining and 
transferred to nylon membranes. The membranes were hybridized with the PCR-DIG-
labeled c D N A fragment H4 (700 bp) and the signal was detected by colorimetric method 
with reagents N B T and BCIP. For normalization, the membranes were decolorized, 
stripped and reprobed with the random-primed DIG-labeled partial G A P D H cDNA 
fragment (827 bp). There was constitutive expression of cDNA fragment H4 in the livers 
of PPARa (+/+) but not in PPARa (-/-) mice injected with control vehicle for 24 hours 
and fed control diet for 1 week, 2 weeks and 6 months. Remarkably, the expression level 
of cDNA fragment H4 was dramatically increased in PPARa (+/+) but not in PPARa 




control diet for 1 week, 2 weeks or 6 months. However, no constitutive expression of 
c D N A fragment H4 was observed in PPARa (一/—) mice control mouse groups at all time 
periods. Up-regulation of cDNA fragment H4 was observed in PPARa (+/+) mice after 
exposure to Wy-14,643 for 24 hours, 1 week, 2 weeks or 6 months, whereas no such 
induction was observed in PPARa (-/-) mice after exposure to Wy-14,643 at all time 
points treated. 
Figure 70 indicated the temporal expression patterns of cDNA fragment H5 in 
‘ _'« 
PPARa (+/+) and PPARa (-/-) mice after exposure to Wy-14,643 for 24 hours, i week, f 
2 weeks or 6 months. There was high level of constitutive expression of cDNA fragment ；|： 
H5 in both PPARa (+/+) and PPARa (-/-) mice injected with control vehicle for 24 ：； 
hours and fed control diet for 1 week, 2 weeks or 6 months. Down-regulation of cDNA 
fragment H5 was observed in PPARa (+/+) mice treated with Wy-14,643 for 1 week, 2 
weeks or 6 months, but no down-regulation was detected in PPARa (+/+) mice after 
exposure to Wy-14,643 for 24 hours. In addition, the expression level of cDNA fragment 
i 
H5 was not affected in PPARa (-/-) mice after treatment with Wy-14,643 at all the time ] 
points examined. 
The temporal expression patterns of cDNA fragment H8 in PPARa (+/+) and 
PPARa (-/-) mice after exposure to Wy-14,643 for 24 hours, 1 week, 2 weeks or 6 
months were shown in Figure 71. There was constitutive expression of cDNA fragment 
H8 in both PPARa (+/+) and PPARa (-/-) mice injected with vehicle control for 24 
hours and fed control diet for 1 week, 2 weeks or 6 months. Up-regulation of cDNA 
fragment H8 was observed in PPARa (+/+) mice after exposure to Wy-14,643 for 1 week, 
2 weeks and 6 months, but no observable induction was observed in PPARa (+/+) mice 
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Figure 70. Temporal expression pattern of cDNA fragment H5 in PPARa (+/+) and 
PPARa (-/-) mice. Fifteen micrograms of total liver R N A from PPARa (+/+) and 
PPARa (-/-) mice injected with control (CTL) vehicle or Wy-14,643 (WY) (50mg/kg), 
or fed control (CTL) or 0.1% Wy-14,643 (WY) diet for 1 week, 2 weeks or 6 months 
were separated on 1.0% agarose-formaldehyde gels with ethidium bromide staining and 
transferred to nylon membranes. The membranes were hybridized with the random-
primed DIG-labeled cDNA fragment H5 (640 bp) and the signal was detected by 
colorimetric method with reagents N B T and BCIP. For normalization, the membranes 
were decolorized, stripped and reprobed with the random-primed DIG-labeled partial 
G A P D H c D N A fragment (827 bp). There was high level of constitutive expression of 
cDNA fragment H5 in the livers of both PPARa (+/+) and PPARa (-/-) mice injected 
with control vehicle for 24 hours and fed control diet for 1 week, 2 weeks and 6 months. 
Remarkably, the expression level was dramatically decreased in PPARa (+/+) mice but 
not in PPARa (-/-) mice fed Wy-14,643 for 1 week, 2 weeks and 6 months. 
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Figure 71. Temporal expression pattern of cDNA fragment H8 in PPARa (+/+) and 
PPARa (-/-) mice. Thirty micrograms of total liver R N A from PPARa (+/+) and 
PPARa (-/-) mice injected with control (CTL) vehicle or Wy-14,643 (WY) (50mg/kg), 
or fed control (CTL) or 0.1% Wy-14,643 (WY) diet for 1 week, 2 weeks or 6 months 
were separated on 1.0% agarose-formaldehyde gels with ethidium bromide staining and 
transferred to nylon membranes. The membranes were hybridized with the random-
primed DIG-labeled cDNA fragment H8 (510 bp) and the signal was detected by 
colorimetric method with reagents N B T and BCIP. For normalization, the membranes 
were decolorized, stripped and reprobed with the random-primed DIG-labeled partial 
G A P D H cDNA fragment (827 bp). There was constitutive expression of cDNA fragment 
in the livers of both PPARa (+/+) and PPARa (-/-) mice injected with control vehicle 
for 24 hours and fed control diet for 1 week, 2 weeks and 6 months. The expression level 
of cDNA fragment H8 was increased in PPARa (+/+) but not in PPARa (-/-) mice after 
exposure to Wy-14,643 for 24 hours, 1 week, 2 weeks and 6 months. 
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after exposure to Wy-14,643 for 24 hours. Furthermore, no induction of cDNA fragment 
H8 was observed in PPARa (-/-) after exposure to Wy-14,643 at the same time periods. 
Since the expression patterns of the five cDNA fragments were not altered in 
PPARa (-/-) mice after exposure to Wy-14,643 for 24 hours, 1 week, 2 weeks and 6 
months based on the results obtained from the first part of the temporal studies, only the 
expression patterns of these five genes in PPARa (+/+) mice were studied in the second 
part of the temporal studies. 
The time-dependent expression pattern of cDNA fragment B14 was shown in ( 
Figure 72. There was no constitutive expression of cDNA fragment B14 in PPARa (+/+) ) 
T 
mice injected with control vehicle for 24 hours or fed control diet for 1 week, 2 weeks, 6 ‘ 
i 
months or 11 months. However, the level of expression of cDNA fragment B14 was 
i 
dramatically induced in PPARa (+/+) mice after exposure to Wy-14,643 for 24 hours 
：丨' 
(13.9-fold), 1 week (19.2-fold), 2 weeks (13.5-fold), 6 months (14-fold) and 11 months ! 
\ 1 
(6.5-fold). Maximal induction of cDNA fragment B14 in PPARa (+/+) mice after I 
exposure to Wy-14,643 was at around 1 week and the level of induction gradually 
declined as the Wy-14,643 treatment continued for 2 weeks, 6 months and 11 months in 
these mice. 
Figure 73 illustrated the time-dependent expression pattern of cDNA fragment HI. 
There was no observable constitutive expression of cDNA fragment HI in PPARa (+/+) 
mice injected with control vehicle for 24 hours or fed control diet for 1 week, 2 weeks, 6 
months or 11 months. In addition, the level of expression of cDNA fragment HI was 
dramatically induced in PPARa (+/+) mice after exposure to Wy-14,643 for 24 hours 
(30.4-fold), 1 week (82.2-fold), 2 weeks (40.6-fold), 6 months (33.8-fold) and 11 months 
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Figure 72. Time-dependent expression pattern of cDNA fragment B14. Fifteen micrograms of 
total liver R N A from PPARa (+/+) mice injected with control vehicle (CTL) or Wy-14,643 
(WY) (50mg/kg), or fed control (CTL) or 0.1% Wy-14,643 (WY) diet for 1 week, 2 weeks, 6 
months or 11 months were separated on a 1.0% agarose-formaldehyde gel and transferred to 
nylon membrane. The membrane was hybridized with PCR-DIG-labeled cDNA fragment B14 
(320 bp) and the signal was detected by colorimetric method with reagents N B T and BCIP. 
For normalization, the membrane was decolorized, stripped and reprobed with the random-
primed DIG-labeled partial G A P D H cDNA fragment (827 bp). The R N A message was 
quantified by a densitometer and the ratio of B14/GAPDH (arbitrary units) was shown on the 
graph. There was no constitutive expression of cDNA fragment B14 in PPARa (+/+) control 
mouse groups at different time periods. The level of expression of cDNA fragment B14 was 
dramatically induced in PPARa (+/+) mice after exposure to Wy-14,643 for 24 hours (13.9-
fold), 1 week (19.2-fold), 2 weeks (13.5-fold), 6 months (14-fold) and 11 months (6.5-fold). 
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Figure 73. Time-dependent expression pattern of cDNA fragment HI. Fifteen micrograms of 
total liver R N A from PPARa (+/+) mice injected with control vehicle (CTL) or Wy-14,643 
(WY) (50mg/kg), or fed control (CTL) or 0.1% Wy-14,643 (WY) diet for 1 week, 2 weeks, 6 
months or 11 months were separated on a 1.0% agarose-formaldehyde gel and transferred to 
nylon membrane. The membrane was hybridized with random-primed DIG-labeled cDNA 
fragment HI (850 bp) and the signal was detected by colorimetric method with reagents N B T 
and BCIP. For normalization, the membrane was decolorized, stripped and reprobed with the 
random-primed DIG-labeled partial G A P D H cDNA fragment (827 bp). The R N A message was 
quantified by a densitometer and the ratio of HI/GAPDH (arbitrary units) was shown on the 
graph. There was no observable constitutive expression of cDNA fragment HI in PPARa (+/+) 
control mouse groups at different time periods. The level of expression of cDNA fragment HI 
was dramatically induced in PPARa (+/+) mice after exposure toWy-14,643 for 24 hours 




(8.2-fold). Maximal induction of cDNA fragment HI in PPARa (+/+) mice was 
observed after exposure to Wy-14,643 for 1 week and the level of induction gradually 
declined as the Wy-14,643 treatment continued for 2 weeks, 6 months and 11 months in 
these mice. 
The time-dependent expression pattern of cDNA fragment H4 was illustrated in 
Figure 74. There was constitutive expression of cDNA fragment H4 in PPARa (+/+) 
mice fed control diet for 1 week and 2 weeks. However, there was no observable 
constitutive expression of cDNA fragment H4 in PPARa (+/+) mice injected with control 
vehicle for 24 hours or fed control diet for 6 months or 11 months. Moreover, the level 
of expression of cDNA fragment H4 was dramatically induced in PPARa (+/+) mice 
after exposure to Wy-14,643 for 24 hours. In addition, the level of expression ofcDNA 
fragment H4 was induced in PPARa (+/+) mice after treatment with Wy-14,643 for 1 
week (49.5-fold), 2 weeks (10.5-fold), 6 months (17.2-fold) and 11 months (19.7-fold). 
Maximal induction of cDNA fragment H4 in PPARa (+/+) mice was observed after 
exposure to Wy-14,643 for 1 week and the level of induction gradually declined as the 
Wy-14,643 treatment continued for 2 weeks and then maintained as the Wy-14,643 
treatment continued for 6 months and 11 months. 
Figure 75 indicated the time-dependent expression pattern ofcDNA fragment H5. 
There was high level of constitutive expression of cDNA fragment H5 in PPARa (+/+) 
mice injected with control vehicle for 24 hours and fed control diet for 1 week, 2 weeks, 
6 months and 11 months. Moreover, the level of expression of cDNA fragment H5 was 
slightly suppressed in PPARa (+/+) mice after exposure to Wy-14,643 for 24 hours (-
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Figure 74. Time-dependent expression pattern of cDNA fragment H4. Fifteen micrograms of 
total liver R N A from PPARa (+/+) mice injected with control vehicle (CTL) or Wy-14,643 
(WY) (50mg/kg), or fed control (CTL) or 0.1% Wy-14,643 (WY) diet for 1 week, 2 weeks, 6 
months or 11 months were separated on a 1.0% agarose-formaldehyde gel and transferred to 
nylon membrane. The membrane was hybridized with PCR-DIG-labeled cDNA fragment H4 
(700 bp) and the signal was detected by colorimetric method with reagents N B T and BCIP. 
For normalization, the membrane was decolorized, stripped and reprobed with the random-
primed DIG-labeled partial G A P D H cDNA fragment (827 bp). The R N A message was 
quantified by a densitometer and the ratio of H4/GAPDH (arbitrary units) was shown on the 
graph. There was constitutive expression of cDNA fragment H4 in PPARa (+/+) mice fed 
control diet for 1 week and 2 weeks. The level of expression of H4 was dramatically induced 
in PPARa (+/+) mice after exposure to Wy-14,643 for 24 hours, 1 weeks (49.5-fold), 2 weeks 
(10.5-fold), 6 months (17.2-fold) and 11 months (19.7-fold). 
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Figure 75. Time-dependent expression pattern of cDNA fragment H5. Fifteen micrograms of 
total liver R N A from PPARa (+/+) mice injected with control vehicle (CTL) or Wy-14,643 
(WY) (50mg/kg), or fed control (CTL) or 0.1% Wy-14,643 (WY) diet for 1 week, 2 weeks, 6 
months or 11 months were separated on a 1.0% agarose-formaldehyde gel and transferred to 
nylon membrane. The membrane was hybridized with random-primed DIG-labeled cDNA 
fragment H5 (640 bp) and the signal was detected by colorimetric method with reagents N B T 
and BCIP. For normalization, the membrane was decolorized，stripped and reprobed with the 
random-primed DIG-labeled partial G A P D H cDNA fragment (827 bp). The R N A message was 
quantified by a densitometer and the ratio of H5/GAPDH (arbitrary units) was shown on the 
graph. There was a high level of constitutive expression of cDNA fragment H5 in PPARa (+/+) 
control mouse groups at different time periods. The level of expression of c D N A fragment H5 
was slightly suppressed in PPARa (+/+) mice injected with Wy-14,643 for 24 hours (-28.5%). 
However, the level of expression was dramatically decreased in PPARa (+/+) mice after 





82.90/0)’ 2 weeks (-85%), 6 months (-93.5%) and 11 months (-90.7%). There was no 
significant change in the level of suppression of cDNA fragment H5 in PPARa (+/+) 
mice after treatment with Wy-14,643 for 1 week, 2 weeks, 6 months and 11 months. 
The time-dependent expression pattern of cDNA fragment H8 was indicated in 
Figure 76. There was constitutive expression of cDNA fragment H8 in PPARa (+/+) 
mice injected with control vehicle for 24 hours and fed control diet for 1 week, 2 weeks, 
6 months and 11 months. In addition, the level of expression of cDNA fragment H8 was 
induced in PPARa (+/+) mice after exposure to Wy-14,643 for 24 hours (1.7-fold), 1 
week (2.4-fold), 2 weeks (2.1-fold), 6 months (1.7-fold) and 11 months (2-fold). The 
level of induction of cDNA fragment H8 in PPARa (+/+) mice after exposure to Wy-
14,643 was maintained for 1 week, 2 weeks, 6 months and 11 months. 
In conclusion, the time-dependent expression patterns of the five c D N A 
fragments (B14, HI, H4, H5 and H8) were quite similar (Table 21). The levels ofcDNA 
fragments B14, HI and H4 were strongly induced in PPARa (+/+) mice after exposure to 
Wy-14,643 for 24 hours, reached the maximal induction after 1 week and then declined 
gradually after 2 weeks, 6 months and 11 months. The level of cDNA fragment H5 was 
dramatically suppressed in PPARa (+/+) mice after feeding Wy-14,643 for 1 week and 
the level of suppression maintained at the similar level as the Wy-14,643 treatment 
continued for 2 weeks, 6 months and 11 months in these mice. The remaining cDNA 
fragment H8 was induced in PPARa (+/+) mice after exposure to Wy-14,643 for 24 
hours and the level of induction also remained at similar level as the Wy-14,643 
treatment continued for 1 week, 2 weeks, 6 months and 11 months in these mice. 
5.12 Tissue distribution pattern of differentially expressed genes 
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Figure 76. Time-dependent expression pattern of cDNA fragment H8. Thirty micrograms of 
total liver R N A from PPARa (+/+) mice injected with control vehicle (CTL) or Wy-14,643 
(WY) (50mg/kg), or fed control (CTL) or 0.1% Wy-14,643 (WY) diet for 1 week, 2 weeks, 6 
months or 11 months were separated on a 1.0% agarose-formaldehyde gel and transferred to 
nylon membrane. The membrane was hybridized with random-primed DIG-labeled cDNA 
fragment H8 (510 bp) and the signal was detected by colorimetric method with reagents N B T 
and BCIP. For normalization, the membrane was decolorized, stripped and reprobed with the 
random-primed DIG-labeled partial G A P D H cDNA fragment (827 bp). The R N A message was 
quantified by a densitometer and the ratio of H8/GAPDH (arbitrary units) was shown on the 
graph. There was constitutive expression of cDNA fragment H8 in PPARa (+/+) control 
mouse groups at different time periods. The level of expression of cDNA fragment H8 was 
induced in PPARa (+/+) mice after exposure to Wy-14,643 for 24 hours (1.7-fold), 1 week 












































































































































































































































































































































































































































































































































































There is a remarkable tissue specificity of PPARa, and this gene is predominant 
expressed in liver, kidney and heart (Issemann and Green, 1990). Therefore, the 
expression level of the differentially expressed genes in kidney and heart was also 
investigated in PPARa (+/+) and PPARa (-/-) mice treated with control or 0.1% Wy-
14,643 rodent diet for 2 weeks. 
Figure 77 demonstrated the expression level ofcDNA fragment B14 in the kidney 
and heart. There was constitutive expression in the kidney of PPARa (+/+) mice fed 
control diet. The expression level of cDNA fragment B14 was induced in the kidney of 
PPARa (+/+) mice after treatment with 0.1% Wy-14,643 diet for 2 weeks, but no such 
induction was observed in the kidney of PPARa (-/-) mice fed the same diet. In contrast, 
no detectable level of expression of cDNA fragment B14 was observed in the heart of 
both PPARa (+/+) and PPARa (-/-) mice fed control or Wy-14,643 diet for 2 weeks. 
The expression level of cDNA fragment HI in kidney and heart was illustrated in 
Figure 78. There was constitutive expression of cDNA fragment HI in the kidney of 
both PPARa (+/+) and PPARa (-/-) mice fed control diet. The expression level of 
cDNA fragment HI was induced in the kidney of PPARa (+/+) mice after treatment with 
0.1% Wy-14,643 diet for 2 weeks, but no such induction was observed in kidney of 
PPARa (-/-) mice fed the same diet. However, no detectable level of expression of 
cDNA fragment HI was observed in the heart of both PPARa (+/+) and PPARa (-/-) 
mice fed control or Wy-14,643 diet for 2 weeks. 
Figure 79 demonstrated the expression level of cDNA fragment H4 in the kidney 
and heart. No constitutive expression of cDNA fragment H4 was exhibited in the kidney 
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Figure 77. Expression pattern of cDNA fragment B14 in the kidney and heart. Fifteen 
micrograms of total kidney and heart R N A from PPARa (+/+) and PPARa (-/-) mice 
after treatment with control (CTL) or 0.1% Wy-14,643 (WY) diet for 2 weeks were 
separated on a 1.0% agarose-formaldehyde gel and transferred to nylon membrane. The 
membrane was hybridized with PCR-DIG-labeled cDNA fragment B14 (320 bp) and the 
signal was detected by colorimetric method with reagents N B T and BCIP. For 
normalization, the membrane was decolorized, stripped and reprobed with the random-
primed DIG-labeled partial G A P D H cDNA fragment (827 bp). There was constitutive 
expression of cDNA fragment B14 in the kidney of PPARa (+/+) mice fed control diet. 
The expression level of cDNA fragment B14 was induced in the kidney of PPARa (+/+) 
mice fed Wy-14,643 diet for 2 weeks, but no such induction was observed in 
PPARa (-/-) mice fed the same diet. However, no detectable constitutive expression or 
induction of cDNA fragment B14 was observed in the heart of both PPARa (+/+) and 
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Figure 78. Expression pattern of cDNA fragment HI in the kidney and heart. Fifteen 
micrograms of total kidney and heart R N A from PPARa (+/+) and PPARa (-/-) mice 
after treatment with control (CTL) or 0.1% Wy-14,643 (WY) diet for 2 weeks were 
separated on a 1.0% agarose-formaldehyde gel and transferred to nylon membrane. The 
membrane was hybridized with random-primed DIG-labeled cDNA fragment HI (850 bp) 
and the signal was detected by colorimetric method with reagents N B T and BCIP. For 
normalization, the membrane was decolorized, stripped and reprobed with the random-
primed DIG-labeled partial G A P D H cDNA fragment (827 bp). There was constitutive 
expression of cDNA fragment HI in the kidney of both PPARa (+/+) and PPARa (-/-) 
mice fed control diet. The expression level of cDNA fragment HI was induced in the 
kidney of PPARa (+/+) mice fed Wy-14,643 for 2 weeks, but no such induction was 
observed in PPARa (-/-) mice fed the same diet. However, no detectable constitutive 
expression or induction of cDNA fragment HI was observed in the heart of both 
PPARa (+/+) and PPARa (-/-) mice fed control or Wy-14,643 for 2 weeks. M，DIG-
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Figure 79. Expression pattern of cDNA fragment H4 in the kidney and heart. Fifteen 
micrograms of total kidney and heart R N A from PPARa (+/+) and PPARa (-/-) mice 
after treatment with control (CTL) or 0.1% Wy-14,643 (WY) diet for 2 weeks were 
separated on a 1.0% agarose-formaldehyde gel and transferred to nylon membrane. The 
membrane was hybridized with PCR-DIG-labeled cDNA fragment H4 (700 bp) and the 
signal was detected by colorimetric method with reagents N B T and BCIP. For 
normalization, the membrane was decolorized, stripped and reprobed with the random-
primed DIG-labeled partial G A P D H cDNA fragment (827 bp). There was no 
constitutive expression of cDNA fragment H4 in the kidney of both PPARa (+/+) and 
PPARa (-/-) mice fed control diet. The expression level of cDNA fragment H4 was 
induced in the kidney of PPARa (+/+) mice fed Wy-14,643 for 2 weeks, but no such 
induction was observed in the kidney of PPARa (-/-) mice fed the same diet. However, 
no detectable constitutive expression or induction of cDNA fragment H4 was observed in 
the heart of both PPARa (+/+) and PPARa (-/-) mice fed control or Wy-14,643 for 2 




c D N A fragment H4 was induced in the kidney of PPARa (+/+) mice after treatment with 
0.1 o/o Wy-14,643 diet for 2 weeks, but no such induction was observed in the kidney of 
PPARa (-/-) mice fed the same diet. Moreover, no detectable level of expression of 
•v 
c O N A fragment H4 was observed in the heart of both PPARa (+/+) and PPARa (-/-) 
mice fed control or Wy-14,643 diet for 2 weeks. 
Figure 80 indicated the expression level of cDNA fragment H5 in the kidney and 
heart. There was constitutive expression of cDNA fragment H5 in the kidney and heart 
of both PPARa (+/+) and PPARa (-/-) mice fed control diet. The expression level of 
c D N A fragment H5 was not significantly affected in the kidney and heart of both 
PPARa (+/+) and PPARa (-/-) mice after treatment with 0.1% Wy-14,643 diet for 2 
weeks. 
The expression level of cDNA fragment H8 in the kidney and heart was 
illustrated in Figure 81. No constitutive expression of cDNA fragment H8 was detected 
in the kidney and heart of both PPARa (+/+) and PPARa (-/-) mice fed control diet. 
The expression level of cDNA fragment H8 was induced in the kidney of PPARa (+/+) 
mice after treatment with 0.1% Wy-14,643 diet for 2 weeks, whereas such no induction 
was observed in PPARa (-/-) mice fed the same diet. In contrast, the expression level of 
cDNA fragment H8 was not detected in the heart of both PPARa (+/+) and PPARa (-/-) 
mice fed control or Wy-14,643 for 2 weeks. 
In conclusion, the level of expression of cDNA fragments B14, HI, H4 and H8 
was induced in the kidney of Wy-14,643-treated PPARa (+/+) mice, but no such 
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Figure 80. Expression pattern of c D N A fragment H5 in the kidney and heart. Fifteen 
micrograms of total kidney and heart R N A from PPARa (+/+) and PPARa (-/-) mice 
after treatment with control (CTL) or 0.1% Wy-14,643 (WY) diet for 2 weeks were 
separated on a 1.0% agarose-formaldehyde gel and transferred to nylon membrane. The 
membrane was hybridized with random-primed DIG-labeled cDNA fragment H5 (640 bp) 
and the signal was detected by colorimetric method with reagents N B T and BCIP. For 
normalization, the membrane was decolorized, stripped and reprobed with the random-
primed DIG-labeled partial G A P D H cDNA fragment (827 bp). There was constitutive 
expression of cDNA fragment H5 in the kidney and heart of both PPARa (+/+) and 
PPARa (-/-) mice fed control diet. The expression level of cDNA fragment H5 was not 
significantly affected in the kidney and heart of both PPARa (+/+) and PPARa (-/-) 
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Figure 81. Expression pattern of cDNA fragment H8 in the kidney and heart. Thirty 
micrograms of total kidney and heart R N A from PPARa (+/+) and PPARa (-/-) mice 
after treatment with control (CTL) or 0.1% Wy-14,643 (WY) diet for 2 weeks were 
separated on a 1.0% agarose-formaldehyde gel and transferred to nylon membrane. The 
membrane was hybridized with random-primed DIG-labeled cDNA fragment H8 (510 bp) 
and the signal was detected by colorimetric method with reagents N B T and BCIP. For 
normalization, the membrane was decolorized, stripped and reprobed with the random-
primed DIG-labeled partial G A P D H cDNA fragment (827 bp). There was no 
constitutive expression of cDNA fragment H8 in the kidney of both PPARa (+/+) and 
PPARa (-/-) fed control diet. The level of cDNA fragment H8 was induced in the 
kidney of PPARa (+/+) mice fed Wy-14,643 for 2 weeks, but no such induction was 
observed in the kidney of PPARa (-/-) mice fed the same diet. However, no detectable 
constitutive expression or induction of cDNA fragment H8 was observed in the heart of 
both PPARa (+/+) and PPARa (-/-) mice fed control or Wy-14,643 for 2 weeks. M， 
DIG-labeled R N A marker I. 
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PPARa (-/-) mice (Table 22). Furthermore, the expression level of cDNA fragment H5 

























































































































































































































































































































































































































































































































































































































































CHAPTER 6: DISCUSSIONS 
The toxicity of peroxisome proliferators like Wy-14,643 has been known for 
-some time. Rodents treated with peroxisome proliferators for short period of time (1-2 
weeks) result in hepatomegaly, peroxisome proliferation, hypolipidemia, and gene 
expression alteration (Cohen and Grasson, 1981; Moddy et al., 1991). Chronic treatment 
(>11 months) with peroxisome proliferators in rodents results in hepatocarcinoma 
formation (Reddy and Lalwani, 1983). However, the underlying molecular mechanism 
of peroxisome proliferator-induced short-term and long-term pleiotropic effects is not 
fully understood. 
The identification of a nuclear hormone receptor, PPARa, which was strongly 
activated by peroxisome proliferators in 1990 opens doors for investigators to uncover 
the molecular mechanism of peroxisome proliferator-induced pleiotropic effects 
(Issemann and Green, 1990). In addition, the development of a PPARa knockout mouse 
model in 1995 (Lee et al, 1995) helps to confirm the essential role of PPARa as a 
transcriptional activator of genes involved in peroxisome proliferator-induced short-term 
(Lee et al., 1995) and long-term (Peters et al., 1997) pleiotropic effects. 
What remains unclear is the whole spectrum of PPARa-dependent genes involved 
in peroxisome proliferator-induced pleiotropic effects. Therefore, identification of such 
PPARa-dependent and peroxisome proliferators responsive genes will be of great help in 
understanding the gene regulation involved in both short-term and long-term pleiotropic 
effects of peroxisome proliferators. The aim of the present study was to identify the 
spectrum of Wy-14,643, a potent peroxisome proliferator, responsive genes that are 




effects using PPARa knockout mouse model and fluorescent differential display 
technique. 
6.1 Lack of hepatomegaly, hypotriglyceridemia and hepatic nodule formation in 
PPARa (- / - ) mice 
As a first step, the Wy-14,643-induced short-term (24 hours, 1 week and 2 weeks) 
and long-term (6 and 11 months) pleiotropic effects including hepatomegaly, 
hypolipidemia, and hepatocarcinoma formation were examined in both wild-type and 
PPARa knockout mice exposed to Wy-14,643. If PPARa is an essential factor involved 
in both short-term and long-term Wy-14,643-induced pleiotropic responses, 
PPARa knockout mouse should be refractory to Wy-14,643-induced hepatomegaly, 
hypolipidemia and hepatic nodule formation. Indeed, there was lack of significant liver 
enlargement, hypotriglyceridemia and hepatic nodule formation in PPARa (-/-) mice 
exposed to Wy-14,643 for 24 hours, 1 week, 2 weeks, 6 months and 11 months. This is 
in contrast to that observed in PPARa (+/+) mice in which significant liver enlargement, 
hypotriglyceridemia and hepatic nodule formation were observed in these mice after 
exposure to Wy-14,643 at different period of time. In addition, this is the first study to 
show the time-dependent increase of liver weight and decrease of serum triglyceride level 
in PPARa (+/+) mice after treatment with Wy-14,643 for 24 hours, 1 week, 2 weeks, 6 
months and 11 months. 
The hepatomegaly induced by Wy-14,643 is due to both hepatocyte hyperplasia 
(increased replicative D N A synthesis and cell division) and hypertrophy (Cohen and 
Grasson, 1981; Reddy and Lalwani, 1983; Moody et al., 1991). The hypotriglyceridemic 




catabolism of serum triglyceride-rich particles (Schonfeld et al., 1979; Olivercrona and 
Bengtsson-Olivercrona, 1987; Sirtori and Franceschini, 1988) and inhibition of secretion 
of triglyceride-rich particles from the liver (Frenkel et al., 1994). Furthermore, the time-
•、dependent increase of serum cholesterol level in PPARa (+/+) mice after exposure to 
Wy-14,643 at 6 and 11 months has never been demonstrated. This could be attributed 
partially to the enhancement of lipolysis of triglyceride-rich lipoproteins and 
redistribution of lipid components from these particles to H D L (Ikewaki et al., 1995; 
Hennuyer et al., 1999). The lipolysis of triglyceride-rich lipoproteins was enhanced by 
Wy-14,643. The exact mechanism for a significant decrease in serum cholesterol level 
observed in PPARa (-/-) mice after exposure to Wy-14,643 for 1 and 2 weeks is unclear. 
Taken together, these data demonstrated that PPARa is a major factor involved in 
Wy-14,643-induced short-term and long-term hepatomegaly, hypotriglyceridemia, and 
hepatic nodule formation, and PPARa knockout mouse is a suitable model for studies 
involving in the identification of PPARa-dependent genes related to both short-term and 
long-term pleiotropic responses. 
6.2 Identification of PPARa-dependent and Wy-14,643 responsive genes 
To begin with identifying the PPARa-dependent and Wy-14,643 responsive 
genes after short-term treatment, m R N A fluorescent differential display was applied to 
compare the patterns of gene expression in livers of PPARa (+/+) and PPARa (-/-) mice 
after administration of control diet or diet containing 0.1% Wy-14,643 for 2 weeks. Two 
weeks of Wy-14,643 exposure was chosen for the F D D studies because of the anticipated 
maximal short-term pleiotropic responses as reported by many investigators (Cohen and 
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Grasso，1981; Reddy and Lalwani, 1983; Moody et al., 1991; Bentley et al., 1993). In 
this study, a total of fifty PPARa-dependent and Wy-14,643 responsive genes were 
excised from F D D gels performed with seven pairs of A P and A R P primers. Forty-two 
-cDNA fragments were reamplified by PCR reaction and only eighteen of them were 
successfully subcloned. Eleven c D N A fragments were sequenced and nine of them 
showed high sequence homology to seven known genes including mouse Cyp4al0 (B14 
and JIO), mouse Cyp4al4 (H3 and H4)，mouse L-specific multifunctional beta-oxidation 
protein，partial c D N A (L-MFP) (HI), mouse alpha-1 protease inhibitor 1 (a-l-PIl) (H5)， 
mouse farnesyl diphosphate famesyl transferase (Fdftl)/squalene synthase (J7)，mouse 2-
hydroxyphytanoyl-CoA lyase (2-HPCL) (H8) and mouse 16s ribosomal R N A of 
mitochondrion complete genome (Jll). The other two c D N A fragments (H6 and H12) 
did not show sequence homology to known genes but showed remarkable homology to 
mouse ESTs. The expression pattern of the five PPARa-dependent and Wy-14,643 
responsive genes [mouse Cyp4al0 (B14), mouse L-MFP (HI), mouse Cyp4al4 (H4), 
mouse a-l-PIl (H5) and mouse 2-HPCL (H8)] were confirmed by Northern blot analysis. 
Four of them (B14, HI, H4 and H8) were up-regulated in PPARa (+/+) mice after 
treatment with 0.1% Wy-14,643 for 2 weeks, but no such induction was observed in 
PPARa (-/-) mice fed the same diet. The remaining gene (H5) was down-regulated in 
PPARa (+/+) mice, but no such suppression was observed in PAPRa (-/-) mice fed the 
same diet. These data indicated that PPARa is the essential mediator involved in the 
transcriptional regulation of these five genes upon Wy-14,643 exposure. 
6.3 Functional roles of the isolated cDNA fragments 
186 
6.3.1 Fragments B14 and H4 
The c D N A fragments B14 and H4 were highly homology to mouse Cyp4al0 and 
Cyp4al4 respectively. These two genes belong to CYP4A subfamily. The data obtained 、 
•in the present study indicated that 
mouse Cyp4al0 and Cyp4al4 expressions were 
induced in PPARa (+/+) mice after 0.1% Wy-14,643 treatment for 2 weeks and their 
expressions were mediated by PPARa. This data is in general agreement with the 
previous work showing that mouse Cyp4al0 m R N A level are increased after treatment 
with other peroxisome proliferators like clofibrate and nafenopin (Hardwick et al., 1987; 
Kimura et al； 1989). The expression level of mouse Cyp4al0 was also induced in rodent 
under cold adaptation, high fat diets, starvation and diabetes (Kroetz et al., 1998). In 
addition, m R N A level of Cyp4al4 expression was induced in rat after treatment with 
methylclofenapate (Heng et al” 1997). 
The mouse Cyp4al0 gene is orthologous to rat gene, CYP4A1. This gene 
catalyzes co- and co-1 hydroxylation of fatty acids and prostaglandins Ei and 
(Hardwick et al., 1987). On the other hand, mouse Cyp4al4 was cloned in 1997 (Heng et 
al., 1997) and it is orthologous to rat genes, CYP4A2 and CYP4A3. The mouse Cyp4al4 
gene spans approximately 13 kb and contains 12 exons. The nucleotide sequence of 
mouse Cyp4al4 is 87% and 83% homology to rat CYP4A2 and CYP4A3 gene sequences 
respectively which falls off 300 bp upstream from the start codon (Heng et al., 1997). It 
could be believed that the catalytic activity of mouse Cyp4al4 is similar to rat CYP4A2 
and CYP4A3. The role of rat CYP4A2 was to catalyze the co-hydroxylation of lauric 
acid and prostaglandins while the catalytic activity of rat CYP4A3 is the same as 
CYP4A1 (Kimura""., 1989; Aoyama et al, 1990; Simpson, 1997). 
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Generally, the microsomal CYP4A enzymes play a role in catalyzing the co-
hydroxylation of medium and long chain fatty acids and prostaglandins. In the case of 
arachidonic acid, the co-hydoxyarachidonic acid formed by the action of CYP4A enzymes -、 
« - ‘ 
has been implicated in diverse biological functions, including the regulation of vascular 
tone, renal tubular ion transport, and broncho-constriction (Harder et al., 1995; Rahman 
et al., 1997). Recent studies with recombinant proteins have confirmed the narrow 
substrate specificity of the CYP4A enzymes. These enzymes can hydroxylate saturated 
and unsaturated fatty acids at the co and co-1 positions, with a clear preference for the co 
position (Aoyama et al., 1990; Roman et al., 1993). During the co-hydroxylation, 
dicarboxylic acids were formed through the subsequent oxidation of the product co-
alcohols by cytosolic enzymes. Dicarboxylic fatty acids are substrates for mitochondrial 
or peroxisomal p-oxidation, and the peroxisomal pathway appears to be more efficient 
for the P-oxidation of dicarboxylic acids than the mitochondrial pathway (Okita, 1994; 
Reddy and Mannaerts, 1994; Johnson et al,, 1996). 
It is known that the transcriptional activation of CYP4A by peroxisome 
proliferators is mediated by PPARa. Once peroxisome proliferator activates PPARa, it 
forms a heterodimer with RXR. Then the PPARa/RXR heterodimer binds to the PPRE 
of the CYP4A genes and enhances the stimulation of CYP4A transcription (Palmer et al” 
1994; Aldridge et al., 1995). Apart from the Cyp4al0 and Cyp4al4 genes, other 
members of the CYP4A subfamily were also induced by peroxisome proliferators 
including the CYP4A2 (Kimura et al., 1989)，CYP4A3 (Aoyama et al., 1990)，CYP4A4 
(Matsubara et al., 1987), CYP4A5 (Yoshimura et aL, 1990), CYP4A6 (Yokotani et al., 
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1989)，CYP4A7 (Yokotani et al” 1989), CYP4A8 (Stromstedt et al., 1990), CYP4A11 
(Kawashima et al., 1992), Cyp4al2 (Bell et al” 1993) and CYP4A13 (Bell et al； 1993). 
•6.3.2 Fragment HI 
The cDNA fragment HI was identified as the mouse L-specific multifiinctional 
beta-oxidation protein, partial cDNA (L-MFP) (Van Veldhove et al, submitted) and the 
gene sequence of L-MFP showed high sequence homology to the rat peroxisomal enoyl-
CoA: hydratase-3-hydroxyacy 1-CoA dehydrogenase bifunctional enzyme (simply 
referred to as bifunctional enzyme) (Osumi et al., 1985; Van Veldhoven et al., 1991; 
Kaikaus et al., 1993). The mouse L-MFP gene was called MFP-1 or L-bifunctional 
protein and it plays a role in catalyzing the hydration and dehydrogenation reactions of 
the latter pathway in peroxisomal P-oxidation (Baes et al” 2000; Wanders et al., 2000). 
At same time, the other multiftinction protein (MFP-2 or D-bifunational protein) also 
involved in P-oxidation because the hydrated species generated has the D-configuration 
(Baes et al； 2000). 
Peroxisomal P-oxidation has a responsibility for the degradation of less abundant 
carboxylates of different molecular structure (Reddy and Mannaerts, 1994; Mannaerts 
and Van Veldhoven, 1996). The substrates for peroxisomal p-oxidation include very 
long chain fatty acid (containing more than 20 carbon atoms) (Jakobs and Wanders, 
1995), 2-methyl branched chain fatty acids (e.g. pristanic acid that is formed after a-
oxidation of the 3-methyl-branched fatty acid phytanic acid)，prostanoids (Wanders and 
Tager, 1998), dicarboxylic acids and the C27 bile acid intermediates di- and 
trihydroxycholestanoic acids (DHCA and THCA) (Reddy and Mannaerts, 1994; Wanders 
and Tager, 1998). Similar to mitochondrial p-oxidation, peroxisomal P-oxidation 
189 
consists of four steps: (1) a desaturation leading to a 2-enoy-CoA; (2) a hydration of the 
enoyl-CoA to a 3-hydroxyl-acyl-CoA; (3) a dehydrogenation with the formation of a 3-
keto-acyl-CoA; and (4) a thiolytic cleavage yielding an acyl-CoA shortened by two 、 
carbon atoms. The peroxisomal P-oxidation reactions are catalyzed by different acyl-
CoA oxidases (Scheper " al., 1990; Van Veldhoven et al, 1991; Vanhove et al., 1993)， 
which form H2O2, different multifunctional proteins (Novikov et al., 1994; Dieuaide-
Noubhani et al, 1996; Novikov et al., 1997) and different thiolases (Antonenkov et al., 
1997; Wanders et al, 1997). . 
Different P-oxidation pathways have been proposed that is based on the substrate 
specificity and stereoselectivity of the multifunctional enzymes (Mannaerts and Van 
Veldhoven, 1996; Baes et al., 2000) (Figure 82). The classical pathway catalyzed by 
palmitoyl-CoA oxidase, L-MFP and peroxisomal thiolase is generally accepted to be 
responsible for the oxidation of straight chain fatty acids. All enzymes of this pathway 
can be strongly induced in rodents by peroxisome proliferators. The oxidation of 2-
methyl-branched fatty acids and bile acid intermediates (DHCA and THCA) is believed 
to occur via a second pathway. In humans, this pathway consists of branched chain acyl-
CoA oxidase (Vanhove et al., 1993), MFP-2 which generates the D-hydroxy intermediate 
and sterol carrier protein-X (SCPx), the N-terminal part of which exerts thiolytic activity 
(Wanders et al, 1997). In rats, the desaturation of bile acid intermediates is executed by 
trihydroycoprostanoyl-CoA oxidase (Scheper et al., 1990). 
As mentioned before, peroxisome proliferators markedly induce the enzymes of 
the peroxisomal P-oxidation, but produce only a small increase in catalase activity (Lake, 
1993 and 1995). Any excess H2O2 cannot be destroyed by peroxisomal catalase and then 
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Figure 82. The schematic pathways of fatty acid P-oxidation machinery in peroxisomes 
catalyzing the oxidation of straight-chain (C26:o) and branched-chain fatty acids (pristanic 
acid an THCA) (Wanders et al., 2000). 
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substrate for cytosolic selenium-dependent glutathione peroxidase. However, this 
enzyme activity of catalase is reduced by the administration of peroxisome proliferators 
to rodents (Lake, 1993) and resulted in increased intracellular levels of H2O2 which may 
either directly or via reactive oxygen species attack membranes and D N A (Reddy and 
Lalwani, 1983; Reddy and Rao, 1992). As a result, the sustained oxidative stress 
contributes to peroxisome proliferator-induced hepatocarcinogenesis in rodent (Lake, 
1995). 
6.3.3 Fragment H5 
The c D N A fragment was identified as the mouse alpha-1 protease inhibitor 1 (al-
PIl) and it was homologous in sequence and function to human alpha-1-antitrypsin (al-
AT) (Borriello and Krauter，1991; Tardiff and Kenneth, 1998). The al-PIl with a 
molecular weight of 53,000 is a single polypeptide consisting of 394 amino acids 
containing three carbohydrate chains (Carrell et al” 1982). The major physiological 
function of al-PIl is to inhibit the activity of neutrophil elastase, cathepsin G and 
proteinase 3. It also involved in inhibition of a broad spectrum of other serine proteases 
including protein C, thrombin, trypsin and chymotrypsin (Perlmutter, 1993; Xie et aL, 
1999). Moreover, al-PIl is synthesized predominantly in heptocytes, but extrahepatic 
synthesis occurs in blood monocytes, tissue macrophages and pulmonary epithelial cell 
lines (Perlmutter et aL, 1985). 
Result obtained from this study showing that the expression of al-PIl was down-
regulated in PPARa (+/+) mice after treatment with 0.1% Wy-14,643 for 2 weeks. This 




regulated in PPARa (+/+) mice after treatment with Wy-14,643 for 1 and 3 weeks 
(Devchand et al., 1996; Anderson et al, 1999). This down-regulation was dependent on 
the presence of PPARa because no such suppression was observed in PPARa (-/-) mice 、 
fed the same diet. The down-regulation of al-PIl expression is in concordance with 
PPARa elicits an anti-inflammatory effect in mice (Devchand et al, 1996). It is possibly 
through increased leukotrience B4 catabolism (Devchand et al； 1996), or inhibition of IL_ 
1-induced production of IL-6, prostaglandin and cyclooxygenase-2 (Staels et al., 1998). 
The regulation of IL-6 by al-PIl has prominent roles in promoting hepatocellular growth 
(Michalopoulos and DeFrances, 1997). Therefore, al-PIl might play an important role 
in peroxisome proliferators-induced both short-term and long-term pleiotropic effects and 
liver disease (Devchand et al, 1996). 
In humans, decreased expression or inhibitory activity of al-AT is associated 
with a deficiency syndrome which can result in emphysema and liver disease and this 
deficiency state of al-AT is due to hereditary present of PiZ phenotype (Sifers et al., 
1987). Homozygosity of PiZ results from a single base mutation with a resulting charged 
amino acid substitution. The mutant protein accumulates within the rough endoplasmic 
reticulum at its site of synthesis and then causing a subsequent deficiency of the al-AT 
circulation protein (Sifers et aL, 1987). The initial clinical correlate of early onset is 
pulmonary emphysema (Laurell and Eriksson; 1963)，later are cholestasis and juvenile 
cirrhosis (Sharp, 1971). Ultimately, an increased risk of cirrhosis is development of 
hepatocarcinoma (Eriksson et al, 1986). According to our result, the activity of al-PIl 
decreased after the PPARa (+/+) mice fed Wy-14,643 for 1 week, 2 weeks, 6 and 11 




suggested that the down-regulation of al-PIl by peroxiosme proliferators could be 
similar to human. Thus, PPARa knockout mouse might be a good model to study the 
role of al-PIl in facilitating the development of peroxisome proliferators-induced 
hepatocellular carcinoma. 
6.3.4 Fragment H8 
The c D N A fragment H8 was highly homology to the rat 2-hydroxyphytanoy 1-
CoA lyase (2-HPCL). This is the first report showing that 2-HPCL gene was induced by 
Wy-14,643 and its expression was regulated by PPARa. The sequence of 2-HPCL 
contains an open reading frame (ORF) of 1,734 bases and encodes a protein of 578 amino 
acids with a calculated molecular mass of 63,732 Da, which corresponds to the size of the 
subunit of the rat enzyme (Foulon et al., 1999). It was found that 2-HPCL was identified 
as a peroxisomal thiamine pyrophospate-dependent enzyme and it plays role in catalysis 
of the carbon-carbon bond cleavage during a-oxidation of 3-methyl-branched fatty acids 
(Foulon et al,, 1999; Jansen et al., 1999). As 3-methyl-branched fatty acids process a 
methyl group in the 3-position, it prevents the dehydrogenation of the 3-hydroxyl group 
during p-oxidation. For this reason, 3-methyl-branched fatty acids first undergo a_ 
oxidation in which they are shortened by one carbon atom (Croes et al., 1996). The 
resulting 2-methyl-substituted fatty acid is subsequently undergoing peroxisomal P-
oxidation (Jakobs et al., 1994; Singh et al., 1994). 
The a-oxidation pathway has been elucidated only recently and it is shown in 
Figure 83. Phytanic acid (3，7，11, 15-tetramethylhexadecanoic acid) is first converted to 
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Figure 83. Schematic representation of the phytanic acid a-oxidation pathway in rat liver. 
After activation to phytanoyl-CoA, 2-hydroxyphytanoyl-CoA is formed by phytanoyl-CoA 
hydroxylase. Hereafter, 2-hydroxyphytanoyl-CoA is converted into pristanal in a reaction 
catalyzed by 2-HPCL. Pristanal is then converted into pristanic acid in an NAD+-dependent 
reaction. Further P-oxidation required to degrade the 2-methyl-branched fatty acid (Wanders 
et al., 2000). 
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phytanoyl-CoA is metabolized into 2-hydroxyphytanoyl-CoA by phytanoyl-CoA 
hydroxylase and this reaction involved 2-oxoglutarate, Fe^^ and ascorbate (Mihalik et al., 
1995; Croes et al., 1996). Followed by oxidative decarboxylation of 2-
、 
-hydroxyphytanoyl-CoA to pristanal with the catalysis of 2-HPCL (Foulon et al.’ 1999; 
Jansen et al., 1999) and formic acid is the primary product of a-oxidation (Poulos et al., 
1993). Pristanal is then dehydrogenated in a NAD+-dependent reaction to pristanic acid. 
This 2-methyl-branched fatty acid is then degraded via peroxisomal P-oxidation (Jakobs 
et al., 1994; Singh et al., 1994; Wanders et al., 2000). 
6.4 Temporal expression patterns of the isolated cDNA fragments 
The temporal expression patterns (24 hours, 1 week, 2 weeks, 6 months and 11 
months) of the isolated Wy-14,643 responsive and PPARa-dependent genes were 
investigated in order to determine whether they could be served as the early gene 
marker(s) from short-term studies for prediction of long-term development of 
hepatocarcinogenesis. 
The temporal expression patterns of the five isolated genes including mouse 
Cyp4al0, Cyp4al4, L-MFP, al-PIl and 2-HPCL could be divided into three types. 
Firstly, mouse Cyp4al0, mouse Cyp4al4 and mouse L-MFP were strongly induced in 
PPARa (+/+) mice after exposure to Wy-14,643 for 24 hours, maximally induced by 1 
week or 2 weeks exposure and decreased after further long-term treatment (11 months) 
(Reddy et al” 1986; Milton et aL, 1990; Bell et al.’ 1993). However, no induction of 
these genes was observed in PPARa (-/-) mice after exposure to the same treatment. 
This data indicated that PPARa is involved in the transcription regulation of CYP4A and 




indicated that mouse Cyp4al0 and Cyp4al4 were induced in PPARa (+/+) mice as early 
as after 3 hours of gavage exposure to Wy-14,643 (Chen et al., SOT poster #203, 2000). 
The temporal expression pattern of mouse al-PIl was different from the mouse 
Gyp4al0, Cyp4al4 and L-MFP genes. Mouse al-PIl was slightly suppressed in PPARa 
(+/+) mice after exposure to Wy-14,643 for 24 hours, significantly down-regulated after 
treatment with Wy-14,643 for 1 week and maintained slightly decreased upon long-term 
(11 months) treatment. However, no such suppression was detected in PPARa (-/-) 
mice exposed to Wy-14,643 at different times indicating that PPARa is involved in the 
down-regulation of this gene upon Wy-14,643 treatment. 
The temporal expression pattern of the mouse 2-HPCL was very different from 
the genes mentioned above. This gene was slightly induced in PPARa (+/+) mice after 
exposure to Wy-14,643 for 24 hours and the induction level maintained up to 11 months 
Wy-14,643 treatment. No such induction was observed in PPARa (-/-) mice after same 
treatment at different time periods suggesting that PPARa is involved in transcriptional 
regulation of this gene upon Wy-14,643 treatment. 
In conclusion, the level of mouse Cyp4al0, L-MFP, Cyp4al4, al-PIl and 2-
HPCL genes were induced or suppressed after 1 week of Wy-14,643 treatment and 
continued onto to 11 months. Therefore, these five genes might serve as the early marker 
genes for prediction of long-term development of peroxisome proliferator-induced 
hepatocarcinogenesis. 




There is a marked tissue-specificity of PPARa and it is predominantly expressed 
not only in liver but also in kidney and heart (Issemann and Green, 1990). Therefore, the 
role of PPARa involved in transcriptional regulation of the five genes after Wy-14,643 
• V 
"exposure was also determined in kidney and heart. 
Similar to the findings obtained from liver, PPARa is required for the induction 
of the mouse Cyp4al0, Cyp4al4，L-MFP and 2-HPCL m R N A s in the kidney of PPARa 
(+/+) mice after exposure to Wy-14,643. These results were in agreement with previous 
study indicating that mouse Cyp4al0 and Cyp4al4 were highly inducible in liver and 
kidney by clofibrate and methylclofenapate (Hardwick et al., 1987; Heng et al., 1997). 
Moreover, previous report revealed that the abundance of 2-HPCL transcript in human 
varied significantly among different tissues, with highest levels in liver and kidney 
(Foulon et al., 1999). Further study is necessary to investigate the expression of 2-HPCL 
in different tissue because the tissue distribution of this gene in mice is not clear. Also 
Wy-14,643 treatment did not result in up-regulation of these genes in the heart of PPARa 
(+/+) mice. There was constitutive expression of al-PIl in both kidney and heart of 
PPARa (+/+) and PPARa (-/-) mice. However, Wy-14,643 treatment had no effect on 
the expression level of this gene in kidney and heart. 
In conclusion, the five identified genes showed different degree of constitutive 
expression and responsiveness to Wy-14,643 in kidney and heart. This indicated that 
they might have different roles in kidney and heart. The Wy-14,643-induced expressions 
of Cyp4al0, Cyp4al4, L-MFP and 2-HPCL in kidney were depended on PPARa, 
whereas Wy-14,643 treatment had no effect on the expression of these gene in heart. 




kidney and heart. Taken together, the role of PPARa in the transcriptional regulation of 




CHAPTER 7: CONCLUSIONS 
Administration of peroxisome proliferators for short-period of time (1-2 weeks) 
:results in hepatomegaly and alteration of gene transcription accompany with the decrease 
in plasma triglyceride level. For the long-term (>11 months) treatment of peroxisome 
proliferators, it leads to formation of hepatocarcinoma in rodents. However, the molecular 
mechanism of peroxisome proliferator-induced short-term and long-term pleiotropic 
effects is still obscure. The identification of a steroid hormone receptor, PPARa, 
uncovered the molecular mechanism of peroxisome proliferator-induced pleiotropic effects 
(Issemann and Green, 1990) and the development of a PPARa knockout mouse model in 
1995 (Lee et al., 1995) confirmed the essential role of PPARa as a transcriptional activator 
of genes involved in peroxisome proliferator-induced short-term (Lee et al., 1995) and 
long-term (Peters et al., 1997) pleiotropic effects. Therefore, identification of PPARa-
dependent and peroxisome proliferators responsive genes will be of great help in 
understanding the gene regulation involved in both short-term and long-term pleiotropic 
responses of peroxisome proliferators. The aim of the present study was to use PPARa 
knockout mouse model and fluorescent differential display technique to identify the 
spectrum of Wy-14,643, a potent peroxisome proliferator, responsive genes that are 
PPARa-dependent and might play a role in both short-term and long-term pleiotropic 
effects of peroxisome proliferators. 
There was significant liver enlargement, hypotriglyceridemia and hepatic nodule 
formation in PPARa (+/+) mice after exposure to Wy-14,643 for 24 hours, 1 week, 2 
weeks, 6 months and 11 months. In contrast, there was lack of significant liver 




after exposure to Wy-14,643 at different period of time. These data demonstrated that 
PPARa is a major factor involved in Wy-14,643-induced short-term and long-term 
pleiotropic responses, and PPARa knockout mouse is a suitable model for studies 
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involving in the identification of PPARa-dependent genes related to both short-term and 
long-term pleiotropic responses. 
In the F D D RT-PCR study, liver R N A samples from both PPARa (+/+) and 
PPARa (-/-) mice after administrated 0.1% Wy-14,643 for 2 weeks were used because 
maximum short-term pleiotropic responses occur after 2 weeks of Wy-14,643 treatment 
as reported by many investigators (Cohen and Grasso, 1981; Reddy and Lalwani, 1983; 
Moody et al., 1991; Bentley et al, 1993). A total of fifty PPARa-dependent and Wy-
14,643 responsive genes were excised from four FDD gels performed with seven pairs of 
AP and ARP primers. Forty-two cDNA fragments were reamplified by PCR reaction and 
only eighteen of them were successfully subcloned. Eleven cDNA fragments were 
sequenced and nine of them showed high sequence homology to seven known gene 
encoding mouse Cyp4al0 (B14 and J10)，mouse Cyp4al4 (H3 and H4), mouse L-specific 
multifunctional beta-oxidation protein, partial cDNA (L-MFP) (HI), mouse alpha-1 
protease inhibitor 1 (a-l-PIl) (H5), mouse famesyl diphosphate famesyl transferase 
(Fdftl)/squalene synthase (J7), mouse 2-hydroxyphytanoyl-CoA lyase (2-HPCL) (H8) 
and mouse 16s ribosomal R N A of mitochondrion complete genome (Jll). The other two 
cDNA fragments (H6 and HI2) did not show sequence homology to known genes but 
showed remarkable homology to mouse ESTs. The expression patterns of the five 
PPARa-dependent and Wy-14,643 responsive genes [mouse Cyp4al0 (B14), mouse L-
M F P (HI), mouse Cyp4al4 (H4), mouse a-l-PIl (H5) and mouse 2-HPCL (H8)] were 
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confirmed by Northern blot analyses. Four of them (B14, HI, H4 and H8) were up-
regulated in PPARa (+/+) mice after treatment with 0.1% Wy-14,643 for 2 weeks, but no 
such induction was observed in PPARa (-/-) mice fed the same diet. The remaining 
gene (H5) was down-regulated in PPARa (+/+) mice, but no such suppression was 
observed in PAPRa (-/-) mice fed the same diet. 
It was revealed that cDNA fragments B14 and H4 were identified as mouse 
Cyp4al0 and Cyp4al4 genes. They belong to CYP4A subfamily and play a catalytic role 
in microsomal co-hydroxylation. The other cDNA fragment HI was identified as* mouse 
L-specific multifunctional beta-oxidation protein (L-MFP) and it involves in peroxisomal 
p-oxidation. The most interesting cDNA fragment H8 was identified as 2-
hydroxyphytanoyl-CoA lyase (2-HPCL) and it catalyzes the carbon-carbon cleavage 
during a-oxidation. This data provided the first evidence to show that PPARa mediates 
the gene regulation of a-oxidation. All of above four genes play a role in fatty acid 
metabolism and their transcriptional regulations were mediated by PPARa. The 
remaining c D N A fragment H5 was identified as mouse a-1-protease inhibitor 1 (al-PIl) 
and the physiological function of it is to inhibit the activity of neutrophil elastase. 
The five isolated PPARa-dependent and Wy-14,643 responsive genes (mouse 
Cyp4al0, Cyp4al4, L-MFP, al-PIl and 2-HPCL) might be served as early markers for 
prediction of long-term development of hepatocarcinogenesis because the induction or 
suppression level of these five genes were altered in PPARa (+/+) mice after exposure to 
Wy-14,643 for 1 week and continued onto 11 months. 
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The five isolated genes showed different degree of constitutive expression and 
responsiveness to Wy-14,643 in kidney and heart. This indicated that they might have 
different roles in kidney and heart. The Wy-14,643-induced expressions of mouse 
-Cyp4al0, Cyp4al4, L-MFP and 2-HPCL in kidney were depended on PPARa whereas 
Wy-14,643 treatment had no effect on the expressions of these genes in heart. There was 
no effect of Wy-14,643 treatment on the constitutive expression of mouse al-PIl in both 
kidney and heart. 
The PPARa-dependent and Wy-14,643 responsive genes isolated from this study 
might serve as early marker genes for prediction of long-term peroxisome proliferator-
induced hepatocarcinogenesis. However, further characterization of these genes is 
necessary to investigate the correlation between those genes and peroxisome proliferator-




CHAPTERS: FUTURE STUDIES 
8.1 Subcloning and characterization of the other differentially expressed genes 
In this study, a total of fifty PPARa-dependent and Wy-14,643 responsive genes 
were excised from F D D gels performed with seven pairs of A P and A R P primers. 
Eighteen c D N A fragments were subcloned and eleven of them were sequenced. 
However, only the expression patterns of five isolated PPARa-dependent and Wy-14,643 
responsive genes were confirmed by Northern blot analyses. Therefore, the expression 
patterns of the other sequenced genes need to be confirmed by Northern blot analyses. 
Apart from the eighteen cloned cDNA fragments, the other twenty-four c D N A fragments 
could not be successfully subcloned and sequenced. Therefore, these c D N A fragments 
require further subcloning and sequencing. Since only seven pairs of AP and A R P 
primers were selected to perform F D D RT-PCR analysis in this study, other AP and A R P 
primer combinations should be used to identify more PPARa-dependent and Wy-14,643 
responsive genes involved in the peroxisome proliferator-induced pleiotropic responses. 
8.2 Overexpression and inhibition expression of specific genes 
In order to define a putative functional role of the isolated genes in mediating the 
pleiotropic responses of peroxisome proliferators in rodents, several experimental 
strategies could be employed. These include, overexpression of isolated genes using 
sense or inducible sense expression vectors in hepatocyte and determining the effects on 
growth, differentiation and tumorigenic potential (Augustine, 1997). An alternate 
strategy would be to inhibit the expression of isolated genes, using antisense technology 




hepatocarcinoma physiology. These studies are well justified and might provide insight 
into the multitude of processes operating during the development of peroxisome 
proliferator-induced pleiotropic responses in rodents. Moreover, this information might 
be used to estimate the development of hepatocarcinoma induced by peroxisome 
proliferators in human.‘ 
8.3 Generating transgenic mice with target disruption of specific gene 
To determine the function or role of the genes that are not shown any homology 
to known gene or ESTs (Ito and Sakaki, 1996) in peroxisome proliferator-induced 
pleiotropic responses, generation of transgenic mice might provide in vivo model to 
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